0001739104-22-000017.txt : 20221108 0001739104-22-000017.hdr.sgml : 20221108 20221108090749 ACCESSION NUMBER: 0001739104-22-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221108 DATE AS OF CHANGE: 20221108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 221367445 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 10-Q 1 elan-20220930.htm 10-Q elan-20220930
false2022Q30001739104--12-311http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember00017391042022-01-012022-09-300001739104elan:CommonStockNoParValueMember2022-01-012022-09-300001739104elan:A500TangibleEquityUnitsMember2022-01-012022-09-3000017391042022-11-03xbrli:shares00017391042022-07-012022-09-30iso4217:USD00017391042021-07-012021-09-3000017391042021-01-012021-09-30iso4217:USDxbrli:shares00017391042022-09-3000017391042021-12-310001739104us-gaap:CommonStockMember2020-12-310001739104us-gaap:AdditionalPaidInCapitalMember2020-12-310001739104us-gaap:RetainedEarningsMember2020-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100017391042020-12-310001739104us-gaap:RetainedEarningsMember2021-01-012021-03-3100017391042021-01-012021-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001739104us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001739104us-gaap:CommonStockMember2021-01-012021-03-310001739104us-gaap:CommonStockMember2021-03-310001739104us-gaap:AdditionalPaidInCapitalMember2021-03-310001739104us-gaap:RetainedEarningsMember2021-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100017391042021-03-310001739104us-gaap:RetainedEarningsMember2021-04-012021-06-3000017391042021-04-012021-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-04-012021-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-04-012021-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-012021-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001739104us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001739104us-gaap:CommonStockMember2021-06-300001739104us-gaap:AdditionalPaidInCapitalMember2021-06-300001739104us-gaap:RetainedEarningsMember2021-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000017391042021-06-300001739104us-gaap:RetainedEarningsMember2021-07-012021-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001739104us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001739104us-gaap:CommonStockMember2021-09-300001739104us-gaap:AdditionalPaidInCapitalMember2021-09-300001739104us-gaap:RetainedEarningsMember2021-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000017391042021-09-300001739104us-gaap:CommonStockMember2021-12-310001739104us-gaap:AdditionalPaidInCapitalMember2021-12-310001739104us-gaap:RetainedEarningsMember2021-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001739104us-gaap:RetainedEarningsMember2022-01-012022-03-3100017391042022-01-012022-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001739104us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001739104us-gaap:CommonStockMember2022-01-012022-03-310001739104us-gaap:CommonStockMember2022-03-310001739104us-gaap:AdditionalPaidInCapitalMember2022-03-310001739104us-gaap:RetainedEarningsMember2022-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100017391042022-03-310001739104us-gaap:RetainedEarningsMember2022-04-012022-06-3000017391042022-04-012022-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-012022-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-012022-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001739104us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001739104us-gaap:CommonStockMember2022-06-300001739104us-gaap:AdditionalPaidInCapitalMember2022-06-300001739104us-gaap:RetainedEarningsMember2022-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000017391042022-06-300001739104us-gaap:RetainedEarningsMember2022-07-012022-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012022-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001739104us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001739104us-gaap:CommonStockMember2022-09-300001739104us-gaap:AdditionalPaidInCapitalMember2022-09-300001739104us-gaap:RetainedEarningsMember2022-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-30elan:countryxbrli:pure0001739104country:USelan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300001739104country:USelan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300001739104elan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2022-07-012022-09-300001739104elan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2021-07-012021-09-300001739104elan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2022-01-012022-09-300001739104elan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2021-01-012021-09-300001739104elan:PetHealthMember2022-07-012022-09-300001739104elan:PetHealthMember2021-07-012021-09-300001739104elan:PetHealthMember2022-01-012022-09-300001739104elan:PetHealthMember2021-01-012021-09-300001739104elan:CattleMember2022-07-012022-09-300001739104elan:CattleMember2021-07-012021-09-300001739104elan:CattleMember2022-01-012022-09-300001739104elan:CattleMember2021-01-012021-09-300001739104elan:PoultryMember2022-07-012022-09-300001739104elan:PoultryMember2021-07-012021-09-300001739104elan:PoultryMember2022-01-012022-09-300001739104elan:PoultryMember2021-01-012021-09-300001739104elan:SwineMember2022-07-012022-09-300001739104elan:SwineMember2021-07-012021-09-300001739104elan:SwineMember2022-01-012022-09-300001739104elan:SwineMember2021-01-012021-09-300001739104elan:AquaMember2022-07-012022-09-300001739104elan:AquaMember2021-07-012021-09-300001739104elan:AquaMember2022-01-012022-09-300001739104elan:AquaMember2021-01-012021-09-300001739104elan:FarmAnimalMember2022-07-012022-09-300001739104elan:FarmAnimalMember2021-07-012021-09-300001739104elan:FarmAnimalMember2022-01-012022-09-300001739104elan:FarmAnimalMember2021-01-012021-09-300001739104elan:ContractManufacturingMember2022-07-012022-09-300001739104elan:ContractManufacturingMember2021-07-012021-09-300001739104elan:ContractManufacturingMember2022-01-012022-09-300001739104elan:ContractManufacturingMember2021-01-012021-09-300001739104elan:KindredBioMember2021-08-270001739104elan:KindredBioMember2021-08-272021-08-270001739104elan:KindredBioMember2021-05-050001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:MicrobiomeRDPlatformCarveOutMember2022-01-012022-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-12-31elan:employee00017391042022-02-010001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeMember2021-08-010001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeMember2021-08-012021-08-010001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeMember2022-01-012022-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeMember2022-07-012022-09-300001739104elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-12-310001739104us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberelan:BexCaFeLLCMember2022-06-090001739104us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberelan:BexCaFeLLCMember2022-06-090001739104us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberelan:FutureMilestonePaymentsAndSalesRoyaltiesMemberelan:BexCaFeLLCMember2022-06-090001739104us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberelan:BexCaFeLLCMember2022-07-012022-09-3000017391042021-01-012021-12-31elan:restructuring_program0001739104elan:January2021RestructuringPlanMember2021-01-012021-01-31elan:position0001739104elan:January2021RestructuringPlanMember2021-07-012021-09-300001739104elan:January2021RestructuringPlanMember2021-01-012021-09-300001739104elan:November2021RestructuringPlanMember2021-11-012021-11-300001739104elan:November2021RestructuringPlanMember2022-01-012022-09-300001739104us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:InProcessResearchAndDevelopmentMemberelan:BexCaFeLLCMember2022-07-012022-09-300001739104us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:InProcessResearchAndDevelopmentMemberelan:BexCaFeLLCMember2022-01-012022-09-300001739104elan:KindredBioMember2022-01-012022-09-300001739104us-gaap:EmployeeSeveranceMember2020-12-310001739104us-gaap:EmployeeSeveranceMember2021-01-012021-09-300001739104us-gaap:EmployeeSeveranceMember2021-09-300001739104us-gaap:EmployeeSeveranceMember2021-12-310001739104us-gaap:EmployeeSeveranceMember2022-01-012022-09-300001739104us-gaap:EmployeeSeveranceMember2022-09-300001739104srt:ScenarioForecastMember2022-10-012023-09-300001739104elan:TangibleEquityUnitMember2020-01-222020-01-220001739104us-gaap:SeniorNotesMemberelan:A500TangibleEquityUnitsMember2020-01-220001739104elan:TangibleEquityUnitMember2020-01-220001739104elan:TangibleEquityUnitEquityComponentMember2020-01-220001739104elan:TangibleEquityUnitDebtComponentMember2020-01-220001739104elan:TangibleEquityUnitEquityComponentMember2020-01-222020-01-220001739104elan:TangibleEquityUnitDebtComponentMember2020-01-222020-01-220001739104elan:A275SeniorAmortizingNotesMemberus-gaap:SeniorNotesMember2020-01-220001739104elan:A275SeniorAmortizingNotesMemberus-gaap:SeniorNotesMember2020-01-222020-01-220001739104elan:TangibleEquityUnitMember2020-01-220001739104us-gaap:SeniorNotesMemberelan:A500TangibleEquityUnitsMember2020-01-222020-01-22elan:trading_day0001739104elan:TangibleEquityUnitMembersrt:MaximumMember2020-01-220001739104elan:TangibleEquityUnitMembersrt:MinimumMember2020-01-220001739104us-gaap:LineOfCreditMemberelan:IncrementalTermFacilityDue2025Memberus-gaap:SecuredDebtMember2022-09-300001739104us-gaap:LineOfCreditMemberelan:IncrementalTermFacilityDue2025Memberus-gaap:SecuredDebtMember2021-12-310001739104us-gaap:LineOfCreditMemberelan:IncrementalTermFacilityDue2028Memberus-gaap:SecuredDebtMember2022-09-300001739104us-gaap:LineOfCreditMemberelan:IncrementalTermFacilityDue2028Memberus-gaap:SecuredDebtMember2021-12-310001739104us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberelan:IncrementalTermFacilityDue2029Member2022-09-300001739104us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberelan:IncrementalTermFacilityDue2029Member2021-12-310001739104us-gaap:LineOfCreditMemberelan:TermBLoanFacilityMember2022-09-300001739104us-gaap:LineOfCreditMemberelan:TermBLoanFacilityMember2021-12-310001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-300001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2022-09-300001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2021-12-310001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-09-300001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-12-310001739104us-gaap:SeniorNotesMemberelan:A500TangibleEquityUnitsMember2022-09-300001739104us-gaap:SeniorNotesMemberelan:A500TangibleEquityUnitsMember2021-12-310001739104us-gaap:LineOfCreditMemberelan:IncrementalTermFacilityDue2025Memberus-gaap:SecuredDebtMember2022-06-300001739104us-gaap:LineOfCreditMemberelan:SecuredOvernightFinancingRateSOFRMemberelan:IncrementalTermFacilityDue2025Memberus-gaap:SecuredDebtMember2022-06-012022-06-300001739104us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberelan:IncrementalTermFacilityDue2029Member2022-04-300001739104us-gaap:LineOfCreditMemberelan:SecuredOvernightFinancingRateSOFRMemberus-gaap:SecuredDebtMemberelan:IncrementalTermFacilityDue2029Member2022-04-012022-04-300001739104us-gaap:LineOfCreditMemberelan:TermBLoanFacilityMember2022-09-012022-09-300001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2022-04-300001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2022-04-302022-04-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-07-012022-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-07-012021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-01-012022-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-01-012021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-07-012022-09-300001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-04-012022-04-300001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-012022-09-300001739104us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-3000017391042020-10-160001739104us-gaap:SalesRevenueNetMemberelan:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001739104us-gaap:SalesRevenueNetMemberelan:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001739104us-gaap:SalesRevenueNetMemberelan:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001739104us-gaap:SalesRevenueNetMemberelan:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001739104us-gaap:ProductMember2022-09-300001739104us-gaap:ProductMember2021-12-310001739104country:US2022-07-012022-09-300001739104country:US2021-07-012021-09-300001739104country:US2022-01-012022-09-300001739104country:US2021-01-012021-09-300001739104us-gaap:NonUsMember2022-07-012022-09-300001739104us-gaap:NonUsMember2021-07-012021-09-300001739104us-gaap:NonUsMember2022-01-012022-09-300001739104us-gaap:NonUsMember2021-01-012021-09-30elan:segment0001739104us-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from _________ to _______
COMMISSION FILE NUMBER 001-38661
elan-20220930_g1.jpg
Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA
 82-5497352
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2500 INNOVATION WAY, GREENFIELD, INDIANA 46140
(Address and zip code of principal executive offices)

Registrant’s telephone number, including area code (877) 352-6261
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, no par valueELANNew York Stock Exchange
5.00% Tangible Equity UnitsELATNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of November 3, 2022 was 474,205,430.
2022 Q3 Form 10-Q | 2
elan-20220930_g1.jpg

ELANCO ANIMAL HEALTH INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2022
TABLE OF CONTENTS
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

2022 Q3 Form 10-Q | 3
elan-20220930_g1.jpg
FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

This Quarterly Report on Form 10-Q (Form 10-Q) includes forward-looking statements within the meaning of the federal securities laws. These forward-looking statements, include, without limitation, statements concerning the impact on Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us or our) caused by the integration of Kindred Biosciences, Inc. (KindredBio) and the animal health business of Bayer Aktiengesellschaft (Bayer), expected synergies and cost savings, product launches, the coronavirus (COVID-19) global pandemic, conflict involving Russia and Ukraine and the potential impact on our business and global economic conditions, reduction of debt, expectations relating to liquidity and sources of capital, our expected compliance with debt covenants, cost savings, expenses, and reserves relating to restructuring actions, our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:
•heightened competition, including from generics;
•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
•changes in regulatory restrictions on the use of antibiotics in farm animals;
•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
•consolidation of our customers and distributors;
•an outbreak of infectious disease carried by farm animals;
•the impact on our operations, the supply chain, customer demand, and our liquidity as a result of the COVID-19 global health pandemic;
•the potential impact on our business and global economic conditions resulting from the conflict involving Russia and Ukraine;
•the success of our R&D and licensing efforts;
•misuse, off-label or counterfeiting use of our products;
•unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;
•fluctuations in our business results due to seasonality and other factors;
•the impact of weather conditions and the availability of natural resources;
•risks related to the modification of foreign trade policy;
•risks related to currency rate fluctuations;
•our dependence on the success of our top products;
•the impact of customer exposure to rising costs and reduced customer income;
•the lack of availability or significant increases in the cost of raw materials;
•use of alternative distribution channels and the impact of increased or decreased sales to our channel distributors resulting in fluctuation in our revenues;
•risks related to the write-down of goodwill or identifiable intangible assets;
•risks related to the evaluation of animals;
•manufacturing problems and capacity imbalances;
2022 Q3 Form 10-Q | 4
elan-20220930_g1.jpg
•the impact of litigation, regulatory investigations, and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters;
•actions by regulatory bodies, including as a result of their interpretation of studies on product safety;
•risks related to tax expense or exposure;
•risks related to environmental, health and safety laws and regulations;
•risks related to our presence in foreign markets;
•challenges to our intellectual property rights or our alleged violation of rights of others;
•our dependence on sophisticated information technology and infrastructure and the impact of breaches of our information technology systems;
•the impact of increased regulation or decreased financial support related to farm animals;
•adverse effects of labor disputes, strikes, work stoppages, and the loss of key personnel or highly skilled employees;
•risks related to underfunded pension plan liabilities;
•our ability to complete acquisitions and successfully integrate the businesses we acquire, including KindredBio and the animal health business of Bayer (Bayer Animal Health);
•the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that will limit our operating flexibility; and
•risks related to certain governance provisions in our constituent documents.
See Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the United States (U.S.) Securities and Exchange Commission (SEC) (2021 Form 10-K), and Part II of this Form 10-Q, for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. If any of these risks materialize, or if any of the assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this quarterly report. Any forward-looking statement made by us in this quarterly report speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.


2022 Q3 Form 10-Q | 5
elan-20220930_g1.jpg
PART I

ITEM 1. FINANCIAL STATEMENTS

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Operations (Unaudited)
(in millions, except per-share data)
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Revenue$1,028 $1,131 $3,430 $3,652 
Costs, expenses and other:
Cost of sales472 502 1,465 1,622 
Research and development78 94 241 277 
Marketing, selling and administrative298 342 961 1,075 
Amortization of intangible assets
128 141 398 417 
Asset impairment, restructuring and other special charges
26 111 158 518 
Interest expense, net of capitalized interest60 60 179 181 
Other expense, net8 11 17 8 
1,070 1,261 3,419 4,098 
Income (loss) before income taxes(42)(130)11 (446)
Income tax expense (benefit)7 (26)34 (71)
Net loss$(49)$(104)$(23)$(375)
Loss per share:
Basic $(0.10)$(0.21)$(0.05)$(0.77)
Diluted$(0.10)$(0.21)$(0.05)$(0.77)
Weighted average shares outstanding:
Basic488.4 487.3 488.3 487.1 
Diluted488.4 487.3 488.3 487.1 
See notes to condensed consolidated financial statements.
2022 Q3 Form 10-Q | 6
elan-20220930_g1.jpg
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
(in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net loss$(49)$(104)$(23)$(375)
Other comprehensive income (loss):
Cash flow hedges, net of taxes62 4 179 52 
Foreign currency translation(418)(209)(973)(506)
Defined benefit pension and retiree health benefit plans, net of taxes(2)(6)(4)5 
Other comprehensive loss, net of taxes(358)(211)(798)(449)
Comprehensive loss$(407)$(315)$(821)$(824)
See notes to condensed consolidated financial statements.

2022 Q3 Form 10-Q | 7
elan-20220930_g1.jpg
Elanco Animal Health Incorporated
Condensed Consolidated Balance Sheets
(in millions, except share data)
September 30, 2022December 31, 2021
(Unaudited)
Assets 
Current Assets
Cash and cash equivalents$460 $638 
Accounts receivable, net of allowances of $10 (2022) and $12 (2021)
804 833 
Other receivables224 195 
Inventories1,340 1,373 
Prepaid expenses and other326 237 
Total current assets3,154 3,276 
Noncurrent Assets
Goodwill5,716 6,172 
Other intangibles, net4,766 5,587 
Other noncurrent assets376 387 
Property and equipment, net of accumulated depreciation of $696 (2022) and $1,041 (2021)
936 1,061 
Total assets$14,948 $16,483 
Liabilities and Equity
Current Liabilities
Accounts payable$350 $418 
Employee compensation136 185 
Sales rebates and discounts298 316 
Current portion of long-term debt394 294 
Other current liabilities435 430 
Total current liabilities1,613 1,643 
Noncurrent Liabilities
Long-term debt5,507 6,025 
Accrued retirement benefits 240 271 
Deferred taxes618 745 
Other noncurrent liabilities225 261 
Total liabilities8,203 8,945 
Commitments and Contingencies
Equity
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued
— — 
Common stock, no par value, 5,000,000,000 shares authorized, 474,124,115 and 473,119,786 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively
— — 
Additional paid-in capital8,724 8,696 
Accumulated deficit(972)(949)
Accumulated other comprehensive loss(1,007)(209)
Total equity6,745 7,538 
Total liabilities and equity$14,948 $16,483 
See notes to condensed consolidated financial statements.
2022 Q3 Form 10-Q | 8
elan-20220930_g1.jpg
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Equity (Unaudited)
(Dollars and shares in millions)
Common StockAccumulated Other Comprehensive Income (Loss)
SharesAmountAdditional Paid-in CapitalAccumulated DeficitCash Flow Hedge Gain (Loss)Foreign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
December 31, 2020
471.9 $— $8,650 $(477)$(61)$360 $4 $303 $8,476 
Net loss— — — (61)— — — — (61)
Other comprehensive income (loss), net of tax— — — — 53 (466)8 (405)(405)
Stock compensation — — 15 — — — — — 15 
Issuance of stock under employee stock plans, net1.1 — (18)— — — — — (18)
March 31, 2021473.0 — 8,647 (538)(8)(106)12 (102)8,007 
Net loss— — — (210)— — — — (210)
Other comprehensive income (loss), net of tax— — — — (5)169 3 167 167 
Stock compensation— — 16 — — — — — 16 
June 30, 2021473.0 — 8,663 (748)(13)63 15 65 7,980 
Net loss— — — (104)— — — — (104)
Other comprehensive income (loss), net of tax— — — — 4 (209)(6)(211)(211)
Stock compensation— — 17 — — — — — 17 
September 30, 2021473.0 $— $8,680 $(852)$(9)$(146)$9 $(146)$7,682 
December 31, 2021
473.1 $— $8,696 $(949)$25 $(253)$19 $(209)$7,538 
Net income— — — 48 — — — — 48 
Other comprehensive income (loss), net of tax— — — — 109 (85)(1)23 23 
Stock compensation— — 14 — — — — — 14 
Issuance of stock under employee stock plans, net1.0 — (11)— — — — — (11)
March 31, 2022474.1 — 8,699 (901)134 (338)18 (186)7,612 
Net loss— — — (22)— — — — (22)
Other comprehensive income (loss), net of tax— — — — 8 (470)(1)(463)(463)
Stock compensation— — 17 — — — — — 17 
Issuance of stock under employee stock plans, net— — (4)— — — — — (4)
June 30, 2022474.1 — 8,712 (923)142 (808)17 (649)7,140 
Net loss— — — (49)— — — — (49)
Other comprehensive income (loss), net of tax— — — — 62 (418)(2)(358)(358)
Stock compensation— — 13 — — — — — 13 
Issuance of stock under employee stock plans, net— — (1)— — — — (1)
September 30, 2022474.1 $— $8,724 $(972)$204 $(1,226)$15 $(1,007)$6,745 

See notes to condensed consolidated financial statements.
2022 Q3 Form 10-Q | 9
elan-20220930_g1.jpg
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Nine Months Ended September 30,
 20222021
Cash Flows from Operating Activities
Net loss$(23)$(375)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization514 542 
Deferred income taxes(36)(119)
Stock-based compensation expense44 48 
Asset impairment and write-down charges87 334 
Loss on sale of assets3 — 
Loss (gain) on divestiture(3)2 
Inventory fair value step-up amortization— 64 
Loss on extinguishment of debt19 — 
Proceeds from interest rate swap settlements207 — 
Changes in operating assets and liabilities, net of acquisitions
(384)(243)
Other non-cash operating activities, net11 7 
Net Cash Provided by Operating Activities439 260 
Cash Flows from Investing Activities
Net purchases of property and equipment(71)(60)
Cash paid for acquisitions, net of cash acquired— (342)
Proceeds from site divestitures11 — 
Purchases of intangible assets(11)(35)
Purchases of software(23)(11)
Other investing activities, net(9)(8)
Net Cash Used for Investing Activities(103)(456)
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt425 500 
Proceeds from revolving credit facility563 500 
Repayments of long-term borrowings(607)(555)
Repayments of revolving credit facility(813)(250)
Debt issuance costs(2)(1)
Early redemption and tender premiums paid(14)— 
Other net financing transactions with Lilly — (11)
Other financing activities, net(17)(17)
Net Cash (Used for) Provided by Financing Activities(465)166 
Effect of exchange rate changes on cash and cash equivalents(49)(23)
Net decrease in cash and cash equivalents(178)(53)
Cash and cash equivalents at January 1638 506 
Cash and cash equivalents at September 30$460 $453 

See notes to condensed consolidated financial statements.
2022 Q3 Form 10-Q | 10
elan-20220930_g1.jpg
Elanco Animal Health Incorporated
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Tables present dollars and shares in millions, except per-share and per-unit data)

Note 1. Background

Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a portfolio of approximately 200 brands to pet owners, veterinarians and farm animal producers in more than 90 countries. Our products are generally sold worldwide directly to wholesalers, distributors, and independent retailers. Certain products are also sold directly to farm animal producers and veterinarians. We have a diversified business of products across species consisting of: dogs and cats (collectively, pet health) and cattle, poultry, swine and aqua (collectively, farm animal).

Elanco was incorporated in Indiana on September 18, 2018, and prior to that was a business unit of Eli Lilly and Company (Lilly).

Note 2. Basis of Presentation and Summary of Significant Accounting Policies

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the U.S. Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2021 included in our Form 10-K filed with the SEC on February 28, 2022 (2021 Form 10-K). In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2022 or any other future period.

In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.

The significant accounting policies set forth in Note 3 to the consolidated financial statements in our 2021 Form 10-K appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to goodwill and the adoption of the standard that was effective January 1, 2022 as described in Note 3: Implementation of New Financial Accounting Pronouncements.

Goodwill

Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. We evaluate goodwill for impairment at least annually and when certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment. We begin by assessing qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying value. Based on that qualitative assessment, if we conclude that it is more likely than not that the fair value of our single reporting unit is less than its carrying value, we conduct a quantitative goodwill impairment test, which involves comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimate the fair value of our single reporting unit using a combination of the income and market approach. If the carrying value of the reporting unit exceeds its estimated fair value, we recognize an impairment loss for the difference.

During the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a quantitative goodwill impairment test. As of September 30, 2022, our single reporting unit was tested for impairment using the quantitative approach described above, resulting in an estimated fair value that exceeded the carrying amount by more than 20%. Therefore, no impairment existed with respect to our goodwill.
2022 Q3 Form 10-Q | 11
elan-20220930_g1.jpg
Note 3. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
ASU 2021-10, Government Assistance (Topic 832)
The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.The adoption of this guidance did not have a material impact on our consolidated financial statements.

The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.
Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur.

Note 4. Revenue

Our sales rebates and discounts are based on specific agreements. The most significant of our sales rebate and discount programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs, and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of September 30, 2022 and 2021, the aggregate liability for sales rebates and discounts for these countries represented approximately 76% and 72%, respectively, of our total liability.

2022 Q3 Form 10-Q | 12
elan-20220930_g1.jpg
The following table summarizes the activity in our global sales rebates and discounts liability:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$284 $303 $316 $295 
Reduction of revenue169 163 524 516 
Payments(143)(146)(525)(489)
Foreign currency translation adjustments(12)(4)(17)(6)
Ending balance$298 $316 $298 $316 

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2022 and 2021 for product shipped in previous periods were not material.

Actual global product returns were approximately 1% and 2% of net revenue for the three months ended September 30, 2022 and 2021, respectively. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2022 and 2021.

Disaggregation of Revenue

The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Pet Health$471 $527 $1,722 $1,857 
Farm Animal:
Cattle227 250 722 735 
Poultry176 179 529 536 
Swine95 110 284 346 
Aqua47 44 132 111 
Total Farm Animal545 583 1,667 1,728 
Contract Manufacturing (1)
12 21 41 67 
Revenue$1,028 $1,131 $3,430 $3,652 
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.

Note 5. Acquisitions, Divestitures and Other Arrangements

KindredBio Acquisition

On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that developed innovative biologics focused on saving and improving the lives of pets. The acquisition further accelerates our pet health expansion, particularly by expanding our presence in dermatology.

The transaction was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of the acquisition are included in our condensed consolidated financial statements from the date of acquisition.

2022 Q3 Form 10-Q | 13
elan-20220930_g1.jpg
In connection with the merger agreement, we acquired all outstanding stock of KindredBio for $9.25 per share, or an aggregate cash purchase consideration of $444 million. We utilized our revolving credit facility and cash on hand to finance the acquisition.

On May 5, 2021, we signed an agreement with KindredBio to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. We calculated the fair value of the liability associated with that agreement using an income approach leveraging the estimated sales royalty, sales milestone and technical milestone payments avoided, and settled the $29 million liability upon the closing of our acquisition of KindredBio.

Revenue and loss from KindredBio included in our condensed consolidated statements of operations for the three and nine months ended September 30, 2022 were immaterial.

The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 27, 2021
Cash and cash equivalents$31 
Other net working capital13 
Property and equipment33 
Intangible assets, primarily acquired in-process research and development (IPR&D)333 
Deferred income taxes, net(30)
Total identifiable net assets380 
Goodwill35 
Settlement of liability related to previous license agreement29 
Total consideration transferred$444 

The valuation of assets acquired and liabilities assumed was finalized during the third quarter of 2022. The measurement period adjustments recorded during 2022, which were made to reflect the facts and circumstances in existence as of the acquisition date, primarily related to changes in the estimated fair value of acquired IPR&D and minor tax and working capital adjustments. The net impact of these adjustments was not material.

Property and equipment is mostly comprised of land, buildings, equipment (including laboratory equipment, furniture and fixtures, and computer equipment), and construction in progress. The estimated fair value of real and personal property was determined using the sales comparison data valuation technique, to the extent that market data for similar assets was available. When market pricing data was not available for a given asset or asset class, the direct replacement cost method was used.

The estimated fair values of acquired IPR&D were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors.

The goodwill recognized from this acquisition is primarily attributable to KindredBio's assembled workforce and expected synergies. The majority of goodwill associated with this acquisition is not deductible for tax purposes.


2022 Q3 Form 10-Q | 14
elan-20220930_g1.jpg
Divestitures

Microbiome R&D platform carve-out

In April 2022, we signed an agreement to transfer assets associated with our microbiome R&D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retain a non-voting, minority stake in the company. Assets transferred include intellectual property and laboratory equipment. The book values of those assets were not material. In addition, we have entered into transitional services agreements with the company for certain services. We have determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results. During the nine months ended September 30, 2022, we recorded a gain on the disposal of approximately $3 million.

Shawnee and Speke

During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the planned transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx will manufacture existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which is included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets. The divestitures did not represent a strategic shift that has or will have a major effect on our operations and financial results, and therefore do not qualify for reporting as discontinued operations. See Note 6: Asset Impairment, Restructuring and Other Special Charges for further information.

Based on the terms of the agreements, we expect to receive aggregate gross cash proceeds of $78 million from the sales of Shawnee and Speke over a period of three years beginning in the second half of 2022. During the three months ended September 30, 2022, we received cash proceeds of $11 million. Receivables for the remaining expected cash proceeds are included in other receivables and other noncurrent assets on our condensed consolidated balance sheets.

Assets Held For Sale

Assets considered held for sale in connection with the Speke divestiture were included in the respective line items on our condensed consolidated balance sheets as follows:
December 31, 2021
Inventories$31 
Property and equipment, net50 
Total assets held for sale$81 
2022 Q3 Form 10-Q | 15
elan-20220930_g1.jpg
BexCaFe Arrangement

On June 9, 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to Bexacat, an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, Consolidation, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. The initial fair value of the contingent payments was calculated based on an income approach, with payments adjusted for probability of success and then discounted to a present value. There is no minimum payout due on the contingent consideration and the maximum payout is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&D asset because we concluded that it did not have an alternative future use. This amount is included in asset impairment, restructuring, and other special charges in our condensed consolidated statement of operations for the nine months ended September 30, 2022.

We paid $10 million to BexCaFe under the terms of this agreement during the three months ended September 30, 2022. Contingent consideration liabilities of $49 million are included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2022.

Subsequent to the effective date of the license agreement, our condensed consolidated financial statements include the assets, liabilities, operating results and cash flows of BexCaFe. Based on the guidance in ASC 810, income and expense between us and BexCaFe have been eliminated against the income or expense included in the financial statements of BexCaFe. The resulting amounts after the effect of these eliminations were included in our condensed consolidated financial statements for the three and nine months ended September 30, 2022 and were not material.

Note 6. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. As discussed further below, restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible assets and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.
2021 Restructuring Programs

In 2021, we announced two separate restructuring programs to improve operating efficiencies.

2022 Q3 Form 10-Q | 16
elan-20220930_g1.jpg
The actions proposed in January 2021 focused on streamlining processes and delivering increased efficiency in functional areas, while improving the productivity of our investments in innovation. As part of the restructuring plan, we closed our R&D sites in Manukau, New Zealand and Cuxhaven, Germany. We also reduced duplication and optimized structures in U.S. operations, marketing, manufacturing and quality central functions, and administrative areas. The restructuring resulted in the elimination of approximately 315 positions around the world. Activities related to this initiative resulted in adjustments of $1 million to reduce severance accruals and net charges of $44 million for the three and nine months ended September 30, 2021, respectively. The adjustments reflect a change in estimate resulting from negotiations. Restructuring charges under this program were substantially complete at the end of 2021.

The program announced in November 2021 included initiatives to consolidate certain international commercial operations into one organization, integrate our centralized global marketing organization into country level commercial organizations, transform and simplify our R&D organizational structure, and other organizational adjustments. In connection with the proposed restructuring, we eliminated 380 positions. During the nine months ended September 30, 2022, we recorded adjustments of $9 million to reduce severance accruals resulting from final negotiations and certain restructured employees filling open positions. Restructuring charges under this program were substantially complete as of September 30, 2022; however, we may continue to make adjustments to our severance accruals to reflect changes in estimates resulting from ongoing negotiations.

Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Restructuring charges (credits):
Severance and other costs (1)
$— $(2)$(9)$26 
Facility exit costs— — 2 — 
Acquisition related charges:
Transaction and integration costs (2)
27 30 77 141 
Non-cash and other items:
Asset impairment (3)
— 50 59 63 
Asset write-down (4)
(1)6 27 275 
Net periodic benefit income (Note 14)— (9)— (26)
Settlements and other (5)
— 36 2 39 
Total expense$26 $111 $158 $518 
(1)2022 credits primarily relate to adjustments resulting from the reversal of severance accruals associated with the November 2021 program. For the nine months ended September 30, 2021, charges primarily related to the restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.
(3)2022 includes a charge of $59 million related to the expensing of an IPR&D asset with no alternative future use licensed from BexCaFe during the second quarter. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. 2021 amounts represent the impact of adjustments to the fair value of certain IPR&D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&D project and fully impair the related asset, which was associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.
2022 Q3 Form 10-Q | 17
elan-20220930_g1.jpg
(4)2022 amounts primarily include the finalization of the write-down charge upon the final sale of the Speke manufacturing site. Asset write-down charges recorded in 2021 included the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the Speke manufacturing site during the three months ended September 30, 2021. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Also included are charges recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with announced restructuring programs.
(5)Amounts recorded during the nine months ended September 30, 2022 represent a $2 million measurement period adjustment to the charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Amounts recorded during the three and nine months ended September 30, 2021 include the initial charge associated with the settlement of the liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&D asset acquired as part of the Bayer Animal Health acquisition.

The following table summarizes the activity in our reserves established in connection with restructuring activities:
Severance
Balance at December 31, 2020$130 
Charges41 
Reserve adjustments(15)
Cash paid(94)
Foreign currency translation adjustments(1)
Balance at September 30, 2021$61 
Balance at December 31, 2021$126 
Reserve adjustments(9)
Cash paid(71)
Foreign currency translation adjustments(5)
Balance at September 30, 2022$41 
These reserves are included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain country negotiations and regulations. As of September 30, 2022, we expect to pay approximately $34 million over the next 12 months. We believe that the reserves are adequate.

Note 7. Inventories

We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
September 30, 2022December 31, 2021
Finished products$612 $598 
Work in process542 565 
Raw materials and supplies240 256 
Total1,394 1,419 
Decrease to LIFO cost(54)(46)
Inventories$1,340 $1,373 

2022 Q3 Form 10-Q | 18
elan-20220930_g1.jpg
Note 8. Equity

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.

The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in current portion of long-term debt on the condensed consolidated balance sheets. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$471 $79 $550 
Less: Issuance costs19 3 22 
Net proceeds$452 $76 $528 

The senior amortizing notes have an aggregate principal amount of $79 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate is equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)

The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14 million shares or a maximum of 17 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period. The entire additional 3 million shares are included in diluted weighted average shares outstanding if the applicable market value is at or below $32.00 and the impact is not anti-dilutive.

2022 Q3 Form 10-Q | 19
elan-20220930_g1.jpg
Note 9. Debt

Long-term debt consisted of the following:
September 30, 2022December 31, 2021
Incremental Term Facility due 2025 (1)
$175 $— 
Incremental Term Facility due 2028495 499 
Incremental Term Facility due 2029 (2)
250 — 
Term Loan B due 2027 (3)
3,941 4,118 
Revolving Credit Facility— 250 
4.272% Senior Notes due 2023 (4)
344 750 
4.900% Senior Notes due 2028
750 750 
TEU Amortizing Notes due 202314 34 
Unamortized debt issuance costs(68)(82)
5,901 6,319 
Less current portion of long-term debt394 294 
Total long-term debt$5,507 $6,025 
(1)In June 2022, we entered into an incremental assumption agreement with Bank of America, N.A. supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $175 million. The new incremental term facility bears interest at the Secured Overnight Financing Rate (Term SOFR), including a credit spread adjustment, plus 175 basis points and is payable in full on June 30, 2025. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.

(2)In April 2022, we entered into an incremental assumption agreement with Farm Credit Mid-America, PCA supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $250 million maturing on April 19, 2029. The new incremental term facility bears interest at Term SOFR, including a credit spread adjustment, plus 175 basis points and will be payable in quarterly installments of principal and interest with a final balloon payment due on April 19, 2029. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.

(3)In September 2022, we repaid indebtedness outstanding under our Term Loan B. We paid $75 million in cash, composed of principal and accrued interest, resulting in a debt extinguishment loss of approximately $2 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations.

(4)In April 2022, we completed a tender offer and retired $406 million in aggregate principal amount of our 4.272% Senior Notes due August 28, 2023, resulting in a debt extinguishment loss of approximately $17 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations. The repayment was funded with proceeds received from a draw under our revolving credit facility.

We were in compliance with all of our debt covenants as of September 30, 2022.

Note 10. Financial Instruments and Fair Value

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of our customers on a regular basis, monitor economic conditions, and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.

A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value.

We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $28 million and $22 million as of September 30, 2022 and December 31, 2021, respectively. Unrealized net gains and losses on our investments for the three and nine months ended September 30, 2022 and 2021 were immaterial.
2022 Q3 Form 10-Q | 20
elan-20220930_g1.jpg

The following table summarizes the fair value information at September 30, 2022 and December 31, 2021 for foreign exchange contract assets (liabilities), investments, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2022
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$39 $— $39 $— $39 
Prepaid expense and other - forward-starting interest rate contracts designated as cash flow hedges3 — 3 — 3 
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges15 — 15 15 
Other noncurrent assets - investments10 10 — — 10 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(29)— (29)— (29)
Long-term debt, including current portion(5,969)— (5,686)— (5,686)
December 31, 2021
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$19 $— $19 $— $19 
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges8 — 8 — 8 
Other noncurrent assets - investments13 13 — — 13 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(20)— (20)— (20)
Long-term debt, including current portion(6,401)— (6,518)— (6,518)
We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.

Derivative Instruments and Hedging Activities

We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing activities section of the consolidated statements of cash flows. Our outstanding positions are discussed below.

2022 Q3 Form 10-Q | 21
elan-20220930_g1.jpg
Derivatives not designated as hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, and Chinese yuan. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2022 and December 31, 2021, we had outstanding foreign exchange contracts with aggregate notional amounts of $821 million and $1,212 million, respectively.

The amount of net losses on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Foreign exchange forward contracts (1)
$(5)$(2)$(20)$(29)

(1)These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.

Derivatives designated as hedges

We are subject to interest rate risk with regard to our existing floating-rate debt, and we utilize interest rate swap contracts to mitigate the variability in cash flows by effectively converting the floating-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated these swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Our outstanding forward-starting interest rate swaps have maturities ranging between 2023 and 2025 with aggregate notional amounts of $3,050 million and $3,800 million as of September 30, 2022 and December 31, 2021, respectively.

The amounts of net gains on cash flow hedges recorded, net of tax, in other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Forward-starting interest rate swaps$62 $4 $179 $52 

During the three months ended September 30, 2022 and 2021, net gains on cash flow hedges recorded in other comprehensive income (loss) included gains of $75 million and $4 million, respectively, related to mark-to-market adjustments. During the nine months ended September 30, 2022 and 2021, net gains on cash flow hedges recorded in other comprehensive income (loss) included gains of $218 million and $52 million, respectively, related to mark-to-market adjustments.

In April 2022 and September 2022, we took advantage of market opportunities to restructure our interest rate swap portfolio. We unwound the existing swaps and simultaneously entered into new agreements with the same notional amounts and covering the same tenors. As a result, we received cash settlements of $132 million and $75 million in the respective periods. These gains were initially recognized in accumulated other comprehensive loss and will be reclassified to interest expense, net of capitalized interest over the period during which the related interest payments will be made.




2022 Q3 Form 10-Q | 22
elan-20220930_g1.jpg
During the three and nine months ended September 30, 2022, we reclassified $13 million and $22 million, respectively, of gains relating to our terminated interest rate swaps from accumulated other comprehensive loss to interest expense, net of capitalized interest. Additionally, as a result of the April 2022 interest rate swap settlement, other comprehensive income (loss) for the nine months ended September 30, 2022 included a $17 million reclassification of a stranded tax benefit from accumulated other comprehensive loss, based on our policy to reclassify income tax effects from accumulated other comprehensive loss using the portfolio approach. Other than the reclassification of the stranded tax benefit, there was no tax effect recorded in relation to our cash flow hedges for the three and nine months ended September 30, 2022 and 2021 after the application of the U.S. valuation allowance. See Note 11: Income Taxes for further discussion.

During the three months ended September 30, 2022 and 2021, we reclassified $2 million and $8 million, respectively, of net losses into interest expense, net of capitalized interest in our condensed consolidated statements of operations. During the nine months ended September 30, 2022 and 2021, we reclassified $12 million and $22 million, respectively, of net losses into interest expense. Over the next 12 months, we expect to reclassify a gain of $106 million, which includes $103 million relating to the interest rate swap settlements, to interest expense, net of capitalized interest.

Note 11. Income Taxes

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Income tax expense (benefit)$7 $(26)$34 $(71)
Effective tax rate(17.1)%20.0 %315.6 %15.9 %

We were included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.

For the three and nine months ended September 30, 2022, we recognized income tax expense of $7 million and $34 million, respectively. Our effective tax rate of (17.1)% and 315.6%, respectively, differs from the statutory income tax rate largely due to changes in earnings mix between periods resulting in projected losses in the U.S. and projected earnings outside of the U.S. The U.S. federal and state jurisdictions are subject to valuation allowances. Income tax expense was partially offset by beneficial net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S. The income tax expense for the nine months ended September 30, 2022 was partially offset by the $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rate swaps during the period and net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S.

For the three and nine months ended September 30, 2021, we recognized an income tax benefit of $26 million and $71 million, respectively. For the three months ended September 30, 2021, our effective tax rate of 20.0% differs from the statutory income tax rate primarily due to preliminary accounting for the acquisition of KindredBio, which caused a partial release of the U.S. federal valuation allowance, as well as profits being located in jurisdictions with higher statutory tax rates. For the nine months ended September 30, 2021, our effective tax rate of 15.9% differs from the statutory income tax rate primarily because the U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances.

2022 Q3 Form 10-Q | 23
elan-20220930_g1.jpg
Note 12. Commitments and Contingencies

Legal Matters

We are party to various legal actions in the normal course of business. We are not currently subject to a significant claim other than the lawsuits noted below.

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. We filed a motion to dismiss on January 13, 2021. On August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint, and we intend to oppose the plaintiffs' motion. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

On October 16, 2020, a shareholder class action lawsuit captioned Saffron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or 5.00% TEUs issued in connection with the public offering. This case was previously stayed in deference to Hunter v. Elanco Animal Health Inc. On October 24, 2022, we filed a motion to dismiss. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.
Claims seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the Seresto collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. We are vigorously defending these lawsuits.

Further, in March 2021, a U.S. House of Representatives subcommittee chair requested that Elanco produce certain documents and information related to the Seresto collar and further made a request to temporarily recall Seresto collars from the market. On June 15, 2022, the subcommittee held a hearing at which our President and Chief Executive Officer (CEO) testified. During and after the hearing, the subcommittee chair repeated his request that Elanco voluntarily recall the collars and also requested that the Environmental Protection Agency (EPA) commence administrative proceedings that would allow the EPA to remove Seresto from the market.

2022 Q3 Form 10-Q | 24
elan-20220930_g1.jpg
Seresto is a pesticide registered with the EPA. A non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. The EPA is considering this petition and asked for public comment. We submitted a comment to the EPA supporting the safety profile of Seresto. Data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. Therefore, we believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for Seresto, and it remains available to consumers globally.

In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful exclusive dealing and tying of its flea and tick products Advantage, Advantix, and Seresto and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive dealing related to Advantage and Advantix and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. We intend to defend our position vigorously. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. We accrue for liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2022 and December 31, 2021, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We are not currently subject to a significant claim other than the lawsuits noted above.

Regulatory Matters

On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. Management believes that its actions were appropriate.

Other Commitments

As of September 30, 2022, we have a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. The increase in estimated minimum lease payments in comparison to prior periods is primarily due to higher expected construction and debt costs. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025.

The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. We expect to refund approximately $15 million to the developer within the next three months, and this amount is included in other current liabilities on our condensed consolidated balance sheet as of September 30, 2022. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive is included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning at the commencement date and offset future rent expense.

2022 Q3 Form 10-Q | 25
elan-20220930_g1.jpg
Note 13. Geographic Information

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both pets and farm animals. Consistent with our operational structure, our CEO, as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.

Our products include AviPro™, Baytril™, Cydectin™, Catosal™, Denagard™, Maxiban™, Rumensin™, Pulmotil™, and other products for livestock and poultry, as well as Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family), Credelio™, Duramune™, Galliprant™, Interceptor™ Plus, Seresto, Trifexis™, and other products for pets.

We have a single customer that accounted for 12% and 11% of revenue for the three months ended September 30, 2022 and 2021, respectively, and 11% and 9% of revenue for the nine months ended September 30, 2022 and 2021, respectively. Product sales with this customer resulted in accounts receivable of $80 million and $74 million as of September 30, 2022 and December 31, 2021, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

Selected geographic area information was as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenue
United States$475 $507 $1,537 $1,621 
International553 624 1,893 2,031 
Revenue$1,028 $1,131 $3,430 $3,652 

2022 Q3 Form 10-Q | 26
elan-20220930_g1.jpg
Note 14. Retirement Benefits

The following table summarizes net periodic benefit cost (income) relating to our defined benefit pension plans:

Three Months Ended September 30,
Nine Months Ended September 30,
2022202120222021
Service cost$4 $4 $11 $14 
Interest cost1 1 3 2 
Expected return on plan assets(2)(2)(5)(5)
Amortization of prior service cost(1)(1)(3)(5)
Amortization of net actuarial loss— — — 1 
Net curtailments and settlements (Note 6)— (9)— (26)
Net periodic benefit cost (income)$2 $(7)$6 $(19)

The components of net periodic benefit cost (income) other than service cost and net curtailments and settlements are included in other expense, net in our condensed consolidated statements of operations. Net curtailments and settlements are included in asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.

Note 15. Loss Per Share

We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts (see Note 8: Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings (loss) per share.

Basic and diluted loss per share are calculated as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net loss available to common shareholders$(49)$(104)$(23)$(375)
Determination of shares:
Weighted average common shares outstanding488.4 487.3488.3 487.1
Assumed conversion of dilutive common stock equivalents (1)
— — — — 
Diluted weighted average shares outstanding488.4 487.3488.3 487.1
Loss per share (2)
Basic$(0.10)$(0.21)$(0.05)$(0.77)
Diluted$(0.10)$(0.21)$(0.05)$(0.77)
(1)For periods with a reported net loss, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2022 and 2021, approximately 4.4 million and 3.7 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2022 and 2021, approximately 2.6 million and 3.9 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.
(2)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.
2022 Q3 Form 10-Q | 27
elan-20220930_g1.jpg
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Form 10-Q. Certain statements in this Item 2 of Part I of this Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" of this Form 10-Q, in Item 1A, "Risk Factors" of Part II of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our 2021 Form 10-K, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.

Overview

Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives.

On August 27, 2021, we acquired KindredBio, a biopharmaceutical company that developed innovative biologics focused on saving and improving the lives of pets. We had previously signed an agreement with KindredBio in the second quarter of 2021 to acquire exclusive global rights to KIND-030, a monoclonal antibody in development for the treatment and prevention of canine parvovirus. The acquisition of KindredBio further accelerates our opportunity for expansion in pet health, notably by expanding our research efforts in dermatology. See Note 5: Acquisitions, Divestitures and Other Arrangements to the condensed consolidated financial statements for additional information on the acquisition. Subsequent to the acquisition date, our consolidated financial statements include the assets, liabilities, operating results and cash flows of KindredBio.

On August 1, 2020, we completed the acquisition of Bayer Animal Health. The acquisition expanded our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our product portfolio and pipeline have been enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure.

We offer a diverse portfolio of approximately 200 brands that make us a trusted partner to pet owners, veterinarians and farm animal producers. Our products are generally sold worldwide to third-party distributors and independent retailers, and directly to farm animal producers and veterinarians. With the acquisition of Bayer Animal Health, we have expanded our presence in retail and e-commerce channels in order to meet pet owners where they want to purchase.

We operate our business in a single segment directed at fulfilling our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. We advance our vision by offering products in these two primary categories:

Pet Health: Our pet health portfolio is focused on parasiticides, vaccines and therapeutics. We have one of the broadest parasiticide portfolios in the pet health sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. Our Seresto and Advantage Family products are over-the-counter treatments for the elimination and prevention, respectively, of fleas and ticks, and complement our prescription parasiticide products, Credelio, Interceptor Plus, and Trifexis. Our vaccines portfolio provides differentiated prevention coverage for a number of important pet health risks and is available in the U.S. only. In therapeutics, we have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our Galliprant product is one of the fastest growing osteoarthritis treatments in the U.S. Additionally, we have products that offer treatment for otitis (ear infections) with Claro, as well as treatments for certain cardiovascular and dermatology indications.
2022 Q3 Form 10-Q | 28
elan-20220930_g1.jpg

Farm Animal: Our farm animal portfolio consists of products designed to prevent, control and treat health challenges primarily focused on cattle (beef and dairy), swine, poultry, and aquaculture (cold and warm water) production. Our products include medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes, among others. We have a wide range of farm animal products, including Rumensin and Baytril, both of which are used extensively in ruminants (e.g., cattle, sheep and goats). In poultry, our Maxiban product, is a valuable offering for the control and prevention of intestinal disease.
A summary of our 2022 revenue and net income (loss) compared with the same period in 2021 is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)2022202120222021
Revenue$1,028 $1,131 $3,430 $3,652 
Net loss(49)(104)(23)(375)
We conduct business in more than 90 countries around the world and significant portions of our revenue and expenses are recorded in currencies other than the U.S. dollar. Accordingly, in any period, our reported revenue, expenses and resulting earnings (loss) are impacted by changes in the exchange rates of those currencies relative to the U.S. dollar.

Increases or decreases in inventory levels at our channel distributors can positively or negatively impact our quarterly and annual revenue results, leading to variations in revenues. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, and procedures and environmental factors beyond our control, including weather conditions and the COVID-19 global pandemic.

Key Trends and Conditions Affecting Our Results of Operations

Industry Trends

The animal health industry, which includes both pets and farm animals, is a growing industry that benefits billions of people worldwide.

We believe that factors influencing growth in demand for pet medicines and vaccines include:

•increased pet ownership globally;
•pets living longer; and
•increased pet spending as pets are viewed as members of the family by owners.

As demand for animal protein grows, farm animal health is becoming increasingly important. We believe that factors influencing growth in demand for farm animal medicines and vaccines include:

•two in three people needing improved nutrition;
•increased global demand for protein, particularly poultry and aquaculture;
•natural resource constraints, such as scarcity of arable land, fresh water and increased competition for cultivated land, driving the need for more efficient food production;
•loss of productivity due to farm animal disease and death;
•increased focus on food safety and food security; and
•human population growth, increased standards of living, particularly in many emerging markets, and increased urbanization.

2022 Q3 Form 10-Q | 29
elan-20220930_g1.jpg
Growth in farm animal nutritional health products (enzymes, probiotics and prebiotics) is influenced, among other factors, by demand for antibiotic alternatives that can promote animal health and increase productivity.

Factors Affecting Our Results of Operations

Global Macroeconomic Environment

Our operations are conducted globally, and we sell our products in over 90 countries. As such, we are exposed to and are impacted by various global macroeconomic factors. Global economic conditions continue to create uncertainty, most notably due to the Russia-Ukraine conflict, the COVID-19 pandemic, supply chain disruptions, and rising inflation. Continued evolution of these conditions has led to economic slowdowns in certain countries and/or regions. It has also led to volatility in consumer behavior, which has reduced demand due to consumption decreases and retailer destocking, particularly impacting our parasiticide products.

Russia-Ukraine Conflict

In February 2022, Russia commenced military action against Ukraine. In response, the U.S. and certain other countries imposed and continue to impose significant sanctions and export controls against Russia, Belarus and certain individuals and entities connected to Russian or Belarusian political, business, and financial organizations. The U.S. and certain other countries could impose further sanctions, trade restrictions, and other retaliatory actions if the conflict continues or worsens. The broader consequences of the conflict, including related inflationary pressures, geopolitical tensions, additional retaliatory actions taken by the U.S. and other countries, and any counter retaliatory actions by Russia or Belarus in response, including, for example, potential cyberattacks or the disruption of energy and commodity exports, are likely to cause regional instability and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy. The situation remains uncertain and it is difficult to predict the impact that the conflict and actions taken in response to the conflict will have on our business; however, they could increase our costs, disrupt our supply chain, reduce our sales and earnings, or otherwise adversely affect our business and results of operations.

As a global animal health leader, we have an obligation to support the health of animals and people. At the center of that work is ensuring access and availability of food. At this time, we are limiting our business in Russia to only the essential products that support these needs, while complying with all imposed sanctions. We do not manufacture products or source any materials from companies in Russia for use in our products, nor do we conduct business with the Russian government. During the nine months ended September 30, 2022, revenue to Russian and Ukrainian customers represented approximately 1% of our consolidated revenue. Assets held in Russia as of September 30, 2022 represented less than 1% of our consolidated assets.

COVID-19 Pandemic

We continue to closely monitor the impact of the COVID-19 pandemic, including its variants, and the related economic effects on all aspects of our business, including impacts on our operations, supply chain, and customer demand. The extent to which the COVID-19 pandemic may impact our financial condition and results of operations remains uncertain and is dependent on developments that are out of our control, including measures being taken by authorities to mitigate against the spread of COVID-19, such as the lockdowns in China, the emergence of new variants and the availability and successful administration of effective vaccines and boosters. We cannot predict the impact that the ongoing COVID-19 pandemic will have on our employees, customers, vendors and suppliers; however, the COVID-19 pandemic has had and may continue to have an adverse impact on our business if these parties continue to experience negative effects.

2022 Q3 Form 10-Q | 30
elan-20220930_g1.jpg
Supply Chain
We continue to experience disruption and volatility in our global supply chain network. This disruption, combined with increased demand for key raw materials and labor constraints, has also impacted our suppliers, resulting in shortages of raw materials or components required to manufacture our products. We continue to work closely with suppliers and freight partners to mitigate impacts to our operations and customers, including the addition of new transportation routes, targeted increases of certain safety stocks, and alternative sources of materials. Although we regularly monitor the financial health of companies in our supply chain, prolonged financial hardship on our suppliers and labor shortages could continue to disrupt our ability to obtain key raw materials, adversely affecting our operations. The global industry freight environment has experienced, and could continue to experience, lead time disruptions and high shipping costs, negatively impacting our profitability.

Inflation
We are experiencing, and expect to continue to experience, inflationary pressures due to, among other things, the geopolitical events and macroeconomic factors noted above. Increased inflation rates primarily impact us by increasing our costs, including raw materials, labor, energy, transportation, and other input costs, adversely affecting our profit margins, operating results, and cash flows.

Our Acquisitions of Bayer Animal Health and KindredBio

We have incurred and expect to continue to incur expenses in connection with our acquisitions of Bayer Animal Health and KindredBio, including fees for professional services such as legal, accounting, consulting, and other advisory fees and expenses. Expenses incurred in 2021 and thus far in 2022 are primarily related to integration activities. In addition, we have incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics and to expand administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources, and manufacturing, to replace services previously provided by the former parent company of Bayer Animal Health. We anticipate that these additional costs will be partially offset by expected synergies.

Product Development and New Product Launches

A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition, and the expansion of the use of our existing products. We believe we are an industry leader in animal health R&D, with a track record of product innovation, business development and commercialization.

Competition

We face intense competition. Principal methods of competition vary depending on the particular region, species, product category, or individual product. Some of these methods include new product development, including generic alternatives to our products, quality, price, service and promotion.

Our primary competitors include animal health medicines and vaccines companies such as Zoetis Inc.; Boehringer Ingelheim Vetmedica, Inc., the animal health division of Boehringer Ingelheim GmbH; and Merck Animal Health, the animal health division of Merck & Co., Inc. We also face competition globally from manufacturers of generic drugs, as well as from producers of nutritional health products, such as DSM Nutritional Products AG and Danisco Animal Nutrition, the animal health division of E.I. du Pont de Nemours and Company, a subsidiary of DowDuPont, Inc. There are also several new start-up companies working in the animal health area. In addition, we compete with numerous other producers of animal health products throughout the world.

Productivity

Our results during the periods presented have benefited from operational and productivity initiatives implemented following recent acquisitions and in response to changing market demand for antibiotics and other headwinds.

2022 Q3 Form 10-Q | 31
elan-20220930_g1.jpg
Prior to the acquisition of Bayer Animal Health, our acquisitions within the last six years added in the aggregate $1.4 billion in revenue, 4,600 full-time employees, and 12 manufacturing and eight R&D sites. The acquisitions of Bayer Animal Health on August 1, 2020 and KindredBio on August 27, 2021 added 3,950 full-time employees, 10 manufacturing sites, and five R&D sites (before company-wide restructuring activities initiated in 2020 and 2021). In addition, from 2015 to 2021, changing market demand for antibiotics and other headwinds, such as competition with generics and innovation, affected some of our highest gross margin products, resulting in a change to our product mix and driving operating margin lower. In response, we implemented a number of initiatives across the manufacturing, R&D and marketing, selling and administrative functions. Our manufacturing cost savings strategies included improving manufacturing processes and headcount through lean manufacturing (minimizing waste while maintaining productivity), closing and selling manufacturing sites, consolidating our CMO network, strategically insourcing certain projects, and pursuing cost savings opportunities through alternate sources of supply. Additional cost savings have resulted from reducing the number of R&D sites, sales force consolidation and reducing discretionary and other general and administrative operating expenses.

Seasonality

The results of our pet health business may fluctuate due to seasonality. For example, based upon historical results, approximately 70% and 60% of total annual revenue contributed by our higher-margin parasiticide products Seresto and Advantage Family, respectively, has occurred during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere. Therefore, a period-to-period comparison of our historical results may not be meaningful and fluctuations in total revenue for our pet health products are not necessarily an indication of future performance.

Foreign Exchange Rates

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 90 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. During the nine months ended September 30, 2022 and 2021, approximately 51% of our revenue was denominated in foreign currencies. As we operate in multiple foreign currencies, including the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, Chinese yuan, and other currencies, changes in those currencies relative to the U.S. dollar impact our revenue, cost of sales and expenses, and consequently, net income. These fluctuations may also affect the ability to buy and sell our products between markets impacted by significant exchange rate variances. Currency movements decreased revenue by 5% and 4% during the three and nine months ended September 30, 2022, respectively, compared to the same period in 2021. Currency movements increased revenue by 1% and 2% during the three and nine months ended September 30, 2021, respectively, compared to the same period in 2020.

2022 Q3 Form 10-Q | 32
elan-20220930_g1.jpg
Results of Operations

The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Revenue $1,028 $1,131 (9)%$3,430 $3,652 (6)%
Costs, expenses and other:
Cost of sales472 502 (6)%1,465 1,622 (10)%
% of revenue46 %44 %2 %43 %44 %(1)%
Research and development78 94 (17)%241 277 (13)%
% of revenue8 %8 %— %7 %8 %(1)%
Marketing, selling and administrative298 342 (13)%961 1,075 (11)%
% of revenue29 %30 %(1)%28 %29 %(1)%
Amortization of intangible assets128 141 (9)%398 417 (5)%
% of revenue12 %12 %— %12 %11 %— %
Asset impairment, restructuring and other special charges26 111 (77)%158 518 (69)%
Interest expense, net of capitalized interest60 60 — %179 181 (1)%
Other expense, net8 11 (27)%17 8 113 %
Income (loss) before income taxes(42)(130)68 %11 (446)102 %
% of revenue(4)%(11)%7 %— %(12)%12 %
Income tax expense (benefit)7 (26)127 %34 (71)148 %
Net loss$(49)$(104)53 %$(23)$(375)94 %
Certain amounts and percentages may reflect rounding adjustments.

Disaggregated Revenue

On a global basis, our revenue by product category for the three months ended September 30, 2022 and 2021 is summarized as follows:
Revenue% of Total RevenueIncrease (Decrease)
(Dollars in millions)2022202120222021$ Change% Change
CER (1)
Pet Health$471 $527 46 %47 %$(56)(11)%(7)%
Farm Animal545 583 53 %52 %(38)(7)%— %
Subtotal1,016 1,110 99 %98 %(94)(8)%(3)%
Contract Manufacturing (2)
12 21 1 %2 %(9)(43)%(36)%
Total$1,028 $1,131 100 %100 %(103)(9)%(4)%
Note: Numbers may not add due to rounding
(1)Constant exchange rate (CER), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.
(2)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.

2022 Q3 Form 10-Q | 33
elan-20220930_g1.jpg
On a global basis, the effect of price, foreign exchange rates and volume on changes in revenue for the three months ended September 30, 2022 and 2021 was as follows:

Three months ended September 30, 2022
(Dollars in millions)

Revenue		PriceFX RateVolumeTotalCER
Pet Health$471 4%(4)%(11)%(11)%(7)%
Farm Animal545 3%(7)%(3)%(7)%—%
Subtotal1,016 3%(5)%(6)%(8)%(3)%
Contract Manufacturing12 —%(6)%(36)%(43)%(36)%
Total$1,028 3%(5)%(7)%(9)%(4)%

Three months ended September 30, 2021
(Dollars in millions)

Revenue		PriceFX Rate
Volume (1)
TotalCER
Pet Health$527 5%1%25%31%30%
Farm Animal583 —%1%22%23%22%
Subtotal1,110 3%1%23%27%26%
Contract Manufacturing21 —%—%31%31%31%
Total$1,131 2%1%24%27%26%
Note: Numbers may not add due to rounding
(1)Impact of 2021 revenue from Bayer Animal Health is reflected in volume.

On a global basis, our revenue by product category for the nine months ended September 30, 2022 and 2021 is summarized as follows:

Revenue% of Total RevenueIncrease (Decrease)
(Dollars in millions)2022202120222021$ Change% ChangeCER
Pet Health$1,722 $1,857 50 %51 %$(135)(7)%(4)%
Farm Animal1,667 1,728 49 %47 %(61)(4)%1 %
Subtotal3,389 3,585 99 %98 %(196)(5)%(1)%
Contract Manufacturing
41 67 1 %2 %(26)(39)%(34)%
Total$3,430 $3,652 100 %100 %(222)(6)%(2)%
Note: Numbers may not add due to rounding

On a global basis, the effect of price, foreign exchange rates and volume on changes in revenue for the nine months ended September 30, 2022 and 2021 was as follows:

Nine months ended September 30, 2022
(Dollars in millions)

Revenue		PriceFX RateVolumeTotalCER
Pet Health$1,722 2%(4)%(6)%(7)%(4)%
Farm Animal1,667 2%(5)%(1)%(4)%1%
Subtotal3,389 2%(4)%(3)%(5)%(1)%
Contract Manufacturing41 —%(3)%(34)%(39)%(34)%
Total$3,430 2%(4)%(4)%(6)%(2)%
2022 Q3 Form 10-Q | 34
elan-20220930_g1.jpg
Nine months ended September 30, 2021
(Dollars in millions)

Revenue		PriceFX Rate
Volume (1)
TotalCER
Pet Health$1,857 4%2%110%116%114%
Farm Animal1,728 1%2%38%41%39%
Subtotal3,585 2%2%68%72%70%
Contract Manufacturing67 —%—%31%31%31%
Total$3,652 2%2%67%71%69%
Note: Numbers may not add due to rounding
(1)Impact of 2021 revenue from Bayer Animal Health is reflected in volume.

Revenue

Pet Health revenue decreased $56 million, or 11%, for the three months ended September 30, 2022, driven by a decrease in volume and an unfavorable impact from foreign exchange rates, partially offset by an increase in price. On a constant currency basis, the decrease of 7% was primarily attributable to lower volumes from the overall deterioration in global macroeconomic conditions, which particularly impacted parasiticide sales in Europe and the U.S. retail channel as well as increased competition related to certain parasiticide products. The impact was partially offset by growth in our global pain portfolio.

Pet Health revenue decreased $135 million, or 7%, for the nine months ended September 30, 2022, driven by a decrease in volume and an unfavorable impact from foreign exchange rates, partially offset by an increase in price. On a constant currency basis, the decrease of 4% was primarily attributable to lower volumes from increased competition related to certain parasiticide products as well as the overall deterioration in global macroeconomic conditions, which particularly impacted parasiticide sales in the U.S. retail channel. The impact was partially offset by growth in our global pain portfolio.

Farm Animal revenue decreased by $38 million, or 7%, for the three months ended September 30, 2022, driven by an unfavorable impact from foreign exchange rates and a decrease in volume, partially offset by an increase in price. On a constant currency basis, revenue was flat due to increased demand for poultry products and strong aqua sales, fully offset by supply constraints related to certain cattle vaccines in the U.S. and a continued decline in demand in the international swine market, particularly in Asia.

Farm Animal revenue decreased by $61 million, or 4%, for the nine months ended September 30, 2022, driven by an unfavorable impact from foreign exchange rates and a decrease in volume, partially offset by an increase in price. On a constant currency basis, growth was driven by increased demand for aqua and poultry products, as well as increased demand for ruminant products internationally, most notably sheep products. These increases were partially offset by a continued decline in swine, particularly driven by market conditions in Asia and to a lesser extent competition in Europe, as well as the impact of generic competition on price for certain cattle brands and the impact of supply chain disruptions.

Cost of Sales
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Cost of sales$472 $502 (6)%$1,465 $1,622 (10)%
% of revenue46 %44 %43 %44 %

Cost of sales as a percentage of revenue increased for the three months ended September 30, 2022, primarily due to inflationary impacts on input costs, freight and conversion costs and unfavorable product mix, partially offset by price increases for certain products and improvements in manufacturing productivity.

Cost of sales as a percentage of revenue decreased for the nine months ended September 30, 2022, primarily due to amortization of the fair value adjustment of $64 million recorded from the acquisition of Bayer Animal Health in 2021. Excluding the $64 million fair value adjustment for the nine months ended September 30, 2021, cost of sales as a percentage of revenue would have been approximately 43%.
2022 Q3 Form 10-Q | 35
elan-20220930_g1.jpg

Research and Development
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Research and development$78 $94 (17)%$241 $277 (13)%
% of revenue8 %8 %7 %8 %

R&D expenses decreased $16 million and $36 million for the three and nine months ended September 30, 2022, respectively. R&D expenses were favorably impacted by cost savings realized as a result of 2021 restructuring activities, lower professional services costs due the rationalization of certain R&D projects, and the impact of foreign exchange.

Marketing, Selling and Administrative
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Marketing, selling and administrative$298 $342 (13)%$961 $1,075 (11)%
% of revenue29 %30 %28 %29 %

Marketing, selling and administrative expenses decreased $44 million and $114 million for the three and nine months ended September 30, 2022, respectively, primarily driven by disciplined cost management across the business, cost savings realized as a result of 2021 restructuring activities, changes in our promotional programs which resulted in a decrease in marketing expense, and the impact of foreign exchange, partially offset by increases in legal expenses during the periods.

Amortization of Intangible Assets
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Amortization of intangible assets$128 $141 (9)%$398 $417(5)%

Amortization of intangible assets decreased $13 million and $19 million for the three and nine months ended September 30, 2022, respectively, primarily due to the impact of foreign exchange rates.

Asset Impairment, Restructuring and Other Special Charges
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Asset impairment, restructuring and other special charges$26 $111 (77)%$158 $518(69)%

For additional information regarding our asset impairment, restructuring and other special charges, see Note 6: Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.

Asset impairment, restructuring and other special charges decreased $85 million for the three months ended September 30, 2022, primarily due to certain nonrecurring charges recorded during the three months ended September 30, 2021, including a $50 million impairment charge for an IPR&D asset that was subject to product rationalization as a result of observed efficacy results, a $26 million charge to establish a liability for future royalty and milestone payments relating to our canine parvovirus license agreement with KindredBio, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health.

2022 Q3 Form 10-Q | 36
elan-20220930_g1.jpg
Asset impairment, restructuring and other special charges decreased $360 million for the nine months ended September 30, 2022, due in part to a $99 million period over period decrease in severance charges and overall acquisition-related expenses. See Note 6: Asset Impairment, Restructuring and Other Special Charges for further discussion. Also contributing to the decrease are certain nonrecurring charges recorded during the nine months ended September 30, 2021, including a $271 million charge to write down assets at our Shawnee and Speke manufacturing sites that were classified as held for sale to an amount equal to fair value less costs to sell, a $50 million impairment charge for an IPR&D asset that was subject to product rationalization as a result of observed efficacy results, and a $26 million charge to establish a liability for future royalty and milestone payments relating to our canine parvovirus license agreement with KindredBio, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. These decreases were partially offset by $26 million of nonrecurring pension curtailment gains recorded during the nine months ended September 30, 2021 as well as a $28 million asset write-down charge recorded upon the final sale of our Speke manufacturing site and a one-time charge of $59 million related to the expensing of an IPR&D asset licensed from BexCaFe during the nine months ended September 30, 2022. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion.

Interest Expense, Net of Capitalized Interest
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Interest expense, net of capitalized interest$60 $60 — %$179 $181(1)%

Interest expense, net of capitalized interest was flat for the three months ended September 30, 2022. The impact of refinancing at lower interest rates was fully offset by a $2 million debt extinguishment loss recorded upon the retirement of a portion of the aggregate principal on our Term Loan B during the period and higher interest on variable-rate debt due to increases in rates.

Interest expense, net of capitalized interest decreased $2 million for the nine months ended September 30, 2022, primarily due to the favorable impact of refinancing at lower interest rates, partially offset by $19 million in debt extinguishment losses recorded upon the retirement of a portion of the aggregate principal on our 4.272% Senior Notes due August 28, 2023 and our Term Loan B during the period, and higher interest on variable-rate debt due to increases in rates.

Other Expense, Net
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Other expense, net$8 $11 (27)%$17 $8113 %

Other expense recorded during the three months ended September 30, 2022 primarily consisted of foreign exchange losses and mark-to-market adjustments on equity investments, partially offset by up-front payments received in relation to license and asset assignment agreements, as well as certain components of net periodic benefit cost. See Note 14: Retirement Benefits to the condensed consolidated financial statements for further discussion related to net periodic benefit cost (income) recorded during the period. Other expense recorded during the three months ended September 30, 2021 primarily consisted of mark-to-market adjustments on equity investments and foreign exchange losses, partially offset by certain components of net periodic benefit income.

Other expense recorded during the nine months ended September 30, 2022 primarily consisted of foreign exchange losses and mark-to-market adjustments on equity investments, partially offset by up-front payments received in relation to license and asset assignment agreements, the gain recognized on the disposal of our microbiome R&D platform, as well as certain components of net periodic benefit cost. See Note 14: Retirement Benefits to the condensed consolidated financial statements for further discussion related to net periodic benefit cost (income) recorded during the period. Other expense recorded during the nine months ended September 30, 2021 primarily consisted of mark-to-market adjustments on equity investments, losses recorded in relation to divestitures, and foreign exchange losses, partially offset by certain components of net periodic benefit income, an up-front payment received in relation to an asset assignment agreement, and up-front payments received, milestones earned, and equity issued to us in relation to a license agreement.
2022 Q3 Form 10-Q | 37
elan-20220930_g1.jpg

Income Tax Expense (Benefit)
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20222021% Change20222021% Change
Income tax expense (benefit)$7 $(26)(127)%$34 $(71)(148)%
Effective tax rate(17.1)%20.0 %315.6 %15.9 %

Income tax expense increased for the three and nine months ended September 30, 2022, primarily due to changes in earnings mix which caused the U.S. federal and state jurisdictions to generate losses, which are subject to valuation allowances. The effective tax rate decreased for the three months ended September 30, 2022 driven by adjustments in jurisdictional earnings mix resulting in taxable earnings outside of the U.S. and taxable losses in the U.S. The effective tax rate for the nine months ended September 30, 2022 increased due to adjustments in jurisdictional earnings mix resulting in taxable earnings outside of the U.S. and taxable losses in the U.S., partially offset by the income tax benefit due to the termination of interest rate swaps during the period and net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S. See Note 11: Income Taxes to the condensed consolidated financial statements.

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, following U.S. tax reforms, the income taxes associated with transferring cash to the U.S. We intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our structure evolves as a standalone company, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.

We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations which include principal and interest payments as well as interest rate swaps, operating lease payments, purchase obligations, and costs associated with the integrations of Bayer Animal Health and KindredBio. In addition, we have the ability to access capital markets to obtain debt refinancing for longer-term funding, if required, to service our long-term debt obligations. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.

Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful" in Part I of our 2021 Form 10-K.

2022 Q3 Form 10-Q | 38
elan-20220930_g1.jpg
Cash Flows

The following table provides a summary of cash flows from operating, investing and financing activities for the periods presented:

(Dollars in millions)Nine Months Ended September 30,
Net cash provided by (used for):20222021$ Change
Operating activities$439 $260 $179 
Investing activities(103)(456)353 
Financing activities(465)166 (631)
Effect of exchange-rate changes on cash and cash equivalents(49)(23)(26)
Net decrease in cash and cash equivalents$(178)$(53)$(125)

Operating activities

Cash provided by operating activities increased $179 million to $439 million for the nine months ended September 30, 2022 from $260 million for the nine months ended September 30, 2021, primarily due to an increase in net income after adjusting for non-cash items as well as proceeds of $207 million from interest rate swap settlements. These increases were partially offset by changes in operating assets and liabilities, net of acquisitions as compared to the prior year. In the past, we have extended our payment terms for distributors on occasion. Although we presently have no plans to do so in the future, it is possible that we will need to extend payment terms in certain situations as a result of the COVID-19 global health pandemic, competitive pressures, macroeconomic factors and the need for certain inventory levels at our channel distributors to avoid supply disruptions. If so, such extensions of customer payment terms could result in additional uses of our cash flow.

Investing activities

Our cash used for investing activities was $103 million for the nine months ended September 30, 2022 as compared to $456 million for the nine months ended September 30, 2021. The decrease was primarily driven by cash paid for the acquisition of KindredBio during the nine months ended September 30, 2021, as well as a year over year decrease in cash paid for purchases of intangible assets. These decreases were partially offset by a year over year increase in cash used for purchases of software and property and equipment.

Financing activities

Our cash used for financing activities was $465 million for the nine months ended September 30, 2022 as compared to cash provided by financing activities of $166 million for the nine months ended September 30, 2021. Cash used for financing activities during the nine months ended September 30, 2022 primarily reflected the tender offer completed during the period as well as net repayments on our revolving credit facility and the repayment of indebtedness outstanding under our term loan B credit facility, partially offset by proceeds from our newly issued incremental term facilities. Cash provided by financing activities during the nine months ended September 30, 2021 primarily reflected proceeds from our borrowings under our debt financing arrangement with Farm Credit Mid-America, PCA, and net proceeds from our revolving credit facility, partially offset by the repayment of indebtedness outstanding under our Senior Notes.

Description of Indebtedness

For a complete description of our existing debt and available credit facilities as of September 30, 2022 and December 31, 2021, see Note 9: Debt within Item 8, “Financial Statements and Supplementary Data,” of Part II of our 2021 Form 10-K. New developments are discussed in Note 9: Debt of this Form 10-Q.

2022 Q3 Form 10-Q | 39
elan-20220930_g1.jpg
Contractual Obligations

Our contractual obligations and commitments as of September 30, 2022 are primarily comprised of long-term debt obligations, operating leases, and purchase obligations. Our long-term debt obligations are comprised of our expected principal and interest obligations and our interest rate swaps. Purchase obligations consist of open purchase orders as of September 30, 2022 and contractual payment obligations with significant vendors which are noncancelable and are not contingent. These obligations are primarily short-term in nature.

As of September 30, 2022, we also have an additional lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025.

Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments by us, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our 2021 Form 10-K. There have been no significant changes or developments in the application of our critical accounting policies during the nine months ended September 30, 2022, except as it relates to below:

Goodwill Impairment Testing

We evaluate goodwill for impairment on an annual basis and when certain qualitative impairment indicators are present that would more likely than not reduce the fair value of our single reporting unit below its carrying amount.
In the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a goodwill impairment review. Based on our qualitative assessment, we concluded that it was more likely than not that the fair value of our single reporting unit was less than its carrying value, and therefore, we were required to perform a quantitative goodwill impairment test, which involved comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimate fair value of our single reporting unit using a combination of the income and market approach.

Significant management judgment is required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that are used in the discounted cash flow method of valuation. These include, but are not limited to, estimates and assumptions regarding (1) our future cash flows, revenue, and other profitability measures, (2) the long-term growth rate of our business, and (3) the determination of our weighted-average cost of capital, which is a factor in determining the discount rate. We make these judgments based on our historical experience, relevant market size, historical pricing of similar products, and expected industry trends. These assumptions are subject to change in future periods because of, among other things, additional information, financial information based on further historical experience, changes in competition, our investment decisions, volatility in foreign currency exchange rates, results of research and development, and changes in macroeconomic conditions, including rising interest rates and inflation. A change in these assumptions or the use of alternative estimates and assumptions could have a significant impact on the estimated fair value and may expose us to goodwill impairment losses.

As a result of our quantitative assessment, we estimated that the fair value of our single reporting unit exceeded the carrying amount by more than 20% as of September 30, 2022 and, therefore, no impairment existed with respect to our goodwill. However, our reporting unit remains at risk for future goodwill impairment as it is reasonably possible that changes in any of the factors identified above could have a material impact on one or more of the estimates and assumptions used to evaluate goodwill for impairment.

2022 Q3 Form 10-Q | 40
elan-20220930_g1.jpg
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Exchange Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, and Chinese yuan.

We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates in future periods.

We estimate that a hypothetical 10% adverse movement in all foreign currency exchange rates related to the translation of the results of our foreign operations would decrease our net income by approximately $14 million for the nine months ended September 30, 2022.

We generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. We have concluded that our Argentina subsidiary is operating in a hyperinflationary market. As a result, beginning in the second quarter of 2018, the functional currency of our Argentina subsidiary changed from the local currency to the U.S. dollar. During the nine months ended September 30, 2022, revenue in Argentina represented less than 1% of our consolidated revenue. Assets held in Argentina as of September 30, 2022 represented less than 1% of our consolidated assets.

During the first quarter of 2022, Turkey’s three-year cumulative inflation rate exceeded 100%, and we concluded that Turkey became a hyperinflationary economy for accounting purposes. As of April 1, 2022, we applied hyperinflationary accounting for our subsidiary in Turkey and changed its functional currency from the Turkish lira to the U.S. dollar. During the nine months ended September 30, 2022, revenue in Turkey represented less than 1% of our consolidated revenue. Assets held in Turkey as of September 30, 2022 represented less than 1% of our consolidated assets.

While the hyperinflationary conditions did not have a material impact on our business during the nine months ended September 30, 2022, in the future, we may incur larger currency devaluations, which could have a material adverse impact on our results of operations.

Interest Risk

Our variable-rate debt is exposed to interest rate fluctuations based on LIBOR and Term SOFR. As of September 30, 2022, we held certain interest rate swap agreements with a notional value of $3,050 million that have the economic effect of modifying our variable interest such that a portion of the variable-rate interest payable becomes fixed. As of September 30, 2022, $4,158 million and $1,811 million of our total long-term debt, including the current portion, is fixed-rate debt (including variable-rate converted to fixed-rate through the use of interest rate swaps) and unhedged variable-rate debt, respectively. During the nine months ended September 30, 2022, we recorded a gain of $179 million, net of taxes on these interest rate swaps in other comprehensive income (loss). See Note 10: Financial Instruments and Fair Value to the condensed consolidated financial statements for further information.

2022 Q3 Form 10-Q | 41
elan-20220930_g1.jpg
ITEM 4. CONTROLS AND PROCEDURES

(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.

Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2022. Based on this evaluation, the chief executive officer and the chief financial officer concluded that the disclosure controls and procedures are effective.

(b)Changes in Internal Controls. During the third quarter of 2022, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


2022 Q3 Form 10-Q | 42
elan-20220930_g1.jpg
PART II

ITEM 1. LEGAL PROCEEDINGS

See Note 12: Commitments and Contingencies to the condensed consolidated financial statements for a summary of our legal proceedings, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Our risk factors are documented in Item 1A of Part I of our 2021 Form 10-K, which is incorporated herein by reference. There have been no material changes from the risk factors previously disclosed in the 2021 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(none)

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

(none)

ITEM 4. MINE SAFETY DISCLOSURES

(none)

ITEM 5. OTHER INFORMATION

(none)
2022 Q3 Form 10-Q | 43
elan-20220930_g1.jpg
ITEM 6. EXHIBITS

The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.

Exhibit NumberDescription
3.1 
3.2 
31.1 
31.2 
32 
101 Interactive Data Files.
104 Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101).

2022 Q3 Form 10-Q | 44
elan-20220930_g1.jpg
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELANCO ANIMAL HEALTH INCORPORATED
(Registrant)
Date:November 8, 2022/s/ Jeffrey N. Simmons
Jeffrey N. Simmons
President and Chief Executive Officer
(Principal Executive Officer)
Date:November 8, 2022/s/ Todd S. Young
Todd S. Young
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)



2022 Q3 Form 10-Q | 45
elan-20220930_g1.jpg
 EX-31.1 2 ex311elanco-20220930xceoce.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATIONS
I, Jeffrey N. Simmons, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 8, 2022
By:/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 ex312elanco-20220930xcfoce.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATIONS
I, Todd S. Young, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 8, 2022
By:/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-32 4 ex32elanco-20220930xsectio.htm EX-32 Document

EXHIBIT 32
CERTIFICATION OF THE
CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2022

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:November 8, 2022/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer
(Principal Executive Officer)
 
Date:November 8, 2022/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-101.SCH 5 elan-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Background link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Acquisitions, Divestitures and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Asset Impairment, Restructuring and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Geographic Information link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Background (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Revenue - Activity in Sales Rebates and Discounts Liability (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Assets and Liabilities Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Equity - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Financial Instruments and Fair Value - Fair Value Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Financial Instruments and Fair Value - Net Gains/Losses on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Geographic Information - Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Retirement Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 elan-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 elan-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 elan-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic Concentration Risk Geographic Concentration Risk [Member] Business Acquisition [Axis] Business Acquisition [Axis] Incremental Term Facility Due 2029 Incremental Term Facility Due 2029 [Member] Incremental Term Facility Due 2029 Reclassification from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Long-term debt, gross Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Other net financing transactions with Lilly Proceeds From (Payments To) Transactions With Parent Proceeds From (Payments To) Transactions With Parent Restructuring reserve, accrual adjustment Reserve adjustments Restructuring Reserve, Accrual Adjustment Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Facility exit costs Business Exit Costs Number of consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Balance at beginning of period Balance at end of period Restructuring Reserve Cross-currency fixed interest rate swap Foreign exchange contracts not designated as hedging instruments Foreign Exchange Contract [Member] Settlement of liability related to previous license agreement Business Acquisition, Preacquisition Contingency, Amount of Settlement Additional paid-in capital Additional Paid in Capital Gross proceeds Proceeds from Issuance or Sale of Equity Term Loan B due 2027 Term B Loan Facility [Member] Term B Loan Facility Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Other investing activities, net Payments for (Proceeds from) Other Investing Activities Range [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Interest rate on debt component Interest rate Debt Instrument, Interest Rate, Stated Percentage Commitments and Contingencies Legal Matters and Contingencies [Text Block] Net periodic benefit income Net periodic benefit cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Repayment of debt Repayments of Debt Net loss Net loss Net loss available to common shareholders Net Income (Loss) Attributable to Parent Antidilutive shares not included in calculating diluted loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Document Information [Line Items] Document Information [Line Items] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Equity Component [Domain] Equity Component [Domain] Secured Debt Secured Debt [Member] Scenario [Axis] Scenario [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] Lessee, operating lease, lease not yet commenced, term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Product Return Concentration Risk Product Return Concentration Risk [Member] Product Return Concentration Risk [Member] Percent of TEUs issued involved in lawsuit Loss Contingency, Percent of TEUs Issued Involved in Lawsuit Loss Contingency, Percent of TEUs Issued Involved in Lawsuit Common stock price (usd per share) Business Acquisition, Share Price Hedging Designation [Domain] Hedging Designation [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Measurement period adjustment related to settlement of preexisting liability Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Settlement Of Preexisting Liability Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Settlement Of Preexisting Liability Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Additional dilutive shares (in shares) Tangible Equity Unit, Shares Considered Dilutive At A Specified Market Value Tangible Equity Unit, Additional Shares Considered Dilutive At A Specified Market Value Refund within next three months Tax Incremental Financing, Expect To Refund Within Next Three Months Tax Incremental Financing, Expect To Refund Within Next Three Months Worldwide rights to Osurnia and U.S. rights to Capstar Worldwide Rights To Osurnia And U.S. Rights To Capstar [Member] Worldwide Rights To Osurnia And U.S. Rights To Capstar Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Acquisition related charges: Asset Impairment Charges [Abstract] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Restructuring costs Restructuring Costs Intangible assets, primarily acquired in-process research and development (IPR&D) In Process Research and Development [Member] Proceeds from interest rate swap settlements Proceeds From Derivative Instrument, Operating Activities Proceeds From Derivative Instrument, Operating Activities Costs, expenses and other: Costs and Expenses [Abstract] Unrealized gains Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Less: Issuance costs Payment of Financing and Stock Issuance Costs Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Liabilities Geographical [Axis] Geographical [Axis] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Payments Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Restructuring Type [Axis] Restructuring Type [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Severance and other costs Severance Costs Debt Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred income taxes Deferred Income Tax Expense (Benefit) 4.900% Senior Notes due 2028 4.9% Senior Notes Due 2028 [Member] 4.9% Senior Notes Due 2028 [Member] Concentration Risk [Table] Concentration Risk [Table] Summary of Gain (loss), Net of Tax Offsetting Liabilities [Table Text Block] Total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed (Including Liability Settlement), Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed (Including Liability Settlement), Net Revenue Revenue Benchmark [Member] Summary of Activity in Sales Rebates and Discounts Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Asset Impairment, Restructuring and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Settlement of liability related to previous license agreement Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Settlement Of Preexisting Liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Settlement Of Preexisting Liability Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Asset impairment, restructuring and other special charges Total expense Restructuring, Settlement and Impairment Provisions Loss per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Farm Animal Farm Animal [Member] Farm Animal Current portion of long-term debt Less current portion of long-term debt Long-Term Debt, Current Maturities Net Cash (Used for) Provided by Financing Activities Net Cash Provided by (Used in) Financing Activities Number of brands in diverse portfolio Number Of Brands In Entity's Portfolio Number Of Brands In Entity's Portfolio Reduction of revenue Contract with Customer, Liability, Revenue Recognized Including Current Year Additions Contract with Customer, Liability, Revenue Recognized Including Current Year Additions Employee compensation Employee-related Liabilities, Current Credit facility Line of Credit [Member] Loss (gain) on divestiture Gain (Loss) on Disposition of Business Equity Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other Prepaid Expense and Other Assets, Current Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Interest cost Defined Benefit Plan, Interest Cost New corporate headquarters, estimated total incentive to be funded by TIF Tax Incremental Financing, Estimated Total Incentive To Be Funded Tax Incremental Financing, Estimated Total Incentive To Be Funded Tax Incremental Financing, commitment amount Tax Incremental Financing, Commitment Amount Tax Incremental Financing, Commitment Amount Schedule of Provision for Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Loss on extinguishment of debt Debt extinguishment loss Gain (Loss) on Extinguishment of Debt Restructuring Plan [Domain] Restructuring Plan [Domain] Cash paid in acquisition Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative Contract [Domain] Finished products Inventory, Finished Goods, Gross Basis of Presentation and Summary of Significant Accounting Policies Basis of Accounting [Text Block] Entity Registrant Name Entity Registrant Name Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Shawnee Shawnee [Member] Shawnee Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Entity Address, City or Town Entity Address, City or Town Restructuring charges (credits): Restructuring, Settlement and Impairment Provisions [Abstract] Retirement Benefits Retirement Benefits [Text Block] Cash Flow Hedge Gain (Loss) Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Swine Swine [Member] Swine Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Unrealized gain (loss) on investments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Unrealized gains associated with cancelled swaps Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Unamortized debt issuance costs Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Pension Plan Pension Plan [Member] Financial Instruments and Fair Value Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Research and development Research and Development Expense Disposal Group Classification [Axis] Disposal Group Classification [Axis] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Proceeds from revolving credit facility Proceeds from Lines of Credit Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Concentration risk Concentration risk (as a percent) Concentration Risk, Percentage Cash flow hedges, net of taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Income Taxes Income Tax Disclosure [Text Block] Quarterly cash installment per amortizing note Debt Instrument, Periodic Payment Per Amortizing Note Debt Instrument, Periodic Payment Per Amortizing Note Early redemption and tender premiums paid Payment for Debt Extinguishment or Debt Prepayment Cost Loss on sale of assets Gain (Loss) on Disposition of Other Assets Credit Facility [Domain] Credit Facility [Domain] Amortization of intangible assets Amortization of Intangible Assets Basic (usd per share) Earnings Per Share, Basic Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total equity Balance at beginning of period Balance at end of period Stockholders' Equity Attributable to Parent Inventory fair value step-up amortization Business Combination, Inventories, Step-Up Fair Value Adjustment Business Combination, Inventories, Step-Up Fair Value Adjustment Entity Interactive Data Current Entity Interactive Data Current Number of shares sold in public offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accumulated Deficit Retained Earnings [Member] Common Stock Common Stock [Member] Microbiome R&D Platform Carve-Out Microbiome R&D Platform Carve-Out [Member] Microbiome R&D Platform Carve-Out 2.75% Senior Amortizing Notes 2.75% Senior Amortizing Notes [Member] 2.75% Senior Amortizing Notes Changes in operating assets and liabilities, net of acquisitions Increase (Decrease) in Operating Capital Class of Stock [Axis] Class of Stock [Axis] First installment payment per amortizing note Debt Instrument, First Periodic Payment Per Amortizing Note Debt Instrument, First Periodic Payment Per Amortizing Note Statement [Table] Statement [Table] Summary of Assets and Liabilities Held for Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Asset write-down Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Document Quarterly Report Document Quarterly Report Current Assets Assets, Current [Abstract] Held for Sale Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Range [Axis] Statistical Measurement [Axis] Schedule of Selected Geographic Area Information Revenue from External Customers by Geographic Areas [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Disposal Group Name [Axis] Disposal Group Name [Axis] Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Accounts receivable, net of allowances of $10 (2022) and $12 (2021) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] November 2021 Restructuring Plan November 2021 Restructuring Plan [Member] November 2021 Restructuring Plan Recurring Fair Value, Recurring [Member] Document Fiscal Year Focus Document Fiscal Year Focus Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Duration over which proceeds will be received Divestiture Of Business, Duration Over Which Proceeds Will Be Received Divestiture Of Business, Duration Over Which Proceeds Will Be Received Cash received in agreement to divest Disposal Group, Including Discontinued Operation, Consideration 4.272% Senior Notes Due 2023 4.272% Senior Notes Due 2023 [Member] 4.272% Senior Notes Due 2023 [Member] Other expense, net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Marketing, selling and administrative Selling, General and Administrative Expense Implementation of New Financial Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Product Sales Product [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Incremental Term Facility due 2025 Incremental Term Facility Due 2025 [Member] Incremental Term Facility Due 2025 Implementation of New Financial Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Document Information [Table] Document Information [Table] Common stock, shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Total Inventory, Gross Goodwill Goodwill Goodwill Other current liabilities Other Current Liabilities [Member] Settlement rate Tangible Equity Unit, Settlement Rate Tangible Equity Unit, Settlement Rate Other net working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital Adjustments to reconcile net loss to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Deferred taxes Deferred Income Tax Liabilities, Net Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cost of sales Cost of Goods and Services Sold Cash received for derivative settlement Proceeds From Derivative Settlement Proceeds From Derivative Settlement Diluted (in shares) Diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Property and equipment, net of accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Derivative assets (liabilities) Derivative Assets (Liabilities), at Fair Value, Net Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Forward-starting interest rate swaps Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Description of Accounting Standards Adopted and Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Table Text Block] Number of countries in which entity operates (more than) Number of Countries in which Entity Operates Common stock, no par value, 5,000,000,000 shares authorized, 474,124,115 and 473,119,786 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Carrying Amount Reported Value Measurement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Transaction and integration costs Business Combination, Integration Related Costs Senior Notes Senior Notes [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Debt Component Tangible Equity Unit, Debt Component [Member] Tangible Equity Unit, Debt Component Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) Applicable Market Value (usd per share) Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Cash and cash equivalents at January 1 Cash and cash equivalents at September 30 Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Pet Health Pet Health [Member] Pet Health Current Liabilities Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity method investments Equity Method Investments Concentration Risk [Line Items] Concentration Risk [Line Items] Proceeds from site divestitures Proceeds from Divestiture of Businesses and Interests in Affiliates Sales rebates and discounts Contract with Customer, Liability, Current Expected payment term Restructuring, Expected Payment Term Restructuring, Expected Payment Term Retirement Plan Type [Domain] Retirement Plan Type [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Incremental Term Facility due 2028 Incremental Term Facility Due 2028 [Member] Incremental Term Facility Due 2028 Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Debt instrument, face amount Debt Instrument, Face Amount Other comprehensive loss, net of taxes Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Summary of Fair Value Information Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Acquisitions, Divestitures and Other Arrangements Mergers, Acquisitions and Dispositions Disclosures [Text Block] Asset impairment Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Deferred income taxes, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other noncurrent assets Other Assets, Noncurrent Cash paid Cash paid Payments for Restructuring Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Severance Employee Severance [Member] Proceeds from issuance of long-term debt Proceeds from Issuance of Senior Long-Term Debt Operating lease, lease not yet commenced liability Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Summary of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] BexCaFe, LLC BexCaFe, LLC [Member] BexCaFe, LLC Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net of accumulated depreciation of $696 (2022) and $1,041 (2021) Property, Plant and Equipment, Net Defined Benefit Plan, Type [Extensible Enumeration] Defined Benefit Plan, Type [Extensible Enumeration] Defined benefit pension and retiree health benefit plans, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Foreign currency translation adjustments Contract With Customer, Liability, Foreign Currency Translation Contract With Customer, Liability, Foreign Currency Translation Settlements and other Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Accounts receivable, net of allowances Accounts Receivable, Allowance for Credit Loss, Current Net proceeds Total debt Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Offering price (usd per share) Fair value per unit (usd per share) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Noncurrent Assets Assets, Noncurrent [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax January 2021 Restructuring Plan January 2021 Restructuring Plan [Member] January 2021 Restructuring Plan Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Work in process Inventory, Work in Process, Gross Total current assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Finite-lived intangible assets Finite-Lived Intangible Assets, Net Intangible assets, primarily acquired in-process research and development (IPR&D) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Title of 12(b) Security Title of 12(b) Security Background Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Long-term debt, including current portion Notes Payable, Fair Value Disclosure Consolidated Entities [Axis] Consolidated Entities [Axis] Costs, expenses and other Costs and Expenses Stranded tax benefits reclassified to earnings Release of stranded tax benefits Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net Repayments of revolving credit facility Repayments of Lines of Credit Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Debt issuance costs Payments of Debt Issuance Costs Amount of debt retired Debt Instrument, Retired Amount Debt Instrument, Retired Amount Geographic Information Segment Reporting Disclosure [Text Block] Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Foreign exchange forward contracts Derivative, Gain (Loss) on Derivative, Net Liabilities and Equity Liabilities and Equity [Abstract] Fair Value Estimate of Fair Value Measurement [Member] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Purchases of intangible assets Payments to Acquire Intangible Assets Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Proceeds after underwriting discounts and commissions Net proceeds Sale of Stock, Consideration Received on Transaction Inventories Disposal Group, Including Discontinued Operation, Inventory Inventories Inventories Inventory, Net Accounts payable Accounts Payable, Current Charges Restructuring Charges Number of employees transferred Disposal Group, Including Discontinued Operation, Number of Employees Transferred Disposal Group, Including Discontinued Operation, Number of Employees Transferred Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Future Milestone Payments And Sales Royalties Future Milestone Payments And Sales Royalties [Member] Future Milestone Payments And Sales Royalties Entity Filer Category Entity Filer Category Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Fair value in excess of carrying amount Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Number of restructuring programs announced Number Of Restructuring Programs Announced Number Of Restructuring Programs Announced Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] United States UNITED STATES Expected number of positions eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Shares issued upon conversion of prepaid stock purchase contracts (in shares) Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Commitments and Contingencies Commitments and Contingencies 5.00% Tangible Equity Units TEU Amortizing Notes due 2023 5.00% Tangible Equity Units [Member] 5.00% Tangible Equity Units Security Exchange Name Security Exchange Name Gain on disposal Gain (Loss) on Disposition of Assets Notional amount Derivative, Notional Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Preferred stock, no par value, 1,000,000,000 shares authorized; none issued Preferred Stock, Value, Issued Non-cash and other items: Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract] Revenue Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Service cost Defined Benefit Plan, Service Cost Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Revenue Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Forecast Forecast [Member] Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Total liabilities and equity Liabilities and Equity Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] International Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Current Fiscal Year End Date Current Fiscal Year End Date Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Diluted (usd per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Stock compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Cattle Cattle [Member] Cattle Customer Concentration Risk Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Net Revenue Revenue from Contract with Customer Benchmark [Member] Entity Address, Address Line One Entity Address, Address Line One Contract with customer, asset, before allowance for credit loss Contract with Customer, Asset, before Allowance for Credit Loss Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing [Member] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Beginning balance Ending balance Contract with Customer, Liability Common stock, no par value Common Stock, No Par Value [Member] Common Stock, No Par Value Product and Service [Axis] Product and Service [Axis] SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Foreign currency translation adjustments Restructuring Reserve, Foreign Currency Translation Gain (Loss) Global Customers Global Customers [Member] Global Customers Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense, net of capitalized interest Interest Expense Credit Facility [Axis] Credit Facility [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Inventories Inventory Disclosure [Text Block] Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Equity [Abstract] Equity [Abstract] Other receivables Other Receivables, Net, Current Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Decrease to LIFO cost Inventory, LIFO Reserve Single Customer Customer A [Member] Customer A [Member] Other noncurrent assets Other Noncurrent Assets [Member] KindredBio KindredBio [Member] KindredBio Asset impairment and write-down charges Asset Impairment Charges, Including Inventory Write-Down Asset Impairment Charges, Including Inventory Write-Down Total Tangible Equity Unit [Member] Tangible Equity Unit Summary of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Interest rate swaps, net of tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax Net curtailments and settlements (Note 6) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Litigation settlement charges Litigation Settlement, Expense Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Summary of Activity in Reserves Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Assumed conversion of dilutive common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Summary of Asset Impairment, Restructuring and Other Special Charges Restructuring and Related Costs [Table Text Block] Entity Central Index Key Entity Central Index Key Equity Component Tangible Equity Unit, Equity Component [Member] Tangible Equity Unit, Equity Component Measurement Frequency [Axis] Measurement Frequency [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Issuance of stock under employee stock plans, net Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Liabilities related to litigation Estimated Litigation Liability City Area Code City Area Code Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Initial principal amount Debt Instrument, Initial Principal Amount Debt Instrument, Initial Principal Amount Purchases of software Payments for Software Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Payment on agreement Payments For License Fees Payment On Agreement Variable Rate [Axis] Variable Rate [Axis] Repayments of long-term borrowings Repayments of Senior Debt Aqua Aqua [Member] Aqua Other noncurrent liabilities Other Liabilities, Noncurrent Forward-starting interest rate contracts designated as cash flow hedges Interest Rate Contract [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Contract With Customer Liability Contract With Customer, Liability [Member] Contract With Customer, Liability [Member] Net purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Basic And Diluted Loss Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Poultry Poultry [Member] Poultry Customer [Domain] Customer [Domain] EX-101.PRE 9 elan-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 elan-20220930_g1.jpg begin 644 elan-20220930_g1.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Nov. 03, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-38661  
Entity Registrant Name Elanco Animal Health Inc  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 82-5497352  
Entity Address, Address Line One 2500 INNOVATION WAY  
Entity Address, City or Town GREENFIELD  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46140  
City Area Code 877  
Local Phone Number 352-6261  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   474,205,430
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001739104  
Current Fiscal Year End Date --12-31  
Common stock, no par value    
Document Information [Line Items]    
Title of 12(b) Security Common stock, no par value  
Trading Symbol ELAN  
Security Exchange Name NYSE  
5.00% Tangible Equity Units    
Document Information [Line Items]    
Title of 12(b) Security 5.00% Tangible Equity Units  
Trading Symbol ELAT  
Security Exchange Name NYSE  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenue $ 1,028 $ 1,131 $ 3,430 $ 3,652
Costs, expenses and other:        
Cost of sales 472 502 1,465 1,622
Research and development 78 94 241 277
Marketing, selling and administrative 298 342 961 1,075
Amortization of intangible assets 128 141 398 417
Asset impairment, restructuring and other special charges 26 111 158 518
Interest expense, net of capitalized interest 60 60 179 181
Other expense, net 8 11 17 8
Costs, expenses and other 1,070 1,261 3,419 4,098
Income (loss) before income taxes (42) (130) 11 (446)
Income tax expense (benefit) 7 (26) 34 (71)
Net loss $ (49) $ (104) $ (23) $ (375)
Loss per share:        
Basic (usd per share) $ (0.10) $ (0.21) $ (0.05) $ (0.77)
Diluted (usd per share) $ (0.10) $ (0.21) $ (0.05) $ (0.77)
Weighted average shares outstanding:        
Basic (in shares) 488.4 487.3 488.3 487.1
Diluted (in shares) 488.4 487.3 488.3 487.1
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net loss $ (49) $ (104) $ (23) $ (375)
Other comprehensive income (loss):        
Cash flow hedges, net of taxes 62 4 179 52
Foreign currency translation (418) (209) (973) (506)
Defined benefit pension and retiree health benefit plans, net of taxes (2) (6) (4) 5
Other comprehensive loss, net of taxes (358) (211) (798) (449)
Comprehensive loss $ (407) $ (315) $ (821) $ (824)
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets    
Cash and cash equivalents $ 460 $ 638
Accounts receivable, net of allowances of $10 (2022) and $12 (2021) 804 833
Other receivables 224 195
Inventories 1,340 1,373
Prepaid expenses and other 326 237
Total current assets 3,154 3,276
Noncurrent Assets    
Goodwill 5,716 6,172
Other intangibles, net 4,766 5,587
Other noncurrent assets 376 387
Property and equipment, net of accumulated depreciation of $696 (2022) and $1,041 (2021) 936 1,061
Total assets 14,948 16,483
Current Liabilities    
Accounts payable 350 418
Employee compensation 136 185
Sales rebates and discounts 298 316
Current portion of long-term debt 394 294
Other current liabilities 435 430
Total current liabilities 1,613 1,643
Noncurrent Liabilities    
Long-term debt 5,507 6,025
Accrued retirement benefits 240 271
Deferred taxes 618 745
Other noncurrent liabilities 225 261
Total liabilities 8,203 8,945
Commitments and Contingencies
Equity    
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued 0 0
Common stock, no par value, 5,000,000,000 shares authorized, 474,124,115 and 473,119,786 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 0 0
Additional paid-in capital 8,724 8,696
Accumulated deficit (972) (949)
Accumulated other comprehensive loss (1,007) (209)
Total equity 6,745 7,538
Total liabilities and equity $ 14,948 $ 16,483
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Accounts receivable, net of allowances $ 10 $ 12
Property and equipment, net of accumulated depreciation $ 696 $ 1,041
Preferred stock, shares authorized (in shares) 1,000,000,000 1,000,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, shares authorized (in shares) 5,000,000,000 5,000,000,000
Common stock, shares issued (in shares) 474,124,115 473,119,786
Common stock, shares outstanding (in shares) 474,124,115 473,119,786
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Cash Flow Hedge Gain (Loss)
Foreign Currency Translation
Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2020   471,900,000            
Balance at beginning of period at Dec. 31, 2020 $ 8,476 $ 0 $ 8,650 $ (477) $ 303 $ (61) $ 360 $ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (61)     (61)        
Other comprehensive income (loss), net of tax (405)       (405) 53 (466) 8
Stock compensation 15   15          
Issuance of stock under employee stock plans, net (in shares)   1,100,000            
Issuance of stock under employee stock plans, net (18)   (18)          
Balance at end of period (in shares) at Mar. 31, 2021   473,000,000.0            
Balance at end of period at Mar. 31, 2021 8,007 $ 0 8,647 (538) (102) (8) (106) 12
Balance at beginning of period (in shares) at Dec. 31, 2020   471,900,000            
Balance at beginning of period at Dec. 31, 2020 8,476 $ 0 8,650 (477) 303 (61) 360 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (375)              
Other comprehensive income (loss), net of tax (449)              
Balance at end of period (in shares) at Sep. 30, 2021   473,000,000.0            
Balance at end of period at Sep. 30, 2021 7,682 $ 0 8,680 (852) (146) (9) (146) 9
Balance at beginning of period (in shares) at Mar. 31, 2021   473,000,000.0            
Balance at beginning of period at Mar. 31, 2021 8,007 $ 0 8,647 (538) (102) (8) (106) 12
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (210)     (210)        
Other comprehensive income (loss), net of tax 167       167 (5) 169 3
Stock compensation 16   16          
Balance at end of period (in shares) at Jun. 30, 2021   473,000,000.0            
Balance at end of period at Jun. 30, 2021 7,980 $ 0 8,663 (748) 65 (13) 63 15
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (104)     (104)        
Other comprehensive income (loss), net of tax (211)       (211) 4 (209) (6)
Stock compensation 17   17          
Balance at end of period (in shares) at Sep. 30, 2021   473,000,000.0            
Balance at end of period at Sep. 30, 2021 $ 7,682 $ 0 8,680 (852) (146) (9) (146) 9
Balance at beginning of period (in shares) at Dec. 31, 2021 473,119,786 473,100,000            
Balance at beginning of period at Dec. 31, 2021 $ 7,538 $ 0 8,696 (949) (209) 25 (253) 19
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss 48     48        
Other comprehensive income (loss), net of tax 23       23 109 (85) (1)
Stock compensation 14   14          
Issuance of stock under employee stock plans, net (in shares)   1,000,000.0            
Issuance of stock under employee stock plans, net (11)   (11)          
Balance at end of period (in shares) at Mar. 31, 2022   474,100,000            
Balance at end of period at Mar. 31, 2022 $ 7,612 $ 0 8,699 (901) (186) 134 (338) 18
Balance at beginning of period (in shares) at Dec. 31, 2021 473,119,786 473,100,000            
Balance at beginning of period at Dec. 31, 2021 $ 7,538 $ 0 8,696 (949) (209) 25 (253) 19
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (23)              
Other comprehensive income (loss), net of tax $ (798)              
Balance at end of period (in shares) at Sep. 30, 2022 474,124,115 474,100,000            
Balance at end of period at Sep. 30, 2022 $ 6,745 $ 0 8,724 (972) (1,007) 204 (1,226) 15
Balance at beginning of period (in shares) at Mar. 31, 2022   474,100,000            
Balance at beginning of period at Mar. 31, 2022 7,612 $ 0 8,699 (901) (186) 134 (338) 18
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (22)     (22)        
Other comprehensive income (loss), net of tax (463)       (463) 8 (470) (1)
Stock compensation 17   17          
Issuance of stock under employee stock plans, net (4)   (4)          
Balance at end of period (in shares) at Jun. 30, 2022   474,100,000            
Balance at end of period at Jun. 30, 2022 7,140 $ 0 8,712 (923) (649) 142 (808) 17
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (49)     (49)        
Other comprehensive income (loss), net of tax (358)       (358) 62 (418) (2)
Stock compensation 13   13          
Issuance of stock under employee stock plans, net $ (1)   (1)          
Balance at end of period (in shares) at Sep. 30, 2022 474,124,115 474,100,000            
Balance at end of period at Sep. 30, 2022 $ 6,745 $ 0 $ 8,724 $ (972) $ (1,007) $ 204 $ (1,226) $ 15
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows from Operating Activities    
Net loss $ (23) $ (375)
Adjustments to reconcile net loss to cash flows from operating activities:    
Depreciation and amortization 514 542
Deferred income taxes (36) (119)
Stock-based compensation expense 44 48
Asset impairment and write-down charges 87 334
Loss on sale of assets 3 0
Loss (gain) on divestiture (3) 2
Inventory fair value step-up amortization 0 64
Loss on extinguishment of debt 19 0
Proceeds from interest rate swap settlements 207 0
Changes in operating assets and liabilities, net of acquisitions (384) (243)
Other non-cash operating activities, net 11 7
Net Cash Provided by Operating Activities 439 260
Cash Flows from Investing Activities    
Net purchases of property and equipment (71) (60)
Cash paid for acquisitions, net of cash acquired 0 (342)
Proceeds from site divestitures 11 0
Purchases of intangible assets (11) (35)
Purchases of software (23) (11)
Other investing activities, net (9) (8)
Net Cash Used for Investing Activities (103) (456)
Cash Flows from Financing Activities    
Proceeds from issuance of long-term debt 425 500
Proceeds from revolving credit facility 563 500
Repayments of long-term borrowings (607) (555)
Repayments of revolving credit facility (813) (250)
Debt issuance costs (2) (1)
Early redemption and tender premiums paid (14) 0
Other net financing transactions with Lilly 0 (11)
Other financing activities, net (17) (17)
Net Cash (Used for) Provided by Financing Activities (465) 166
Effect of exchange rate changes on cash and cash equivalents (49) (23)
Net decrease in cash and cash equivalents (178) (53)
Cash and cash equivalents at January 1 638 506
Cash and cash equivalents at September 30 $ 460 $ 453
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Background
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background
Note 1. Background

Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a portfolio of approximately 200 brands to pet owners, veterinarians and farm animal producers in more than 90 countries. Our products are generally sold worldwide directly to wholesalers, distributors, and independent retailers. Certain products are also sold directly to farm animal producers and veterinarians. We have a diversified business of products across species consisting of: dogs and cats (collectively, pet health) and cattle, poultry, swine and aqua (collectively, farm animal).
Elanco was incorporated in Indiana on September 18, 2018, and prior to that was a business unit of Eli Lilly and Company (Lilly).
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Note 2. Basis of Presentation and Summary of Significant Accounting Policies

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the U.S. Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2021 included in our Form 10-K filed with the SEC on February 28, 2022 (2021 Form 10-K). In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2022 or any other future period.

In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.

The significant accounting policies set forth in Note 3 to the consolidated financial statements in our 2021 Form 10-K appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to goodwill and the adoption of the standard that was effective January 1, 2022 as described in Note 3: Implementation of New Financial Accounting Pronouncements.

Goodwill

Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. We evaluate goodwill for impairment at least annually and when certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment. We begin by assessing qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying value. Based on that qualitative assessment, if we conclude that it is more likely than not that the fair value of our single reporting unit is less than its carrying value, we conduct a quantitative goodwill impairment test, which involves comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimate the fair value of our single reporting unit using a combination of the income and market approach. If the carrying value of the reporting unit exceeds its estimated fair value, we recognize an impairment loss for the difference.

During the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a quantitative goodwill impairment test. As of September 30, 2022, our single reporting unit was tested for impairment using the quantitative approach described above, resulting in an estimated fair value that exceeded the carrying amount by more than 20%. Therefore, no impairment existed with respect to our goodwill.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Implementation of New Financial Accounting Pronouncements
 9 Months Ended
Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]  
Implementation of New Financial Accounting Pronouncements
Note 3. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
ASU 2021-10, Government Assistance (Topic 832)
The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.The adoption of this guidance did not have a material impact on our consolidated financial statements.

The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.
Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue
Note 4. Revenue

Our sales rebates and discounts are based on specific agreements. The most significant of our sales rebate and discount programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs, and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of September 30, 2022 and 2021, the aggregate liability for sales rebates and discounts for these countries represented approximately 76% and 72%, respectively, of our total liability.
The following table summarizes the activity in our global sales rebates and discounts liability:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$284 $303 $316 $295 
Reduction of revenue169 163 524 516 
Payments(143)(146)(525)(489)
Foreign currency translation adjustments(12)(4)(17)(6)
Ending balance$298 $316 $298 $316 

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2022 and 2021 for product shipped in previous periods were not material.

Actual global product returns were approximately 1% and 2% of net revenue for the three months ended September 30, 2022 and 2021, respectively. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2022 and 2021.

Disaggregation of Revenue

The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Pet Health$471 $527 $1,722 $1,857 
Farm Animal:
Cattle227 250 722 735 
Poultry176 179 529 536 
Swine95 110 284 346 
Aqua47 44 132 111 
Total Farm Animal545 583 1,667 1,728 
Contract Manufacturing (1)
12 21 41 67 
Revenue$1,028 $1,131 $3,430 $3,652 
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Divestitures and Other Arrangements
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions, Divestitures and Other Arrangements
Note 5. Acquisitions, Divestitures and Other Arrangements

KindredBio Acquisition

On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that developed innovative biologics focused on saving and improving the lives of pets. The acquisition further accelerates our pet health expansion, particularly by expanding our presence in dermatology.

The transaction was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of the acquisition are included in our condensed consolidated financial statements from the date of acquisition.
In connection with the merger agreement, we acquired all outstanding stock of KindredBio for $9.25 per share, or an aggregate cash purchase consideration of $444 million. We utilized our revolving credit facility and cash on hand to finance the acquisition.

On May 5, 2021, we signed an agreement with KindredBio to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. We calculated the fair value of the liability associated with that agreement using an income approach leveraging the estimated sales royalty, sales milestone and technical milestone payments avoided, and settled the $29 million liability upon the closing of our acquisition of KindredBio.

Revenue and loss from KindredBio included in our condensed consolidated statements of operations for the three and nine months ended September 30, 2022 were immaterial.

The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 27, 2021
Cash and cash equivalents$31 
Other net working capital13 
Property and equipment33 
Intangible assets, primarily acquired in-process research and development (IPR&D)333 
Deferred income taxes, net(30)
Total identifiable net assets380 
Goodwill35 
Settlement of liability related to previous license agreement29 
Total consideration transferred$444 

The valuation of assets acquired and liabilities assumed was finalized during the third quarter of 2022. The measurement period adjustments recorded during 2022, which were made to reflect the facts and circumstances in existence as of the acquisition date, primarily related to changes in the estimated fair value of acquired IPR&D and minor tax and working capital adjustments. The net impact of these adjustments was not material.

Property and equipment is mostly comprised of land, buildings, equipment (including laboratory equipment, furniture and fixtures, and computer equipment), and construction in progress. The estimated fair value of real and personal property was determined using the sales comparison data valuation technique, to the extent that market data for similar assets was available. When market pricing data was not available for a given asset or asset class, the direct replacement cost method was used.

The estimated fair values of acquired IPR&D were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors.

The goodwill recognized from this acquisition is primarily attributable to KindredBio's assembled workforce and expected synergies. The majority of goodwill associated with this acquisition is not deductible for tax purposes.
Divestitures

Microbiome R&D platform carve-out

In April 2022, we signed an agreement to transfer assets associated with our microbiome R&D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retain a non-voting, minority stake in the company. Assets transferred include intellectual property and laboratory equipment. The book values of those assets were not material. In addition, we have entered into transitional services agreements with the company for certain services. We have determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results. During the nine months ended September 30, 2022, we recorded a gain on the disposal of approximately $3 million.

Shawnee and Speke

During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the planned transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx will manufacture existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which is included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets. The divestitures did not represent a strategic shift that has or will have a major effect on our operations and financial results, and therefore do not qualify for reporting as discontinued operations. See Note 6: Asset Impairment, Restructuring and Other Special Charges for further information.

Based on the terms of the agreements, we expect to receive aggregate gross cash proceeds of $78 million from the sales of Shawnee and Speke over a period of three years beginning in the second half of 2022. During the three months ended September 30, 2022, we received cash proceeds of $11 million. Receivables for the remaining expected cash proceeds are included in other receivables and other noncurrent assets on our condensed consolidated balance sheets.

Assets Held For Sale

Assets considered held for sale in connection with the Speke divestiture were included in the respective line items on our condensed consolidated balance sheets as follows:
December 31, 2021
Inventories$31 
Property and equipment, net50 
Total assets held for sale$81 
BexCaFe Arrangement

On June 9, 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to Bexacat, an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, Consolidation, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. The initial fair value of the contingent payments was calculated based on an income approach, with payments adjusted for probability of success and then discounted to a present value. There is no minimum payout due on the contingent consideration and the maximum payout is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&D asset because we concluded that it did not have an alternative future use. This amount is included in asset impairment, restructuring, and other special charges in our condensed consolidated statement of operations for the nine months ended September 30, 2022.

We paid $10 million to BexCaFe under the terms of this agreement during the three months ended September 30, 2022. Contingent consideration liabilities of $49 million are included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2022.

Subsequent to the effective date of the license agreement, our condensed consolidated financial statements include the assets, liabilities, operating results and cash flows of BexCaFe. Based on the guidance in ASC 810, income and expense between us and BexCaFe have been eliminated against the income or expense included in the financial statements of BexCaFe. The resulting amounts after the effect of these eliminations were included in our condensed consolidated financial statements for the three and nine months ended September 30, 2022 and were not material.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Asset Impairment, Restructuring and Other Special Charges
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring and Other Special Charges
Note 6. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. As discussed further below, restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible assets and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.
2021 Restructuring Programs

In 2021, we announced two separate restructuring programs to improve operating efficiencies.
The actions proposed in January 2021 focused on streamlining processes and delivering increased efficiency in functional areas, while improving the productivity of our investments in innovation. As part of the restructuring plan, we closed our R&D sites in Manukau, New Zealand and Cuxhaven, Germany. We also reduced duplication and optimized structures in U.S. operations, marketing, manufacturing and quality central functions, and administrative areas. The restructuring resulted in the elimination of approximately 315 positions around the world. Activities related to this initiative resulted in adjustments of $1 million to reduce severance accruals and net charges of $44 million for the three and nine months ended September 30, 2021, respectively. The adjustments reflect a change in estimate resulting from negotiations. Restructuring charges under this program were substantially complete at the end of 2021.

The program announced in November 2021 included initiatives to consolidate certain international commercial operations into one organization, integrate our centralized global marketing organization into country level commercial organizations, transform and simplify our R&D organizational structure, and other organizational adjustments. In connection with the proposed restructuring, we eliminated 380 positions. During the nine months ended September 30, 2022, we recorded adjustments of $9 million to reduce severance accruals resulting from final negotiations and certain restructured employees filling open positions. Restructuring charges under this program were substantially complete as of September 30, 2022; however, we may continue to make adjustments to our severance accruals to reflect changes in estimates resulting from ongoing negotiations.

Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Restructuring charges (credits):
Severance and other costs (1)
$— $(2)$(9)$26 
Facility exit costs— — 2 — 
Acquisition related charges:
Transaction and integration costs (2)
27 30 77 141 
Non-cash and other items:
Asset impairment (3)
— 50 59 63 
Asset write-down (4)
(1)6 27 275 
Net periodic benefit income (Note 14)— (9)— (26)
Settlements and other (5)
— 36 2 39 
Total expense$26 $111 $158 $518 
(1)2022 credits primarily relate to adjustments resulting from the reversal of severance accruals associated with the November 2021 program. For the nine months ended September 30, 2021, charges primarily related to the restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.
(3)2022 includes a charge of $59 million related to the expensing of an IPR&D asset with no alternative future use licensed from BexCaFe during the second quarter. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. 2021 amounts represent the impact of adjustments to the fair value of certain IPR&D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&D project and fully impair the related asset, which was associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.
(4)2022 amounts primarily include the finalization of the write-down charge upon the final sale of the Speke manufacturing site. Asset write-down charges recorded in 2021 included the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the Speke manufacturing site during the three months ended September 30, 2021. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Also included are charges recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with announced restructuring programs.
(5)Amounts recorded during the nine months ended September 30, 2022 represent a $2 million measurement period adjustment to the charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Amounts recorded during the three and nine months ended September 30, 2021 include the initial charge associated with the settlement of the liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&D asset acquired as part of the Bayer Animal Health acquisition.

The following table summarizes the activity in our reserves established in connection with restructuring activities:
Severance
Balance at December 31, 2020$130 
Charges41 
Reserve adjustments(15)
Cash paid(94)
Foreign currency translation adjustments(1)
Balance at September 30, 2021$61 
Balance at December 31, 2021$126 
Reserve adjustments(9)
Cash paid(71)
Foreign currency translation adjustments(5)
Balance at September 30, 2022$41 
These reserves are included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain country negotiations and regulations. As of September 30, 2022, we expect to pay approximately $34 million over the next 12 months. We believe that the reserves are adequate.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories
Note 7. Inventories

We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
September 30, 2022December 31, 2021
Finished products$612 $598 
Work in process542 565 
Raw materials and supplies240 256 
Total1,394 1,419 
Decrease to LIFO cost(54)(46)
Inventories$1,340 $1,373 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Equity
Note 8. Equity

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.

The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in current portion of long-term debt on the condensed consolidated balance sheets. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$471 $79 $550 
Less: Issuance costs19 3 22 
Net proceeds$452 $76 $528 

The senior amortizing notes have an aggregate principal amount of $79 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate is equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)
The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14 million shares or a maximum of 17 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period. The entire additional 3 million shares are included in diluted weighted average shares outstanding if the applicable market value is at or below $32.00 and the impact is not anti-dilutive.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt
Note 9. Debt

Long-term debt consisted of the following:
September 30, 2022December 31, 2021
Incremental Term Facility due 2025 (1)
$175 $— 
Incremental Term Facility due 2028495 499 
Incremental Term Facility due 2029 (2)
250 — 
Term Loan B due 2027 (3)
3,941 4,118 
Revolving Credit Facility— 250 
4.272% Senior Notes due 2023 (4)
344 750 
4.900% Senior Notes due 2028
750 750 
TEU Amortizing Notes due 202314 34 
Unamortized debt issuance costs(68)(82)
5,901 6,319 
Less current portion of long-term debt394 294 
Total long-term debt$5,507 $6,025 
(1)In June 2022, we entered into an incremental assumption agreement with Bank of America, N.A. supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $175 million. The new incremental term facility bears interest at the Secured Overnight Financing Rate (Term SOFR), including a credit spread adjustment, plus 175 basis points and is payable in full on June 30, 2025. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.

(2)In April 2022, we entered into an incremental assumption agreement with Farm Credit Mid-America, PCA supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $250 million maturing on April 19, 2029. The new incremental term facility bears interest at Term SOFR, including a credit spread adjustment, plus 175 basis points and will be payable in quarterly installments of principal and interest with a final balloon payment due on April 19, 2029. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.

(3)In September 2022, we repaid indebtedness outstanding under our Term Loan B. We paid $75 million in cash, composed of principal and accrued interest, resulting in a debt extinguishment loss of approximately $2 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations.

(4)In April 2022, we completed a tender offer and retired $406 million in aggregate principal amount of our 4.272% Senior Notes due August 28, 2023, resulting in a debt extinguishment loss of approximately $17 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations. The repayment was funded with proceeds received from a draw under our revolving credit facility.

We were in compliance with all of our debt covenants as of September 30, 2022.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments and Fair Value
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Note 10. Financial Instruments and Fair Value
Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of our customers on a regular basis, monitor economic conditions, and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.

A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value.

We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $28 million and $22 million as of September 30, 2022 and December 31, 2021, respectively. Unrealized net gains and losses on our investments for the three and nine months ended September 30, 2022 and 2021 were immaterial.
The following table summarizes the fair value information at September 30, 2022 and December 31, 2021 for foreign exchange contract assets (liabilities), investments, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2022
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$39 $— $39 $— $39 
Prepaid expense and other - forward-starting interest rate contracts designated as cash flow hedges3 — 3 — 3 
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges15 — 15 15 
Other noncurrent assets - investments10 10 — — 10 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(29)— (29)— (29)
Long-term debt, including current portion(5,969)— (5,686)— (5,686)
December 31, 2021
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$19 $— $19 $— $19 
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges8 — 8 — 8 
Other noncurrent assets - investments13 13 — — 13 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(20)— (20)— (20)
Long-term debt, including current portion(6,401)— (6,518)— (6,518)
We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.

Derivative Instruments and Hedging Activities

We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing activities section of the consolidated statements of cash flows. Our outstanding positions are discussed below.
Derivatives not designated as hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, and Chinese yuan. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2022 and December 31, 2021, we had outstanding foreign exchange contracts with aggregate notional amounts of $821 million and $1,212 million, respectively.

The amount of net losses on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Foreign exchange forward contracts (1)
$(5)$(2)$(20)$(29)

(1)These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.

Derivatives designated as hedges

We are subject to interest rate risk with regard to our existing floating-rate debt, and we utilize interest rate swap contracts to mitigate the variability in cash flows by effectively converting the floating-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated these swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Our outstanding forward-starting interest rate swaps have maturities ranging between 2023 and 2025 with aggregate notional amounts of $3,050 million and $3,800 million as of September 30, 2022 and December 31, 2021, respectively.

The amounts of net gains on cash flow hedges recorded, net of tax, in other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Forward-starting interest rate swaps$62 $4 $179 $52 

During the three months ended September 30, 2022 and 2021, net gains on cash flow hedges recorded in other comprehensive income (loss) included gains of $75 million and $4 million, respectively, related to mark-to-market adjustments. During the nine months ended September 30, 2022 and 2021, net gains on cash flow hedges recorded in other comprehensive income (loss) included gains of $218 million and $52 million, respectively, related to mark-to-market adjustments.

In April 2022 and September 2022, we took advantage of market opportunities to restructure our interest rate swap portfolio. We unwound the existing swaps and simultaneously entered into new agreements with the same notional amounts and covering the same tenors. As a result, we received cash settlements of $132 million and $75 million in the respective periods. These gains were initially recognized in accumulated other comprehensive loss and will be reclassified to interest expense, net of capitalized interest over the period during which the related interest payments will be made.
During the three and nine months ended September 30, 2022, we reclassified $13 million and $22 million, respectively, of gains relating to our terminated interest rate swaps from accumulated other comprehensive loss to interest expense, net of capitalized interest. Additionally, as a result of the April 2022 interest rate swap settlement, other comprehensive income (loss) for the nine months ended September 30, 2022 included a $17 million reclassification of a stranded tax benefit from accumulated other comprehensive loss, based on our policy to reclassify income tax effects from accumulated other comprehensive loss using the portfolio approach. Other than the reclassification of the stranded tax benefit, there was no tax effect recorded in relation to our cash flow hedges for the three and nine months ended September 30, 2022 and 2021 after the application of the U.S. valuation allowance. See Note 11: Income Taxes for further discussion.

During the three months ended September 30, 2022 and 2021, we reclassified $2 million and $8 million, respectively, of net losses into interest expense, net of capitalized interest in our condensed consolidated statements of operations. During the nine months ended September 30, 2022 and 2021, we reclassified $12 million and $22 million, respectively, of net losses into interest expense. Over the next 12 months, we expect to reclassify a gain of $106 million, which includes $103 million relating to the interest rate swap settlements, to interest expense, net of capitalized interest.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes
Note 11. Income Taxes

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Income tax expense (benefit)$7 $(26)$34 $(71)
Effective tax rate(17.1)%20.0 %315.6 %15.9 %

We were included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.

For the three and nine months ended September 30, 2022, we recognized income tax expense of $7 million and $34 million, respectively. Our effective tax rate of (17.1)% and 315.6%, respectively, differs from the statutory income tax rate largely due to changes in earnings mix between periods resulting in projected losses in the U.S. and projected earnings outside of the U.S. The U.S. federal and state jurisdictions are subject to valuation allowances. Income tax expense was partially offset by beneficial net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S. The income tax expense for the nine months ended September 30, 2022 was partially offset by the $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rate swaps during the period and net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S.

For the three and nine months ended September 30, 2021, we recognized an income tax benefit of $26 million and $71 million, respectively. For the three months ended September 30, 2021, our effective tax rate of 20.0% differs from the statutory income tax rate primarily due to preliminary accounting for the acquisition of KindredBio, which caused a partial release of the U.S. federal valuation allowance, as well as profits being located in jurisdictions with higher statutory tax rates. For the nine months ended September 30, 2021, our effective tax rate of 15.9% differs from the statutory income tax rate primarily because the U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 12. Commitments and Contingencies

Legal Matters

We are party to various legal actions in the normal course of business. We are not currently subject to a significant claim other than the lawsuits noted below.

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. We filed a motion to dismiss on January 13, 2021. On August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint, and we intend to oppose the plaintiffs' motion. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

On October 16, 2020, a shareholder class action lawsuit captioned Saffron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or 5.00% TEUs issued in connection with the public offering. This case was previously stayed in deference to Hunter v. Elanco Animal Health Inc. On October 24, 2022, we filed a motion to dismiss. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.
Claims seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the Seresto collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. We are vigorously defending these lawsuits.

Further, in March 2021, a U.S. House of Representatives subcommittee chair requested that Elanco produce certain documents and information related to the Seresto collar and further made a request to temporarily recall Seresto collars from the market. On June 15, 2022, the subcommittee held a hearing at which our President and Chief Executive Officer (CEO) testified. During and after the hearing, the subcommittee chair repeated his request that Elanco voluntarily recall the collars and also requested that the Environmental Protection Agency (EPA) commence administrative proceedings that would allow the EPA to remove Seresto from the market.
Seresto is a pesticide registered with the EPA. A non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. The EPA is considering this petition and asked for public comment. We submitted a comment to the EPA supporting the safety profile of Seresto. Data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. Therefore, we believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for Seresto, and it remains available to consumers globally.

In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful exclusive dealing and tying of its flea and tick products Advantage, Advantix, and Seresto and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive dealing related to Advantage and Advantix and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. We intend to defend our position vigorously. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. We accrue for liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2022 and December 31, 2021, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We are not currently subject to a significant claim other than the lawsuits noted above.

Regulatory Matters

On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. Management believes that its actions were appropriate.

Other Commitments

As of September 30, 2022, we have a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. The increase in estimated minimum lease payments in comparison to prior periods is primarily due to higher expected construction and debt costs. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025.
The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. We expect to refund approximately $15 million to the developer within the next three months, and this amount is included in other current liabilities on our condensed consolidated balance sheet as of September 30, 2022. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive is included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning at the commencement date and offset future rent expense.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic Information
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Geographic Information
Note 13. Geographic Information

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both pets and farm animals. Consistent with our operational structure, our CEO, as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.

Our products include AviPro™, Baytril™, Cydectin™, Catosal™, Denagard™, Maxiban™, Rumensin™, Pulmotil™, and other products for livestock and poultry, as well as Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family), Credelio™, Duramune™, Galliprant™, Interceptor™ Plus, Seresto, Trifexis™, and other products for pets.

We have a single customer that accounted for 12% and 11% of revenue for the three months ended September 30, 2022 and 2021, respectively, and 11% and 9% of revenue for the nine months ended September 30, 2022 and 2021, respectively. Product sales with this customer resulted in accounts receivable of $80 million and $74 million as of September 30, 2022 and December 31, 2021, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

Selected geographic area information was as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenue
United States$475 $507 $1,537 $1,621 
International553 624 1,893 2,031 
Revenue$1,028 $1,131 $3,430 $3,652 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Retirement Benefits
 9 Months Ended
Sep. 30, 2022
Retirement Benefits [Abstract]  
Retirement Benefits
Note 14. Retirement Benefits

The following table summarizes net periodic benefit cost (income) relating to our defined benefit pension plans:

Three Months Ended September 30,
Nine Months Ended September 30,
2022202120222021
Service cost$4 $4 $11 $14 
Interest cost1 1 3 2 
Expected return on plan assets(2)(2)(5)(5)
Amortization of prior service cost(1)(1)(3)(5)
Amortization of net actuarial loss— — — 1 
Net curtailments and settlements (Note 6)— (9)— (26)
Net periodic benefit cost (income)$2 $(7)$6 $(19)

The components of net periodic benefit cost (income) other than service cost and net curtailments and settlements are included in other expense, net in our condensed consolidated statements of operations. Net curtailments and settlements are included in asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Loss Per Share
Note 15. Loss Per Share

We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts (see Note 8: Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings (loss) per share.

Basic and diluted loss per share are calculated as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net loss available to common shareholders$(49)$(104)$(23)$(375)
Determination of shares:
Weighted average common shares outstanding488.4 487.3488.3 487.1
Assumed conversion of dilutive common stock equivalents (1)
— — — — 
Diluted weighted average shares outstanding488.4 487.3488.3 487.1
Loss per share (2)
Basic$(0.10)$(0.21)$(0.05)$(0.77)
Diluted$(0.10)$(0.21)$(0.05)$(0.77)
(1)For periods with a reported net loss, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2022 and 2021, approximately 4.4 million and 3.7 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2022 and 2021, approximately 2.6 million and 3.9 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.
(2)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the U.S. Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2021 included in our Form 10-K filed with the SEC on February 28, 2022 (2021 Form 10-K). In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2022 or any other future period.

In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.
Goodwill
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. We evaluate goodwill for impairment at least annually and when certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment. We begin by assessing qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying value. Based on that qualitative assessment, if we conclude that it is more likely than not that the fair value of our single reporting unit is less than its carrying value, we conduct a quantitative goodwill impairment test, which involves comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimate the fair value of our single reporting unit using a combination of the income and market approach. If the carrying value of the reporting unit exceeds its estimated fair value, we recognize an impairment loss for the difference.

During the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a quantitative goodwill impairment test. As of September 30, 2022, our single reporting unit was tested for impairment using the quantitative approach described above, resulting in an estimated fair value that exceeded the carrying amount by more than 20%. Therefore, no impairment existed with respect to our goodwill.
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
ASU 2021-10, Government Assistance (Topic 832)
The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.The adoption of this guidance did not have a material impact on our consolidated financial statements.

The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.
Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Implementation of New Financial Accounting Pronouncements (Tables)
 9 Months Ended
Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]  
Description of Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
ASU 2021-10, Government Assistance (Topic 832)
The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.The adoption of this guidance did not have a material impact on our consolidated financial statements.

The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.
Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Sales Rebates and Discounts Liability The following table summarizes the activity in our global sales rebates and discounts liability:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$284 $303 $316 $295 
Reduction of revenue169 163 524 516 
Payments(143)(146)(525)(489)
Foreign currency translation adjustments(12)(4)(17)(6)
Ending balance$298 $316 $298 $316 
Summary of Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Pet Health$471 $527 $1,722 $1,857 
Farm Animal:
Cattle227 250 722 735 
Poultry176 179 529 536 
Swine95 110 284 346 
Aqua47 44 132 111 
Total Farm Animal545 583 1,667 1,728 
Contract Manufacturing (1)
12 21 41 67 
Revenue$1,028 $1,131 $3,430 $3,652 
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Divestitures and Other Arrangements (Tables)
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Summary of Recognized Identified Assets Acquired and Liabilities Assumed The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at August 27, 2021
Cash and cash equivalents$31 
Other net working capital13 
Property and equipment33 
Intangible assets, primarily acquired in-process research and development (IPR&D)333 
Deferred income taxes, net(30)
Total identifiable net assets380 
Goodwill35 
Settlement of liability related to previous license agreement29 
Total consideration transferred$444 
Summary of Assets and Liabilities Held for Sale
Assets considered held for sale in connection with the Speke divestiture were included in the respective line items on our condensed consolidated balance sheets as follows:
December 31, 2021
Inventories$31 
Property and equipment, net50 
Total assets held for sale$81 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Asset Impairment, Restructuring and Other Special Charges (Tables)
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Summary of Asset Impairment, Restructuring and Other Special Charges
Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Restructuring charges (credits):
Severance and other costs (1)
$— $(2)$(9)$26 
Facility exit costs— — 2 — 
Acquisition related charges:
Transaction and integration costs (2)
27 30 77 141 
Non-cash and other items:
Asset impairment (3)
— 50 59 63 
Asset write-down (4)
(1)6 27 275 
Net periodic benefit income (Note 14)— (9)— (26)
Settlements and other (5)
— 36 2 39 
Total expense$26 $111 $158 $518 
(1)2022 credits primarily relate to adjustments resulting from the reversal of severance accruals associated with the November 2021 program. For the nine months ended September 30, 2021, charges primarily related to the restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.
(3)2022 includes a charge of $59 million related to the expensing of an IPR&D asset with no alternative future use licensed from BexCaFe during the second quarter. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. 2021 amounts represent the impact of adjustments to the fair value of certain IPR&D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&D project and fully impair the related asset, which was associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.
(4)2022 amounts primarily include the finalization of the write-down charge upon the final sale of the Speke manufacturing site. Asset write-down charges recorded in 2021 included the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the Speke manufacturing site during the three months ended September 30, 2021. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Also included are charges recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with announced restructuring programs.
(5)Amounts recorded during the nine months ended September 30, 2022 represent a $2 million measurement period adjustment to the charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Amounts recorded during the three and nine months ended September 30, 2021 include the initial charge associated with the settlement of the liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&D asset acquired as part of the Bayer Animal Health acquisition.
Summary of Activity in Reserves
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Severance
Balance at December 31, 2020$130 
Charges41 
Reserve adjustments(15)
Cash paid(94)
Foreign currency translation adjustments(1)
Balance at September 30, 2021$61 
Balance at December 31, 2021$126 
Reserve adjustments(9)
Cash paid(71)
Foreign currency translation adjustments(5)
Balance at September 30, 2022$41 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories Inventories consisted of the following:
September 30, 2022December 31, 2021
Finished products$612 $598 
Work in process542 565 
Raw materials and supplies240 256 
Total1,394 1,419 
Decrease to LIFO cost(54)(46)
Inventories$1,340 $1,373 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Stockholders Equity
The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$471 $79 $550 
Less: Issuance costs19 3 22 
Net proceeds$452 $76 $528 
Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt consisted of the following:
September 30, 2022December 31, 2021
Incremental Term Facility due 2025 (1)
$175 $— 
Incremental Term Facility due 2028495 499 
Incremental Term Facility due 2029 (2)
250 — 
Term Loan B due 2027 (3)
3,941 4,118 
Revolving Credit Facility— 250 
4.272% Senior Notes due 2023 (4)
344 750 
4.900% Senior Notes due 2028
750 750 
TEU Amortizing Notes due 202314 34 
Unamortized debt issuance costs(68)(82)
5,901 6,319 
Less current portion of long-term debt394 294 
Total long-term debt$5,507 $6,025 
(1)In June 2022, we entered into an incremental assumption agreement with Bank of America, N.A. supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $175 million. The new incremental term facility bears interest at the Secured Overnight Financing Rate (Term SOFR), including a credit spread adjustment, plus 175 basis points and is payable in full on June 30, 2025. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.

(2)In April 2022, we entered into an incremental assumption agreement with Farm Credit Mid-America, PCA supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $250 million maturing on April 19, 2029. The new incremental term facility bears interest at Term SOFR, including a credit spread adjustment, plus 175 basis points and will be payable in quarterly installments of principal and interest with a final balloon payment due on April 19, 2029. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.

(3)In September 2022, we repaid indebtedness outstanding under our Term Loan B. We paid $75 million in cash, composed of principal and accrued interest, resulting in a debt extinguishment loss of approximately $2 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations.
(4)In April 2022, we completed a tender offer and retired $406 million in aggregate principal amount of our 4.272% Senior Notes due August 28, 2023, resulting in a debt extinguishment loss of approximately $17 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations. The repayment was funded with proceeds received from a draw under our revolving credit facility.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments and Fair Value (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Fair Value Information
The following table summarizes the fair value information at September 30, 2022 and December 31, 2021 for foreign exchange contract assets (liabilities), investments, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2022
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$39 $— $39 $— $39 
Prepaid expense and other - forward-starting interest rate contracts designated as cash flow hedges3 — 3 — 3 
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges15 — 15 15 
Other noncurrent assets - investments10 10 — — 10 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(29)— (29)— (29)
Long-term debt, including current portion(5,969)— (5,686)— (5,686)
December 31, 2021
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$19 $— $19 $— $19 
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges8 — 8 — 8 
Other noncurrent assets - investments13 13 — — 13 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(20)— (20)— (20)
Long-term debt, including current portion(6,401)— (6,518)— (6,518)
Summary of Gain (loss), Net of Tax
The amount of net losses on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Foreign exchange forward contracts (1)
$(5)$(2)$(20)$(29)

(1)These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.
The amounts of net gains on cash flow hedges recorded, net of tax, in other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Forward-starting interest rate swaps$62 $4 $179 $52 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Schedule of Provision for Taxes on Income
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Income tax expense (benefit)$7 $(26)$34 $(71)
Effective tax rate(17.1)%20.0 %315.6 %15.9 %
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic Information (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Selected Geographic Area Information
Selected geographic area information was as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenue
United States$475 $507 $1,537 $1,621 
International553 624 1,893 2,031 
Revenue$1,028 $1,131 $3,430 $3,652 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Retirement Benefits (Tables)
 9 Months Ended
Sep. 30, 2022
Retirement Benefits [Abstract]  
Summary of Net Benefit Costs
The following table summarizes net periodic benefit cost (income) relating to our defined benefit pension plans:

Three Months Ended September 30,
Nine Months Ended September 30,
2022202120222021
Service cost$4 $4 $11 $14 
Interest cost1 1 3 2 
Expected return on plan assets(2)(2)(5)(5)
Amortization of prior service cost(1)(1)(3)(5)
Amortization of net actuarial loss— — — 1 
Net curtailments and settlements (Note 6)— (9)— (26)
Net periodic benefit cost (income)$2 $(7)$6 $(19)
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Basic And Diluted Loss
Basic and diluted loss per share are calculated as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net loss available to common shareholders$(49)$(104)$(23)$(375)
Determination of shares:
Weighted average common shares outstanding488.4 487.3488.3 487.1
Assumed conversion of dilutive common stock equivalents (1)
— — — — 
Diluted weighted average shares outstanding488.4 487.3488.3 487.1
Loss per share (2)
Basic$(0.10)$(0.21)$(0.05)$(0.77)
Diluted$(0.10)$(0.21)$(0.05)$(0.77)
(1)For periods with a reported net loss, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2022 and 2021, approximately 4.4 million and 3.7 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2022 and 2021, approximately 2.6 million and 3.9 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.
(2)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Background (Details)
Sep. 30, 2022
country
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of brands in diverse portfolio 200
Number of countries in which entity operates (more than) 90
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies (Details)
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Fair value in excess of carrying amount 20.00%
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Geographic Concentration Risk | Contract With Customer Liability | United States        
Concentration Risk [Line Items]        
Concentration risk     76.00% 72.00%
Product Return Concentration Risk | Net Revenue | Global Customers        
Concentration Risk [Line Items]        
Concentration risk 1.00% 2.00% 1.00% 1.00%
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Activity in Sales Rebates and Discounts Liability (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Change In Contract With Customer, Liability [Roll Forward]        
Beginning balance $ 284 $ 303 $ 316 $ 295
Reduction of revenue 169 163 524 516
Payments (143) (146) (525) (489)
Foreign currency translation adjustments (12) (4) (17) (6)
Ending balance $ 298 $ 316 $ 298 $ 316
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Revenue $ 1,028 $ 1,131 $ 3,430 $ 3,652
Pet Health        
Disaggregation of Revenue [Line Items]        
Revenue 471 527 1,722 1,857
Farm Animal        
Disaggregation of Revenue [Line Items]        
Revenue 545 583 1,667 1,728
Cattle        
Disaggregation of Revenue [Line Items]        
Revenue 227 250 722 735
Poultry        
Disaggregation of Revenue [Line Items]        
Revenue 176 179 529 536
Swine        
Disaggregation of Revenue [Line Items]        
Revenue 95 110 284 346
Aqua        
Disaggregation of Revenue [Line Items]        
Revenue 47 44 132 111
Contract Manufacturing        
Disaggregation of Revenue [Line Items]        
Revenue $ 12 $ 21 $ 41 $ 67
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Divestitures and Other Arrangements - Narrative (Details)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Aug. 27, 2021
USD ($)
$ / shares
Aug. 01, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 09, 2022
USD ($)
Feb. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
employee
May 05, 2021
USD ($)
Business Acquisition [Line Items]                  
Contract with customer, asset, before allowance for credit loss             $ 55    
Proceeds from site divestitures       $ 11 $ 0        
Liabilities     $ 8,203 8,203       $ 8,945  
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC                  
Business Acquisition [Line Items]                  
Liabilities           $ 59      
Payment on agreement     10            
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC | Future Milestone Payments And Sales Royalties                  
Business Acquisition [Line Items]                  
Liabilities           49      
Intangible assets, primarily acquired in-process research and development (IPR&D) | Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC                  
Business Acquisition [Line Items]                  
Finite-lived intangible assets           $ 59      
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations                  
Business Acquisition [Line Items]                  
Number of employees transferred | employee               600  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Microbiome R&D Platform Carve-Out                  
Business Acquisition [Line Items]                  
Gain on disposal       3          
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Shawnee                  
Business Acquisition [Line Items]                  
Cash received in agreement to divest   $ 78              
Duration over which proceeds will be received   3 years              
Proceeds from site divestitures     $ 11 $ 11          
KindredBio                  
Business Acquisition [Line Items]                  
Common stock price (usd per share) | $ / shares $ 9.25                
Cash paid in acquisition $ 444                
Settlement of liability related to previous license agreement                 $ 29
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Aug. 27, 2021
Business Acquisition [Line Items]      
Goodwill $ 5,716 $ 6,172  
KindredBio      
Business Acquisition [Line Items]      
Cash and cash equivalents     $ 31
Other net working capital     13
Property and equipment     33
Intangible assets, primarily acquired in-process research and development (IPR&D)     333
Deferred income taxes, net     (30)
Total identifiable net assets     380
Goodwill     35
Settlement of liability related to previous license agreement     29
Total consideration transferred     $ 444
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Divestitures and Other Arrangements - Assets and Liabilities Held for Sale (Details) - Worldwide rights to Osurnia and U.S. rights to Capstar - Held for Sale
$ in Millions
Dec. 31, 2021
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Inventories $ 31
Property and equipment, net 50
Total assets held for sale $ 81
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 30, 2021
position
Jan. 31, 2021
position
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2021
restructuring_program
Restructuring Cost and Reserve [Line Items]              
Number of restructuring programs announced | restructuring_program             2
Expected payment term       12 months      
Forecast              
Restructuring Cost and Reserve [Line Items]              
Cash paid           $ 34  
January 2021 Restructuring Plan              
Restructuring Cost and Reserve [Line Items]              
Expected number of positions eliminated | position   315          
Restructuring costs     $ 1   $ 44    
November 2021 Restructuring Plan              
Restructuring Cost and Reserve [Line Items]              
Expected number of positions eliminated | position 380            
Restructuring reserve, accrual adjustment       $ 9      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Restructuring charges (credits):        
Severance and other costs $ 0 $ (2) $ (9) $ 26
Facility exit costs 0 0 2 0
Acquisition related charges:        
Transaction and integration costs 27 30 77 141
Non-cash and other items:        
Asset impairment 0 50 59 63
Asset write-down (1) 6 27 275
Net periodic benefit income 0 (9) 0 (26)
Settlements and other 0 36 2 39
Total expense 26 111 158 518
Litigation settlement charges   $ 8   $ 8
KindredBio        
Non-cash and other items:        
Measurement period adjustment related to settlement of preexisting liability     2  
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC | Intangible assets, primarily acquired in-process research and development (IPR&D)        
Non-cash and other items:        
Asset impairment $ 59   $ 59  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) - Severance - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Restructuring Reserve [Roll Forward]    
Balance at beginning of period $ 126 $ 130
Charges   41
Reserve adjustments (9) (15)
Cash paid (71) (94)
Foreign currency translation adjustments (5) (1)
Balance at end of period $ 41 $ 61
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Finished products $ 612 $ 598
Work in process 542 565
Raw materials and supplies 240 256
Total 1,394 1,419
Decrease to LIFO cost (54) (46)
Inventories $ 1,340 $ 1,373
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity - Narrative (Details)
$ / shares in Units, shares in Millions
Jan. 22, 2020
USD ($)
trading_day
$ / shares
shares
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Class of Stock [Line Items]      
Net proceeds   $ 5,901,000,000 $ 6,319,000,000
Total      
Class of Stock [Line Items]      
Number of shares sold in public offering (in shares) | shares 11    
Proceeds after underwriting discounts and commissions $ 528,000,000    
Offering price (usd per share) | $ / shares $ 50    
Additional dilutive shares (in shares) | shares 3    
Total | Minimum      
Class of Stock [Line Items]      
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares 14    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares $ 32.00    
Total | Maximum      
Class of Stock [Line Items]      
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares 17    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares $ 38.40    
5.00% Tangible Equity Units | Senior Notes      
Class of Stock [Line Items]      
Interest rate on debt component 5.00%    
Number of consecutive trading days | trading_day 20    
2.75% Senior Amortizing Notes | Senior Notes      
Class of Stock [Line Items]      
Interest rate on debt component 2.75%    
Net proceeds $ 79,000,000    
Quarterly cash installment per amortizing note 0.6250    
Initial principal amount 7.2007    
First installment payment per amortizing note $ 0.6528    
Total      
Class of Stock [Line Items]      
Offering price (usd per share) | $ / shares $ 50    
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity - Stockholders' Equity (Details)
$ / shares in Units, $ in Millions
Jan. 22, 2020
USD ($)
$ / shares
Equity Component  
Class of Stock [Line Items]  
Fair value per unit (usd per share) | $ / shares $ 42.80
Gross proceeds $ 471
Less: Issuance costs 19
Net proceeds $ 452
Debt Component  
Class of Stock [Line Items]  
Fair value per unit (usd per share) | $ / shares $ 7.20
Gross proceeds $ 79
Less: Issuance costs 3
Net proceeds $ 76
Total  
Class of Stock [Line Items]  
Fair value per unit (usd per share) | $ / shares $ 50
Gross proceeds $ 550
Less: Issuance costs 22
Net proceeds $ 528
Total | Minimum  
Class of Stock [Line Items]  
Applicable Market Value (usd per share) | $ / shares $ 32.00
Settlement rate 130.21%
Total | Maximum  
Class of Stock [Line Items]  
Applicable Market Value (usd per share) | $ / shares $ 38.40
Settlement rate 156.25%
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Long-term Debt (Details) - USD ($)
 1 Months Ended 9 Months Ended
Apr. 30, 2022
Sep. 30, 2022
Jun. 30, 2022
Apr. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jan. 22, 2020
Debt Instrument [Line Items]                
Unamortized debt issuance costs   $ (68,000,000)     $ (68,000,000)   $ (82,000,000)  
Total debt   5,901,000,000     5,901,000,000   6,319,000,000  
Less current portion of long-term debt   394,000,000     394,000,000   294,000,000  
Total long-term debt   5,507,000,000     5,507,000,000   6,025,000,000  
Debt extinguishment loss         19,000,000 $ 0    
Credit facility | Secured Debt | Incremental Term Facility due 2025                
Debt Instrument [Line Items]                
Long-term debt, gross   175,000,000     175,000,000   0  
Debt instrument, face amount     $ 175,000,000          
Credit facility | Secured Debt | Incremental Term Facility due 2025 | SOFR                
Debt Instrument [Line Items]                
Basis spread on variable rate     1.75%          
Credit facility | Secured Debt | Incremental Term Facility due 2028                
Debt Instrument [Line Items]                
Long-term debt, gross   495,000,000     495,000,000   499,000,000  
Credit facility | Secured Debt | Incremental Term Facility Due 2029                
Debt Instrument [Line Items]                
Long-term debt, gross   250,000,000     250,000,000   0  
Debt instrument, face amount $ 250,000,000     $ 250,000,000        
Credit facility | Secured Debt | Incremental Term Facility Due 2029 | SOFR                
Debt Instrument [Line Items]                
Basis spread on variable rate       1.75%        
Credit facility | Term Loan B due 2027                
Debt Instrument [Line Items]                
Long-term debt, gross   3,941,000,000     3,941,000,000   4,118,000,000  
Repayment of debt   75,000,000            
Debt extinguishment loss   2,000,000            
Credit facility | Revolving Credit Facility                
Debt Instrument [Line Items]                
Long-term debt, gross   0     0   250,000,000  
Senior Notes | 4.272% Senior Notes Due 2023                
Debt Instrument [Line Items]                
Long-term debt, gross   $ 344,000,000     $ 344,000,000   750,000,000  
Interest rate 4.272% 4.272%   4.272% 4.272%      
Debt extinguishment loss $ 17,000,000              
Amount of debt retired $ 406,000,000     $ 406,000,000        
Senior Notes | 4.900% Senior Notes due 2028                
Debt Instrument [Line Items]                
Long-term debt, gross   $ 750,000,000     $ 750,000,000   750,000,000  
Interest rate   4.90%     4.90%      
Senior Notes | TEU Amortizing Notes due 2023                
Debt Instrument [Line Items]                
Long-term debt, gross   $ 14,000,000     $ 14,000,000   $ 34,000,000  
Interest rate               5.00%
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments and Fair Value - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Apr. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Equity method investments $ 28,000,000   $ 28,000,000   $ 28,000,000   $ 22,000,000
Unrealized gains associated with cancelled swaps     13,000,000   22,000,000    
Stranded tax benefits reclassified to earnings         17,000,000    
Reclassification from AOCI     2,000,000 $ 8,000,000 12,000,000 $ 22,000,000  
Unrealized gains 106,000,000   106,000,000   106,000,000    
Designated as Hedging Instrument              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Unrealized gain (loss) on investments     75,000,000 4,000,000 218,000,000 52,000,000  
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Notional amount 821,000,000   821,000,000   821,000,000   1,212,000,000
Cross-currency fixed interest rate swap | Designated as Hedging Instrument              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Notional amount 3,050,000,000   3,050,000,000   3,050,000,000   $ 3,800,000,000
Forward-starting interest rate contracts designated as cash flow hedges | Designated as Hedging Instrument              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Unrealized gains 103,000,000   103,000,000   103,000,000    
Forward-starting interest rate contracts designated as cash flow hedges | Designated as Hedging Instrument | Cash Flow Hedging              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Cash received for derivative settlement $ 75,000,000 $ 132,000,000          
Interest rate swaps, net of tax     $ 0 $ 0 $ 0 $ 0  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments and Fair Value - Fair Value Information (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion $ 0 $ 0
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion (5,686) (6,518)
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion 0 0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion (5,969) (6,401)
Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion (5,686) (6,518)
Prepaid expenses and other | Foreign exchange contracts not designated as hedging instruments | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Prepaid expenses and other | Foreign exchange contracts not designated as hedging instruments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 39 19
Prepaid expenses and other | Foreign exchange contracts not designated as hedging instruments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Prepaid expenses and other | Foreign exchange contracts not designated as hedging instruments | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 39 19
Prepaid expenses and other | Foreign exchange contracts not designated as hedging instruments | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 39 19
Prepaid expenses and other | Forward-starting interest rate contracts designated as cash flow hedges | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0  
Prepaid expenses and other | Forward-starting interest rate contracts designated as cash flow hedges | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 3  
Prepaid expenses and other | Forward-starting interest rate contracts designated as cash flow hedges | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0  
Prepaid expenses and other | Forward-starting interest rate contracts designated as cash flow hedges | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 3  
Prepaid expenses and other | Forward-starting interest rate contracts designated as cash flow hedges | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 3  
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 10 13
Other noncurrent assets | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 10 13
Other noncurrent assets | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 10 13
Other noncurrent assets | Foreign exchange contracts not designated as hedging instruments | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Foreign exchange contracts not designated as hedging instruments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 15 8
Other noncurrent assets | Foreign exchange contracts not designated as hedging instruments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0
Other noncurrent assets | Foreign exchange contracts not designated as hedging instruments | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 15 8
Other noncurrent assets | Foreign exchange contracts not designated as hedging instruments | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 15 8
Other current liabilities | Foreign exchange contracts not designated as hedging instruments | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0  
Other current liabilities | Foreign exchange contracts not designated as hedging instruments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (29)  
Other current liabilities | Foreign exchange contracts not designated as hedging instruments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0  
Other current liabilities | Foreign exchange contracts not designated as hedging instruments | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (29)  
Other current liabilities | Foreign exchange contracts not designated as hedging instruments | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) $ (29)  
Other current liabilities | Forward-starting interest rate contracts designated as cash flow hedges | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   0
Other current liabilities | Forward-starting interest rate contracts designated as cash flow hedges | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   (20)
Other current liabilities | Forward-starting interest rate contracts designated as cash flow hedges | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   0
Other current liabilities | Forward-starting interest rate contracts designated as cash flow hedges | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   (20)
Other current liabilities | Forward-starting interest rate contracts designated as cash flow hedges | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities)   $ (20)
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments and Fair Value - Net Gains/Losses on Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Foreign exchange forward contracts $ (5) $ (2) $ (20) $ (29)
Forward-starting interest rate contracts designated as cash flow hedges | Designated as Hedging Instrument | Cash Flow Hedging        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Forward-starting interest rate swaps $ 62 $ 4 $ 179 $ 52
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Provision for Taxes on Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Income tax expense (benefit) $ 7 $ (26) $ 34 $ (71)
Effective tax rate (17.10%) 20.00% 315.60% 15.90%
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Income tax expense (benefit) $ 7 $ (26) $ 34 $ (71)
Effective tax rate (17.10%) 20.00% 315.60% 15.90%
Release of stranded tax benefits     $ 17  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Narrative (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Oct. 16, 2020
Commitments and Contingencies Disclosure [Abstract]      
Percent of TEUs issued involved in lawsuit     5.00%
Liabilities related to litigation $ 0 $ 0  
Operating lease, lease not yet commenced liability $ 378,000,000    
Lessee, operating lease, lease not yet commenced, term of contract 25 years    
New corporate headquarters, estimated total incentive to be funded by TIF $ 64,000,000    
Tax Incremental Financing, commitment amount   $ 64,000,000  
Refund within next three months $ 15,000,000    
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic Information - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
Dec. 31, 2021
USD ($)
Concentration Risk [Line Items]          
Number of operating segments | segment     1    
Accounts receivable $ 804   $ 804   $ 833
Product Sales          
Concentration Risk [Line Items]          
Accounts receivable $ 80   $ 80   $ 74
Customer Concentration Risk | Revenue | Single Customer          
Concentration Risk [Line Items]          
Concentration risk (as a percent) 12.00% 11.00% 11.00% 9.00%  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic Information - Selected Geographic Area Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue $ 1,028 $ 1,131 $ 3,430 $ 3,652
United States        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue 475 507 1,537 1,621
International        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue $ 553 $ 624 $ 1,893 $ 2,031
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Retirement Benefits (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Defined Benefit Plan, Type [Extensible Enumeration]     Pension Plan  
Net periodic benefit cost (income) $ 0 $ (9) $ 0 $ (26)
Pension Plan        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Service cost 4 4 11 14
Interest cost 1 1 3 2
Expected return on plan assets (2) (2) (5) (5)
Amortization of prior service cost (1) (1) (3) (5)
Amortization of net actuarial loss 0 0 0 1
Net curtailments and settlements (Note 6) 0 (9) 0 (26)
Net periodic benefit cost (income) $ 2 $ (7) $ 6 $ (19)
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]                
Net loss available to common shareholders $ (49) $ (22) $ 48 $ (104) $ (210) $ (61) $ (23) $ (375)
Weighted average common shares outstanding (in shares) 488.4     487.3     488.3 487.1
Assumed conversion of dilutive common stock equivalents (in shares) 0.0     0.0     0.0 0.0
Diluted weighted average shares outstanding (in shares) 488.4     487.3     488.3 487.1
Basic (usd per share) $ (0.10)     $ (0.21)     $ (0.05) $ (0.77)
Diluted (usd per share) $ (0.10)     $ (0.21)     $ (0.05) $ (0.77)
Antidilutive shares not included in calculating diluted loss per share (in shares) 4.4     3.7     2.6 3.9
XML 71 elan-20220930_htm.xml IDEA: XBRL DOCUMENT 0001739104 2022-01-01 2022-09-30 0001739104 elan:CommonStockNoParValueMember 2022-01-01 2022-09-30 0001739104 elan:A500TangibleEquityUnitsMember 2022-01-01 2022-09-30 0001739104 2022-11-03 0001739104 2022-07-01 2022-09-30 0001739104 2021-07-01 2021-09-30 0001739104 2021-01-01 2021-09-30 0001739104 2022-09-30 0001739104 2021-12-31 0001739104 us-gaap:CommonStockMember 2020-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001739104 us-gaap:RetainedEarningsMember 2020-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001739104 2020-12-31 0001739104 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001739104 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001739104 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001739104 us-gaap:CommonStockMember 2021-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001739104 us-gaap:RetainedEarningsMember 2021-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001739104 2021-03-31 0001739104 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001739104 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001739104 us-gaap:CommonStockMember 2021-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001739104 us-gaap:RetainedEarningsMember 2021-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001739104 2021-06-30 0001739104 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001739104 us-gaap:CommonStockMember 2021-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001739104 us-gaap:RetainedEarningsMember 2021-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001739104 2021-09-30 0001739104 us-gaap:CommonStockMember 2021-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001739104 us-gaap:RetainedEarningsMember 2021-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001739104 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001739104 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001739104 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001739104 us-gaap:CommonStockMember 2022-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001739104 us-gaap:RetainedEarningsMember 2022-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001739104 2022-03-31 0001739104 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001739104 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001739104 us-gaap:CommonStockMember 2022-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001739104 us-gaap:RetainedEarningsMember 2022-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001739104 2022-06-30 0001739104 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001739104 us-gaap:CommonStockMember 2022-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001739104 us-gaap:RetainedEarningsMember 2022-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2022-07-01 2022-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2021-07-01 2021-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2022-01-01 2022-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2021-01-01 2021-09-30 0001739104 elan:PetHealthMember 2022-07-01 2022-09-30 0001739104 elan:PetHealthMember 2021-07-01 2021-09-30 0001739104 elan:PetHealthMember 2022-01-01 2022-09-30 0001739104 elan:PetHealthMember 2021-01-01 2021-09-30 0001739104 elan:CattleMember 2022-07-01 2022-09-30 0001739104 elan:CattleMember 2021-07-01 2021-09-30 0001739104 elan:CattleMember 2022-01-01 2022-09-30 0001739104 elan:CattleMember 2021-01-01 2021-09-30 0001739104 elan:PoultryMember 2022-07-01 2022-09-30 0001739104 elan:PoultryMember 2021-07-01 2021-09-30 0001739104 elan:PoultryMember 2022-01-01 2022-09-30 0001739104 elan:PoultryMember 2021-01-01 2021-09-30 0001739104 elan:SwineMember 2022-07-01 2022-09-30 0001739104 elan:SwineMember 2021-07-01 2021-09-30 0001739104 elan:SwineMember 2022-01-01 2022-09-30 0001739104 elan:SwineMember 2021-01-01 2021-09-30 0001739104 elan:AquaMember 2022-07-01 2022-09-30 0001739104 elan:AquaMember 2021-07-01 2021-09-30 0001739104 elan:AquaMember 2022-01-01 2022-09-30 0001739104 elan:AquaMember 2021-01-01 2021-09-30 0001739104 elan:FarmAnimalMember 2022-07-01 2022-09-30 0001739104 elan:FarmAnimalMember 2021-07-01 2021-09-30 0001739104 elan:FarmAnimalMember 2022-01-01 2022-09-30 0001739104 elan:FarmAnimalMember 2021-01-01 2021-09-30 0001739104 elan:ContractManufacturingMember 2022-07-01 2022-09-30 0001739104 elan:ContractManufacturingMember 2021-07-01 2021-09-30 0001739104 elan:ContractManufacturingMember 2022-01-01 2022-09-30 0001739104 elan:ContractManufacturingMember 2021-01-01 2021-09-30 0001739104 elan:KindredBioMember 2021-08-27 0001739104 elan:KindredBioMember 2021-08-27 2021-08-27 0001739104 elan:KindredBioMember 2021-05-05 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:MicrobiomeRDPlatformCarveOutMember 2022-01-01 2022-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2021-12-31 0001739104 2022-02-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeMember 2021-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeMember 2021-08-01 2021-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeMember 2022-01-01 2022-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeMember 2022-07-01 2022-09-30 0001739104 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMember 2021-12-31 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember us-gaap:InProcessResearchAndDevelopmentMember 2022-06-09 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember 2022-06-09 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember elan:FutureMilestonePaymentsAndSalesRoyaltiesMember 2022-06-09 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember 2022-07-01 2022-09-30 0001739104 2021-01-01 2021-12-31 0001739104 elan:January2021RestructuringPlanMember 2021-01-01 2021-01-31 0001739104 elan:January2021RestructuringPlanMember 2021-07-01 2021-09-30 0001739104 elan:January2021RestructuringPlanMember 2021-01-01 2021-09-30 0001739104 elan:November2021RestructuringPlanMember 2021-11-01 2021-11-30 0001739104 elan:November2021RestructuringPlanMember 2022-01-01 2022-09-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember us-gaap:InProcessResearchAndDevelopmentMember 2022-07-01 2022-09-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-09-30 0001739104 elan:KindredBioMember 2022-01-01 2022-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2020-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2021-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2021-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2022-09-30 0001739104 srt:ScenarioForecastMember 2022-10-01 2023-09-30 0001739104 elan:TangibleEquityUnitMember 2020-01-22 2020-01-22 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-22 0001739104 elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:TangibleEquityUnitEquityComponentMember 2020-01-22 0001739104 elan:TangibleEquityUnitDebtComponentMember 2020-01-22 0001739104 elan:TangibleEquityUnitEquityComponentMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitDebtComponentMember 2020-01-22 2020-01-22 0001739104 elan:A275SeniorAmortizingNotesMember us-gaap:SeniorNotesMember 2020-01-22 0001739104 elan:A275SeniorAmortizingNotesMember us-gaap:SeniorNotesMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-22 2020-01-22 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember 2020-01-22 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember 2020-01-22 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2025Member us-gaap:LineOfCreditMember 2022-09-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2025Member us-gaap:LineOfCreditMember 2021-12-31 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2028Member us-gaap:LineOfCreditMember 2022-09-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2028Member us-gaap:LineOfCreditMember 2021-12-31 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2029Member us-gaap:LineOfCreditMember 2022-09-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2029Member us-gaap:LineOfCreditMember 2021-12-31 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2022-09-30 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2021-12-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-12-31 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-09-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2021-12-31 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2022-09-30 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-12-31 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2022-09-30 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2021-12-31 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2025Member us-gaap:LineOfCreditMember 2022-06-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2025Member us-gaap:LineOfCreditMember elan:SecuredOvernightFinancingRateSOFRMember 2022-06-01 2022-06-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2029Member us-gaap:LineOfCreditMember 2022-04-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDue2029Member us-gaap:LineOfCreditMember elan:SecuredOvernightFinancingRateSOFRMember 2022-04-01 2022-04-30 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2022-09-01 2022-09-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-04-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-04-30 2022-04-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-07-01 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-07-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-01-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-04-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-01 2022-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0001739104 2020-10-16 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001739104 us-gaap:ProductMember 2022-09-30 0001739104 us-gaap:ProductMember 2021-12-31 0001739104 country:US 2022-07-01 2022-09-30 0001739104 country:US 2021-07-01 2021-09-30 0001739104 country:US 2022-01-01 2022-09-30 0001739104 country:US 2021-01-01 2021-09-30 0001739104 us-gaap:NonUsMember 2022-07-01 2022-09-30 0001739104 us-gaap:NonUsMember 2021-07-01 2021-09-30 0001739104 us-gaap:NonUsMember 2022-01-01 2022-09-30 0001739104 us-gaap:NonUsMember 2021-01-01 2021-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares elan:country pure elan:employee elan:restructuring_program elan:position elan:trading_day elan:segment false 2022 Q3 0001739104 --12-31 1 http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember 10-Q true 2022-09-30 false 001-38661 Elanco Animal Health Inc IN 82-5497352 2500 INNOVATION WAY GREENFIELD IN 46140 877 352-6261 Common stock, no par value ELAN NYSE 5.00% Tangible Equity Units ELAT NYSE Yes Yes Large Accelerated Filer false false false 474205430 1028000000 1131000000 3430000000 3652000000 472000000 502000000 1465000000 1622000000 78000000 94000000 241000000 277000000 298000000 342000000 961000000 1075000000 128000000 141000000 398000000 417000000 26000000 111000000 158000000 518000000 60000000 60000000 179000000 181000000 -8000000 -11000000 -17000000 -8000000 1070000000 1261000000 3419000000 4098000000 -42000000 -130000000 11000000 -446000000 7000000 -26000000 34000000 -71000000 -49000000 -104000000 -23000000 -375000000 -0.10 -0.21 -0.05 -0.77 -0.10 -0.21 -0.05 -0.77 488400000 487300000 488300000 487100000 488400000 487300000 488300000 487100000 -49000000 -104000000 -23000000 -375000000 62000000 4000000 179000000 52000000 -418000000 -209000000 -973000000 -506000000 2000000 6000000 4000000 -5000000 -358000000 -211000000 -798000000 -449000000 -407000000 -315000000 -821000000 -824000000 460000000 638000000 10000000 12000000 804000000 833000000 224000000 195000000 1340000000 1373000000 326000000 237000000 3154000000 3276000000 5716000000 6172000000 4766000000 5587000000 376000000 387000000 696000000 1041000000 936000000 1061000000 14948000000 16483000000 350000000 418000000 136000000 185000000 298000000 316000000 394000000 294000000 435000000 430000000 1613000000 1643000000 5507000000 6025000000 240000000 271000000 618000000 745000000 225000000 261000000 8203000000 8945000000 1000000000 1000000000 0 0 0 0 5000000000 5000000000 474124115 474124115 473119786 473119786 0 0 8724000000 8696000000 -972000000 -949000000 -1007000000 -209000000 6745000000 7538000000 14948000000 16483000000 471900000 0 8650000000 -477000000 -61000000 360000000 4000000 303000000 8476000000 -61000000 -61000000 53000000 -466000000 8000000 -405000000 -405000000 15000000 15000000 1100000 18000000 18000000 473000000.0 0 8647000000 -538000000 -8000000 -106000000 12000000 -102000000 8007000000 -210000000 -210000000 -5000000 169000000 3000000 167000000 167000000 16000000 16000000 473000000.0 0 8663000000 -748000000 -13000000 63000000 15000000 65000000 7980000000 -104000000 -104000000 4000000 -209000000 -6000000 -211000000 -211000000 17000000 17000000 473000000.0 0 8680000000 -852000000 -9000000 -146000000 9000000 -146000000 7682000000 473100000 0 8696000000 -949000000 25000000 -253000000 19000000 -209000000 7538000000 48000000 48000000 109000000 -85000000 -1000000 23000000 23000000 14000000 14000000 1000000.0 11000000 11000000 474100000 0 8699000000 -901000000 134000000 -338000000 18000000 -186000000 7612000000 -22000000 -22000000 8000000 -470000000 -1000000 -463000000 -463000000 17000000 17000000 4000000 4000000 474100000 0 8712000000 -923000000 142000000 -808000000 17000000 -649000000 7140000000 -49000000 -49000000 62000000 -418000000 -2000000 -358000000 -358000000 13000000 13000000 1000000 1000000 474100000 0 8724000000 -972000000 204000000 -1226000000 15000000 -1007000000 6745000000 -23000000 -375000000 514000000 542000000 -36000000 -119000000 44000000 48000000 87000000 334000000 -3000000 0 3000000 -2000000 0 64000000 -19000000 0 207000000 0 384000000 243000000 11000000 7000000 439000000 260000000 71000000 60000000 0 342000000 11000000 0 11000000 35000000 23000000 11000000 9000000 8000000 -103000000 -456000000 425000000 500000000 563000000 500000000 607000000 555000000 813000000 250000000 2000000 1000000 14000000 0 0 -11000000 -17000000 -17000000 -465000000 166000000 -49000000 -23000000 -178000000 -53000000 638000000 506000000 460000000 453000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. Background</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a portfolio of approximately 200 brands to pet owners, veterinarians and farm animal producers in more than 90 countries. Our products are generally sold worldwide directly to wholesalers, distributors, and independent retailers. Certain products are also sold directly to farm animal producers and veterinarians. We have a diversified business of products across species consisting of: dogs and cats (collectively, pet health) and cattle, poultry, swine and aqua (collectively, farm animal).</span></div>Elanco was incorporated in Indiana on September 18, 2018, and prior to that was a business unit of Eli Lilly and Company (Lilly). 200 90 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Basis of Presentation and Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the U.S. Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2021 included in our Form 10-K filed with the SEC on February 28, 2022 (</span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910422000005/elan-20211231.htm" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2022 or any other future period. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies set forth in Note 3 to the consolidated financial statements in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910422000005/elan-20211231.htm" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to goodwill and the adoption of the standard that was effective January 1, 2022 as described in Note 3: Implementation of New Financial Accounting Pronouncements.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Goodwill</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. We evaluate goodwill for impairment at least annually and when certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment. We begin by assessing qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying value. Based on that qualitative assessment, if we conclude that it is more likely than not that the fair value of our single reporting unit is less than its carrying value, we conduct a quantitative goodwill impairment test, which involves comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimate the fair value of our single reporting unit using a combination of the income and market approach. If the carrying value of the reporting unit exceeds its estimated fair value, we recognize an impairment loss for the difference.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a quantitative goodwill impairment test. As of September 30, 2022, our single reporting unit was tested for impairment using the quantitative approach described above, resulting in an estimated fair value that exceeded the carrying amount by more than 20%. Therefore, no impairment existed with respect to our goodwill.</span></div> <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the U.S. Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2021 included in our Form 10-K filed with the SEC on February 28, 2022 (</span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910422000005/elan-20211231.htm" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2022 or any other future period. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div> <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. We evaluate goodwill for impairment at least annually and when certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment. We begin by assessing qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying value. Based on that qualitative assessment, if we conclude that it is more likely than not that the fair value of our single reporting unit is less than its carrying value, we conduct a quantitative goodwill impairment test, which involves comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimate the fair value of our single reporting unit using a combination of the income and market approach. If the carrying value of the reporting unit exceeds its estimated fair value, we recognize an impairment loss for the difference.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a quantitative goodwill impairment test. As of September 30, 2022, our single reporting unit was tested for impairment using the quantitative approach described above, resulting in an estimated fair value that exceeded the carrying amount by more than 20%. Therefore, no impairment existed with respect to our goodwill.</span></div> 0.20 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. Implementation of New Financial Accounting Pronouncements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 832) </span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur. </span></div></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 832) </span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur. </span></div></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was effective January 1, 2022 and was adopted on that date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 832) </span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update require annual disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature, terms and conditions associated with the transactions and the financial statement line items affected.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2022. Adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current credit facilities reference London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. The underlying credit agreements include provisions which outline criteria for establishing a consistent replacement benchmark rate in the event that LIBOR is discontinued. Therefore, it is unlikely that we will need to adopt this optional guidance. However, we will continue to evaluate the impact as reference rate reform activities occur. </span></div></td></tr></table></div> <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. Revenue </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales rebates and discounts are based on specific agreements. The most significant of our sales rebate and discount programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs, and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of September 30, 2022 and 2021, the aggregate liability for sales rebates and discounts for these countries represented approximately 76% and 72%, respectively, of our total liability. </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our global sales rebates and discounts liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022 and 2021 for product shipped in previous periods were not material.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual global product returns were approximately 1% and 2% of net revenue for the three months ended September 30, 2022 and 2021, respectively. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by product category:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cattle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poultry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swine</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aqua</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Farm Animal</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. 0.76 0.72 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our global sales rebates and discounts liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 284000000 303000000 316000000 295000000 169000000 163000000 524000000 516000000 143000000 146000000 525000000 489000000 12000000 4000000 17000000 6000000 298000000 316000000 298000000 316000000 0.01 0.02 0.01 0.01 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by product category:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cattle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poultry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swine</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aqua</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Farm Animal</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. 471000000 527000000 1722000000 1857000000 227000000 250000000 722000000 735000000 176000000 179000000 529000000 536000000 95000000 110000000 284000000 346000000 47000000 44000000 132000000 111000000 545000000 583000000 1667000000 1728000000 12000000 21000000 41000000 67000000 1028000000 1131000000 3430000000 3652000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. Acquisitions, Divestitures and Other Arrangements</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KindredBio Acquisition</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that developed innovative biologics focused on saving and improving the lives of pets. The acquisition further accelerates our pet health expansion, particularly by expanding our presence in dermatology.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of the acquisition are included in our condensed consolidated financial statements from the date of acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the merger agreement, we acquired all outstanding stock of KindredBio for $9.25 per share, or an aggregate cash purchase consideration of $444 million. We utilized our revolving credit facility and cash on hand to finance the acquisition. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, we signed an agreement with KindredBio to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. We calculated the fair value of the liability associated with that agreement using an income approach leveraging the estimated sales royalty, sales milestone and technical milestone payments avoided, and settled the $29 million liability upon the closing of our acquisition of KindredBio.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and loss from KindredBio included in our condensed consolidated statements of operations for the three and nine months ended September 30, 2022 were immaterial.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at August 27, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other net working capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, primarily acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of liability related to previous license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of assets acquired and liabilities assumed was finalized during the third quarter of 2022. The measurement period adjustments recorded during 2022, which were made to reflect the facts and circumstances in existence as of the acquisition date, primarily related to changes in the estimated fair value of acquired IPR&amp;D and minor tax and working capital adjustments. The net impact of these adjustments was not material. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is mostly comprised of land, buildings, equipment (including laboratory equipment, furniture and fixtures, and computer equipment), and construction in progress. The estimated fair value of real and personal property was determined using the sales comparison data valuation technique, to the extent that market data for similar assets was available. When market pricing data was not available for a given asset or asset class, the direct replacement cost method was used.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset (including revenues, cost of sales, R&amp;D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is primarily attributable to KindredBio's assembled workforce and expected synergies. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Microbiome R&amp;D platform carve-out</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we signed an agreement to transfer assets associated with our microbiome R&amp;D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retain a non-voting, minority stake in the company. Assets transferred include intellectual property and laboratory equipment. The book values of those assets were not material. In addition, we have entered into transitional services agreements with the company for certain services. We have determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results. During the nine months ended September 30, 2022, we recorded a gain on the disposal of approximately $3 million. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shawnee and Speke</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the planned transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx will manufacture existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which is included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets. The divestitures did not represent a strategic shift that has or will have a major effect on our operations and financial results, and therefore do not qualify for reporting as discontinued operations. See Note 6: Asset Impairment, Restructuring and Other Special Charges for further information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the terms of the agreements, we expect to receive aggregate gross cash proceeds of $78 million from the sales of Shawnee and Speke over a period of three years beginning in the second half of 2022. During the three months ended September 30, 2022, we received cash proceeds of $11 million. Receivables for the remaining expected cash proceeds are included in other receivables and other noncurrent assets on our condensed consolidated balance sheets. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets considered held for sale in connection with the Speke divestiture were included in the respective line items on our condensed consolidated balance sheets as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BexCaFe Arrangement</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bexacat, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&amp;D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. The initial fair value of the contingent payments was calculated based on an income approach, with payments adjusted for probability of success and then discounted to a present value. There is no minimum payout due on the contingent consideration and the maximum payout is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&amp;D asset because we concluded that it did not have an alternative future use. This amount is included in asset impairment, restructuring, and other special charges in our condensed consolidated statement of operations for the nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $10 million to BexCaFe under the terms of this agreement during the three months ended September 30, 2022. Contingent consideration liabilities of $49 million are included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2022. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the effective date of the license agreement, our condensed consolidated financial statements include the assets, liabilities, operating results and cash flows of BexCaFe. Based on the guidance in ASC 810, income and expense between us and BexCaFe have been eliminated against the income or expense included in the financial statements of BexCaFe. The resulting amounts after the effect of these eliminations were included in our condensed consolidated financial statements for the three and nine months ended September 30, 2022 and were not material.</span></div> 9.25 444000000 -29000000 The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at August 27, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other net working capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, primarily acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of liability related to previous license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 31000000 13000000 33000000 333000000 30000000 380000000 35000000 29000000 444000000 3000000 600 55000000 78000000 P3Y 11000000 11000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets considered held for sale in connection with the Speke divestiture were included in the respective line items on our condensed consolidated balance sheets as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 31000000 50000000 81000000 59000000 59000000 49000000 10000000 49000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. Asset Impairment, Restructuring and Other Special Charges </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. As discussed further below, restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For finite-lived intangible assets and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">2021 Restructuring Programs</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we announced two separate restructuring programs to improve operating efficiencies.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions proposed in January 2021 focused on streamlining processes and delivering increased efficiency in functional areas, while improving the productivity of our investments in innovation. As part of the restructuring plan, we closed our R&amp;D sites in Manukau, New Zealand and Cuxhaven, Germany. We also reduced duplication and optimized structures in U.S. operations, marketing, manufacturing and quality central functions, and administrative areas. The restructuring resulted in the elimination of approximately 315 positions around the world. Activities related to this initiative resulted in adjustments of $1 million to reduce severance accruals and net charges of $44 million for the three and nine months ended September 30, 2021, respectively. The adjustments reflect a change in estimate resulting from negotiations. Restructuring charges under this program were substantially complete at the end of 2021.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program announced in November 2021 included initiatives to consolidate certain international commercial operations into one organization, integrate our centralized global marketing organization into country level commercial organizations, transform and simplify our R&amp;D organizational structure, and other organizational adjustments. In connection with the proposed restructuring, we eliminated 380 positions. During the nine months ended September 30, 2022, we recorded adjustments of $9 million to reduce severance accruals resulting from final negotiations and certain restructured employees filling open positions. Restructuring charges under this program were substantially complete as of September 30, 2022; however, we may continue to make adjustments to our severance accruals to reflect changes in estimates resulting from ongoing negotiations.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Components of asset impairment, restructuring and other special charges are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges (credits): </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition related charges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash and other items:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-down</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income (Note 14)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expense</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">2022 credits primarily relate to adjustments resulting from the reversal of severance accruals associated with the November 2021 program. For the nine months ended September 30, 2021, charges primarily related to the restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">2022 includes a charge of $59 million related to the expensing of an IPR&amp;D asset with no alternative future use licensed from BexCaFe during the second quarter. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. 2021 amounts represent the impact of adjustments to the fair value of certain IPR&amp;D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&amp;D project and fully impair the related asset, which was associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">2022 amounts primarily include the finalization of the write-down charge upon the final sale of the Speke manufacturing site. Asset write-down charges recorded in 2021 included the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the Speke manufacturing site during the three months ended September 30, 2021. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Also included are charges recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with announced restructuring programs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Amounts recorded during the nine months ended September 30, 2022 represent a $2 million measurement period adjustment to the charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Amounts recorded during the three and nine months ended September 30, 2021 include the initial charge associated with the settlement of the liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&amp;D asset acquired as part of the Bayer Animal Health acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our reserves established in connection with restructuring activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain country negotiations and regulations. As of September 30, 2022, we expect to pay approximately $34 million over the next 12 months. We believe that the reserves are adequate.</span></div> 2 315 1000000 44000000 380 -9000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Components of asset impairment, restructuring and other special charges are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges (credits): </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition related charges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash and other items:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-down</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income (Note 14)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expense</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">2022 credits primarily relate to adjustments resulting from the reversal of severance accruals associated with the November 2021 program. For the nine months ended September 30, 2021, charges primarily related to the restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">2022 includes a charge of $59 million related to the expensing of an IPR&amp;D asset with no alternative future use licensed from BexCaFe during the second quarter. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. 2021 amounts represent the impact of adjustments to the fair value of certain IPR&amp;D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&amp;D project and fully impair the related asset, which was associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">2022 amounts primarily include the finalization of the write-down charge upon the final sale of the Speke manufacturing site. Asset write-down charges recorded in 2021 included the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the Speke manufacturing site during the three months ended September 30, 2021. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Also included are charges recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with announced restructuring programs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Amounts recorded during the nine months ended September 30, 2022 represent a $2 million measurement period adjustment to the charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion. Amounts recorded during the three and nine months ended September 30, 2021 include the initial charge associated with the settlement of the liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&amp;D asset acquired as part of the Bayer Animal Health acquisition.</span></div> 0 -2000000 -9000000 26000000 0 0 2000000 0 27000000 30000000 77000000 141000000 0 50000000 59000000 63000000 -1000000 6000000 27000000 275000000 0 -9000000 0 -26000000 0 -36000000 -2000000 -39000000 26000000 111000000 158000000 518000000 59000000 59000000 2000000 8000000 8000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our reserves established in connection with restructuring activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 130000000 41000000 -15000000 94000000 -1000000 61000000 126000000 -9000000 71000000 -5000000 41000000 34000000 P12M <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. Inventories </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 612000000 598000000 542000000 565000000 240000000 256000000 1394000000 1419000000 54000000 46000000 1340000000 1373000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. Equity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tangible Equity Unit (TEU) Offering</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in current portion of long-term debt on the condensed consolidated balance sheets. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per unit</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.00 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The senior amortizing notes have an aggregate principal amount of $79 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate is equivalent to 5.00% per year with respect to the $50 stated amount per TEU.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Market Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Issued</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equal to or greater than $38.40</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3021 shares (minimum settlement rate)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than $38.40, but greater than $32.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 divided by applicable market value</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to $32.00</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5625 (maximum settlement rate)</span></div></td></tr></table></div>The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14 million shares or a maximum of 17 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period. The entire additional 3 million shares are included in diluted weighted average shares outstanding if the applicable market value is at or below $32.00 and the impact is not anti-dilutive. 11000000 0.0500 528000000 50 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per unit</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.00 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Market Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Issued</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equal to or greater than $38.40</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3021 shares (minimum settlement rate)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than $38.40, but greater than $32.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 divided by applicable market value</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to $32.00</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5625 (maximum settlement rate)</span></div></td></tr></table></div> 42.80 7.20 50.00 471000000 79000000 550000000 19000000 3000000 22000000 452000000 76000000 528000000 79000000 0.0275 0.6250 7.2007 0.6528 0.0500 50 20 38.40 1.3021 38.40 32.00 50 32.00 1.5625 14000000 17000000 14000000 32.00 38.40 3000000 32.00 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Debt </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2025 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2029 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B due 2027 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU Amortizing Notes due 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,319 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In June 2022, we entered into an incremental assumption agreement with Bank of America, N.A. supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $175 million. The new incremental term facility bears interest at the Secured Overnight Financing Rate (Term SOFR), including a credit spread adjustment, plus 175 basis points and is payable in full on June 30, 2025. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In April 2022, we entered into an incremental assumption agreement with Farm Credit Mid-America, PCA supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $250 million maturing on April 19, 2029. The new incremental term facility bears interest at Term SOFR, including a credit spread adjustment, plus 175 basis points and will be payable in quarterly installments of principal and interest with a final balloon payment due on April 19, 2029. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In September 2022, we repaid indebtedness outstanding under our Term Loan B. We paid $75 million in cash, composed of principal and accrued interest, resulting in a debt extinguishment loss of approximately $2 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In April 2022, we completed a tender offer and retired $406 million in aggregate principal amount of our 4.272% Senior Notes due August 28, 2023, resulting in a debt extinguishment loss of approximately $17 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations. The repayment was funded with proceeds received from a draw under our revolving credit facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all of our debt covenants as of September 30, 2022.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2025 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2029 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B due 2027 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU Amortizing Notes due 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,319 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In June 2022, we entered into an incremental assumption agreement with Bank of America, N.A. supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $175 million. The new incremental term facility bears interest at the Secured Overnight Financing Rate (Term SOFR), including a credit spread adjustment, plus 175 basis points and is payable in full on June 30, 2025. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In April 2022, we entered into an incremental assumption agreement with Farm Credit Mid-America, PCA supplementing and amending our existing credit agreement dated August 1, 2020 relating to our senior secured credit facility. The incremental assumption agreement provides for a new incremental term facility with an aggregate principal amount of $250 million maturing on April 19, 2029. The new incremental term facility bears interest at Term SOFR, including a credit spread adjustment, plus 175 basis points and will be payable in quarterly installments of principal and interest with a final balloon payment due on April 19, 2029. The proceeds were used to repay a portion of our outstanding obligations under our revolving credit facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">In September 2022, we repaid indebtedness outstanding under our Term Loan B. We paid $75 million in cash, composed of principal and accrued interest, resulting in a debt extinguishment loss of approximately $2 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations.</span></div>(4)In April 2022, we completed a tender offer and retired $406 million in aggregate principal amount of our 4.272% Senior Notes due August 28, 2023, resulting in a debt extinguishment loss of approximately $17 million recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations. The repayment was funded with proceeds received from a draw under our revolving credit facility. 175000000 0 495000000 499000000 250000000 0 3941000000 4118000000 0 250000000 0.04272 344000000 750000000 0.04900 750000000 750000000 14000000 34000000 68000000 82000000 5901000000 6319000000 394000000 294000000 5507000000 6025000000 175000000 0.0175 250000000 0.0175 75000000 -2000000 406000000 0.04272 -17000000 Note 10. Financial Instruments and Fair Value <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of our customers on a regular basis, monitor economic conditions, and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $28 million and $22 million as of September 30, 2022 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Unrealized net gains and losses on our investments for the three and nine months ended September 30, 2022 and 2021 were immaterial.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2022 and December 31, 2021 for foreign exchange contract assets (liabilities), investments, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,969)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,686)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,686)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,401)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,518)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,518)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing activities section of the consolidated statements of cash flows. Our outstanding positions are discussed below. </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, and Chinese yuan. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2022 and December 31, 2021, we had outstanding foreign exchange contracts with aggregate notional amounts of $821 million and $1,212 million, respectively. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net losses on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives designated as hedges</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate risk with regard to our existing floating-rate debt, and we utilize interest rate swap contracts to mitigate the variability in cash flows by effectively converting the floating-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated these swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Our outstanding forward-starting interest rate swaps have maturities ranging between 2023 and 2025 with aggregate notional amounts of $3,050 million and $3,800 million as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gains on cash flow hedges recorded, net of tax, in other comprehensive income (loss), are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022 and 2021, net gains on cash flow hedges recorded in other comprehensive income (loss) included gains of $75 million and $4 million, respectively, related to mark-to-market adjustments. During the nine months ended September 30, 2022 and 2021, net gains on cash flow hedges recorded in other comprehensive income (loss) included gains of $218 million and $52 million, respectively, related to mark-to-market adjustments. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 and September 2022, we took advantage of market opportunities to restructure our interest rate swap portfolio. We unwound the existing swaps and simultaneously entered into new agreements with the same notional amounts and covering the same tenors. As a result, we received cash settlements of $132 million and $75 million in the respective periods. These gains were initially recognized in accumulated other comprehensive loss and will be reclassified to interest expense, net of capitalized interest over the period during which the related interest payments will be made. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, we reclassified $13 million and $22 million, respectively, of gains relating to our terminated interest rate swaps from accumulated other comprehensive loss to interest expense, net of capitalized interest. Additionally, as a result of the April 2022 interest rate swap settlement, other comprehensive income (loss) for the nine months ended September 30, 2022 included a $17 million reclassification of a stranded tax benefit from accumulated other comprehensive loss, based on our policy to reclassify income tax effects from accumulated other comprehensive loss using the portfolio approach. Other than the reclassification of the stranded tax benefit, there was no tax effect recorded in relation to our cash flow hedges for the three and nine months ended September 30, 2022 and 2021 after the application of the U.S. valuation allowance. See Note 11: Income Taxes for further discussion. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, we reclassified $2 million and $8 million, respectively, of net losses into interest expense, net of capitalized interest in our condensed consolidated statements of operations. During the nine months ended September 30, 2022 and 2021, we reclassified $12 million and $22 million, respectively, of net losses into interest expense. Over the next 12 months, we expect to reclassify a gain of $106 million, which includes $103 million relating to the interest rate swap settlements, to interest expense, net of capitalized interest.</span></div> 28000000 22000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2022 and December 31, 2021 for foreign exchange contract assets (liabilities), investments, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,969)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,686)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,686)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,401)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,518)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,518)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 39000000 0 39000000 0 39000000 3000000 0 3000000 0 3000000 15000000 0 15000000 15000000 10000000 10000000 0 0 10000000 -29000000 0 -29000000 0 -29000000 5969000000 0 5686000000 0 5686000000 19000000 0 19000000 0 19000000 8000000 0 8000000 0 8000000 13000000 13000000 0 0 13000000 -20000000 0 -20000000 0 -20000000 6401000000 0 6518000000 0 6518000000 821000000 1212000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net losses on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gains on cash flow hedges recorded, net of tax, in other comprehensive income (loss), are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -5000000 -2000000 -20000000 -29000000 3050000000 3800000000 62000000 4000000 179000000 52000000 75000000 4000000 218000000 52000000 132000000 75000000 13000000 22000000 17000000 0 0 0 0 -2000000 -8000000 -12000000 -22000000 106000000 103000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, we recognized income tax expense of $7 million and $34 million, respectively. Our effective tax rate of (17.1)% and 315.6%, respectively, differs from the statutory income tax rate largely due to changes in earnings mix between periods resulting in projected losses in the U.S. and projected earnings outside of the U.S. The U.S. federal and state jurisdictions are subject to valuation allowances. Income tax expense was partially offset by beneficial net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S. The income tax expense for the nine months ended September 30, 2022 was partially offset by the $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rate swaps during the period and net foreign currency gains, which are nontaxable in certain tax jurisdictions outside of the U.S.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized an income tax benefit of $26 million and $71 million, respectively. For the three months ended September 30, 2021, our effective tax rate of 20.0% differs from the statutory income tax rate primarily due to preliminary accounting for the acquisition of KindredBio, which caused a partial release of the U.S. federal valuation allowance, as well as profits being located in jurisdictions with higher statutory tax rates. For the nine months ended September 30, 2021, our effective tax rate of 15.9% differs from the statutory income tax rate primarily because the U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 7000000 -26000000 34000000 -71000000 -0.171 0.200 3.156 0.159 7000000 34000000 -0.171 3.156 17000000 -26000000 -71000000 0.200 0.159 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. Commitments and Contingencies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various legal actions in the normal course of business. We are not currently subject to a significant claim other than the lawsuits noted below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hunter v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. We filed a motion to dismiss on January 13, 2021. On August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint, and we intend to oppose the plaintiffs' motion. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Saffron Capital Corporation v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or 5.00% TEUs issued in connection with the public offering. This case was previously stayed in deference to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hunter v. Elanco Animal Health Inc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On October 24, 2022, we filed a motion to dismiss. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. We are vigorously defending these lawsuits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in March 2021, a U.S. House of Representatives subcommittee chair requested that Elanco produce certain documents and information related to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collar and further made a request to temporarily recall </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collars from the market. On June 15, 2022, the subcommittee held a hearing at which our President and Chief Executive Officer (CEO) testified. During and after the hearing, the subcommittee chair repeated his request that Elanco voluntarily recall the collars and also requested that the Environmental Protection Agency (EPA) commence administrative proceedings that would allow the EPA to remove </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the market.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a pesticide registered with the EPA. A non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto’s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pesticide registration and suspend the registration pending cancellation. The EPA is considering this petition and asked for public comment. We submitted a comment to the EPA supporting the safety profile of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. Therefore, we believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and it remains available to consumers globally.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful exclusive dealing and tying of its flea and tick products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive dealing related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantix </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. We intend to defend our position vigorously. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. We accrue for liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2022 and December 31, 2021, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We are not currently subject to a significant claim other than the lawsuits noted above.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. Management believes that its actions were appropriate.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we have a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. The increase in estimated minimum lease payments in comparison to prior periods is primarily due to higher expected construction and debt costs. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025. </span></div>The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. We expect to refund approximately $15 million to the developer within the next three months, and this amount is included in other current liabilities on our condensed consolidated balance sheet as of September 30, 2022. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive is included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning at the commencement date and offset future rent expense. 0.0500 0 0 378000000 P25Y 64000000 64000000 15000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. Geographic Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both pets and farm animals. Consistent with our operational structure, our CEO, as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AviPro™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Baytril™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cydectin™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Catosal™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denagard™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maxiban™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rumensin™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pulmotil™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other products for livestock and poultry, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantix™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advocate™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (collectively referred to as the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage Family</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credelio™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duramune™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Galliprant™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interceptor™ Plus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trifexis™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other products for pets.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a single customer that accounted for 12% and 11% of revenue for the three months ended September 30, 2022 and 2021, respectively, and 11% and 9% of revenue for the nine months ended September 30, 2022 and 2021, respectively. Product sales with this customer resulted in accounts receivable of $80 million and $74 million as of September 30, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected geographic area information was as follows:</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.12 0.11 0.11 0.09 80000000 74000000 <div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected geographic area information was as follows:</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 475000000 507000000 1537000000 1621000000 553000000 624000000 1893000000 2031000000 1028000000 1131000000 3430000000 3652000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. Retirement Benefits</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost (income) relating to our defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNDJlODYwMzgyYjRiMWNhNTZlZjFjMDQxMDIwM2JjL3NlYzpjYzQyZTg2MDM4MmI0YjFjYTU2ZWYxYzA0MTAyMDNiY184NS9mcmFnOjZkMzdkMWJlY2U0NjQ5OTU5YTBkNDA4ODNkYzlkMzJmL3RleHRyZWdpb246NmQzN2QxYmVjZTQ2NDk5NTlhMGQ0MDg4M2RjOWQzMmZfNTAx_2af73369-bfd0-400e-aaca-8e451ceafc86">pension plans</span>:</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net curtailments and settlements (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (income) other than service cost and net curtailments and settlements are included in other expense, net in our condensed consolidated statements of operations. Net curtailments and settlements are included in asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.</span></div> <div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost (income) relating to our defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNjNDJlODYwMzgyYjRiMWNhNTZlZjFjMDQxMDIwM2JjL3NlYzpjYzQyZTg2MDM4MmI0YjFjYTU2ZWYxYzA0MTAyMDNiY184NS9mcmFnOjZkMzdkMWJlY2U0NjQ5OTU5YTBkNDA4ODNkYzlkMzJmL3RleHRyZWdpb246NmQzN2QxYmVjZTQ2NDk5NTlhMGQ0MDg4M2RjOWQzMmZfNTAx_2af73369-bfd0-400e-aaca-8e451ceafc86">pension plans</span>:</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net curtailments and settlements (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4000000 4000000 11000000 14000000 1000000 1000000 3000000 2000000 2000000 2000000 5000000 5000000 -1000000 -1000000 -3000000 -5000000 0 0 0 -1000000 0 9000000 0 26000000 2000000 -7000000 6000000 -19000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts (see Note 8: Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings (loss) per share. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share are calculated as follows:</span></div><div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common shareholders</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Determination of shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed conversion of dilutive common stock equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For periods with a reported net loss, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2022 and 2021, approximately 4.4 million and 3.7 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2022 and 2021, approximately 2.6 million and 3.9 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.</span></div> <div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share are calculated as follows:</span></div><div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common shareholders</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Determination of shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed conversion of dilutive common stock equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For periods with a reported net loss, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2022 and 2021, approximately 4.4 million and 3.7 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2022 and 2021, approximately 2.6 million and 3.9 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.</span></div> -49000000 -104000000 -23000000 -375000000 488400000 487300000 488300000 487100000 0 0 0 0 488400000 487300000 488300000 487100000 -0.10 -0.21 -0.05 -0.77 -0.10 -0.21 -0.05 -0.77 4400000 3700000 2600000 3900000 EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 307 259 1 false 76 0 false 10 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.elanco.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited Condensed Consolidated Statements of Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Background Sheet http://www.elanco.com/role/Background Background Notes 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 10 false false R11.htm 0000011 - Disclosure - Revenue Sheet http://www.elanco.com/role/Revenue Revenue Notes 11 false false R12.htm 0000012 - Disclosure - Acquisitions, Divestitures and Other Arrangements Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements Acquisitions, Divestitures and Other Arrangements Notes 12 false false R13.htm 0000013 - Disclosure - Asset Impairment, Restructuring and Other Special Charges Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges Asset Impairment, Restructuring and Other Special Charges Notes 13 false false R14.htm 0000014 - Disclosure - Inventories Sheet http://www.elanco.com/role/Inventories Inventories Notes 14 false false R15.htm 0000015 - Disclosure - Equity Sheet http://www.elanco.com/role/Equity Equity Notes 15 false false R16.htm 0000016 - Disclosure - Debt Sheet http://www.elanco.com/role/Debt Debt Notes 16 false false R17.htm 0000017 - Disclosure - Financial Instruments and Fair Value Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValue Financial Instruments and Fair Value Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://www.elanco.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://www.elanco.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Geographic Information Sheet http://www.elanco.com/role/GeographicInformation Geographic Information Notes 20 false false R21.htm 0000021 - Disclosure - Retirement Benefits Sheet http://www.elanco.com/role/RetirementBenefits Retirement Benefits Notes 21 false false R22.htm 0000022 - Disclosure - Loss Per Share Sheet http://www.elanco.com/role/LossPerShare Loss Per Share Notes 22 false false R23.htm 0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 23 false false R24.htm 0000024 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables Implementation of New Financial Accounting Pronouncements (Tables) Tables http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements 24 false false R25.htm 0000025 - Disclosure - Revenue (Tables) Sheet http://www.elanco.com/role/RevenueTables Revenue (Tables) Tables http://www.elanco.com/role/Revenue 25 false false R26.htm 0000026 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables Acquisitions, Divestitures and Other Arrangements (Tables) Tables http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements 26 false false R27.htm 0000027 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables Asset Impairment, Restructuring and Other Special Charges (Tables) Tables http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges 27 false false R28.htm 0000028 - Disclosure - Inventories (Tables) Sheet http://www.elanco.com/role/InventoriesTables Inventories (Tables) Tables http://www.elanco.com/role/Inventories 28 false false R29.htm 0000029 - Disclosure - Equity (Tables) Sheet http://www.elanco.com/role/EquityTables Equity (Tables) Tables http://www.elanco.com/role/Equity 29 false false R30.htm 0000030 - Disclosure - Debt (Tables) Sheet http://www.elanco.com/role/DebtTables Debt (Tables) Tables http://www.elanco.com/role/Debt 30 false false R31.htm 0000031 - Disclosure - Financial Instruments and Fair Value (Tables) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueTables Financial Instruments and Fair Value (Tables) Tables http://www.elanco.com/role/FinancialInstrumentsandFairValue 31 false false R32.htm 0000032 - Disclosure - Income Taxes (Tables) Sheet http://www.elanco.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.elanco.com/role/IncomeTaxes 32 false false R33.htm 0000033 - Disclosure - Geographic Information (Tables) Sheet http://www.elanco.com/role/GeographicInformationTables Geographic Information (Tables) Tables http://www.elanco.com/role/GeographicInformation 33 false false R34.htm 0000034 - Disclosure - Retirement Benefits (Tables) Sheet http://www.elanco.com/role/RetirementBenefitsTables Retirement Benefits (Tables) Tables http://www.elanco.com/role/RetirementBenefits 34 false false R35.htm 0000035 - Disclosure - Loss Per Share (Tables) Sheet http://www.elanco.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.elanco.com/role/LossPerShare 35 false false R36.htm 0000036 - Disclosure - Background (Details) Sheet http://www.elanco.com/role/BackgroundDetails Background (Details) Details http://www.elanco.com/role/Background 36 false false R37.htm 0000037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) Details http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies 37 false false R38.htm 0000038 - Disclosure - Revenue - Narrative (Details) Sheet http://www.elanco.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 38 false false R39.htm 0000039 - Disclosure - Revenue - Activity in Sales Rebates and Discounts Liability (Details) Sheet http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails Revenue - Activity in Sales Rebates and Discounts Liability (Details) Details 39 false false R40.htm 0000040 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 40 false false R41.htm 0000041 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Narrative (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails Acquisitions, Divestitures and Other Arrangements - Narrative (Details) Details http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables 41 false false R42.htm 0000042 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Details 42 false false R43.htm 0000043 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Assets and Liabilities Held for Sale (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails Acquisitions, Divestitures and Other Arrangements - Assets and Liabilities Held for Sale (Details) Details 43 false false R44.htm 0000044 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Details http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables 44 false false R45.htm 0000045 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) Details 45 false false R46.htm 0000046 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) Details 46 false false R47.htm 0000047 - Disclosure - Inventories (Details) Sheet http://www.elanco.com/role/InventoriesDetails Inventories (Details) Details http://www.elanco.com/role/InventoriesTables 47 false false R48.htm 0000048 - Disclosure - Equity - Narrative (Details) Sheet http://www.elanco.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 48 false false R49.htm 0000049 - Disclosure - Equity - Stockholders' Equity (Details) Sheet http://www.elanco.com/role/EquityStockholdersEquityDetails Equity - Stockholders' Equity (Details) Details 49 false false R50.htm 0000050 - Disclosure - Debt - Long-term Debt (Details) Sheet http://www.elanco.com/role/DebtLongtermDebtDetails Debt - Long-term Debt (Details) Details 50 false false R51.htm 0000051 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails Financial Instruments and Fair Value - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - Financial Instruments and Fair Value - Fair Value Information (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails Financial Instruments and Fair Value - Fair Value Information (Details) Details 52 false false R53.htm 0000053 - Disclosure - Financial Instruments and Fair Value - Net Gains/Losses on Derivative Instruments (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails Financial Instruments and Fair Value - Net Gains/Losses on Derivative Instruments (Details) Details 53 false false R54.htm 0000054 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) Sheet http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails Income Taxes - Provision for Taxes on Income (Details) Details 54 false false R55.htm 0000055 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.elanco.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 56 false false R57.htm 0000057 - Disclosure - Geographic Information - Narrative (Details) Sheet http://www.elanco.com/role/GeographicInformationNarrativeDetails Geographic Information - Narrative (Details) Details 57 false false R58.htm 0000058 - Disclosure - Geographic Information - Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails Geographic Information - Selected Geographic Area Information (Details) Details 58 false false R59.htm 0000059 - Disclosure - Retirement Benefits (Details) Sheet http://www.elanco.com/role/RetirementBenefitsDetails Retirement Benefits (Details) Details http://www.elanco.com/role/RetirementBenefitsTables 59 false false R60.htm 0000060 - Disclosure - Loss Per Share (Details) Sheet http://www.elanco.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.elanco.com/role/LossPerShareTables 60 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:NumberOfOperatingSegments - elan-20220930.htm 4 elan-20220930.htm elan-20220930.xsd elan-20220930_cal.xml elan-20220930_def.xml elan-20220930_lab.xml elan-20220930_pre.xml ex311elanco-20220930xceoce.htm ex312elanco-20220930xcfoce.htm ex32elanco-20220930xsectio.htm elan-20220930_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elan-20220930.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 307, "dts": { "calculationLink": { "local": [ "elan-20220930_cal.xml" ] }, "definitionLink": { "local": [ "elan-20220930_def.xml" ] }, "inline": { "local": [ "elan-20220930.htm" ] }, "labelLink": { "local": [ "elan-20220930_lab.xml" ] }, "presentationLink": { "local": [ "elan-20220930_pre.xml" ] }, "schema": { "local": [ "elan-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 463, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 2, "http://xbrl.sec.gov/dei/2022": 5, "total": 7 }, "keyCustom": 34, "keyStandard": 225, "memberCustom": 32, "memberStandard": 41, "nsprefix": "elan", "nsuri": "http://www.elanco.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.elanco.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Implementation of New Financial Accounting Pronouncements", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements", "shortName": "Implementation of New Financial Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Revenue", "role": "http://www.elanco.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Acquisitions, Divestitures and Other Arrangements", "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements", "shortName": "Acquisitions, Divestitures and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Asset Impairment, Restructuring and Other Special Charges", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges", "shortName": "Asset Impairment, Restructuring and Other Special Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Inventories", "role": "http://www.elanco.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Equity", "role": "http://www.elanco.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Debt", "role": "http://www.elanco.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Financial Instruments and Fair Value", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValue", "shortName": "Financial Instruments and Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Income Taxes", "role": "http://www.elanco.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Commitments and Contingencies", "role": "http://www.elanco.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Geographic Information", "role": "http://www.elanco.com/role/GeographicInformation", "shortName": "Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Retirement Benefits", "role": "http://www.elanco.com/role/RetirementBenefits", "shortName": "Retirement Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Loss Per Share", "role": "http://www.elanco.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables)", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables", "shortName": "Implementation of New Financial Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Revenue (Tables)", "role": "http://www.elanco.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables)", "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables", "shortName": "Acquisitions, Divestitures and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables", "shortName": "Asset Impairment, Restructuring and Other Special Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Inventories (Tables)", "role": "http://www.elanco.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Equity (Tables)", "role": "http://www.elanco.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Debt (Tables)", "role": "http://www.elanco.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Financial Instruments and Fair Value (Tables)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables", "shortName": "Financial Instruments and Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Income Taxes (Tables)", "role": "http://www.elanco.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Geographic Information (Tables)", "role": "http://www.elanco.com/role/GeographicInformationTables", "shortName": "Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Retirement Benefits (Tables)", "role": "http://www.elanco.com/role/RetirementBenefitsTables", "shortName": "Retirement Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Loss Per Share (Tables)", "role": "http://www.elanco.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-2", "first": true, "lang": "en-US", "name": "elan:NumberOfBrandsInEntitysPortfolio", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Background (Details)", "role": "http://www.elanco.com/role/BackgroundDetails", "shortName": "Background (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-2", "first": true, "lang": "en-US", "name": "elan:NumberOfBrandsInEntitysPortfolio", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iead0bf4f562f4a66a04f2c790ab78875_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.elanco.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iead0bf4f562f4a66a04f2c790ab78875_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i9cef804df3474579873237484b428cea_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Revenue - Activity in Sales Rebates and Discounts Liability (Details)", "role": "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails", "shortName": "Revenue - Activity in Sales Rebates and Discounts Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i9cef804df3474579873237484b428cea_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i8687cae1c9a64231a5ebbda41146ddd5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iba0668d4509b4ade9f2c93306bf1dae5_I20220201", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Narrative (Details)", "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "shortName": "Acquisitions, Divestitures and Other Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iba0668d4509b4ade9f2c93306bf1dae5_I20220201", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i5d69849dc5d14687837df4b689a22be7_I20210827", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i2a03d3045c59488eb27d47872def24a8_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Assets and Liabilities Held for Sale (Details)", "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails", "shortName": "Acquisitions, Divestitures and Other Arrangements - Assets and Liabilities Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i2a03d3045c59488eb27d47872def24a8_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iec8f73cea99f4ec8b6ef7da7c43dd5c9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "elan:NumberOfRestructuringProgramsAnnounced", "reportCount": 1, "unique": true, "unitRef": "restructuring_program", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iec8f73cea99f4ec8b6ef7da7c43dd5c9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "elan:NumberOfRestructuringProgramsAnnounced", "reportCount": 1, "unique": true, "unitRef": "restructuring_program", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i56af5d9e64d2479fbd46cdee9b565a3a_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i56af5d9e64d2479fbd46cdee9b565a3a_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Inventories (Details)", "role": "http://www.elanco.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Equity - Narrative (Details)", "role": "http://www.elanco.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "idab288071342462187c34131d45aee9e_D20200122-20200122", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ic509b65c24024075b27a9d2788443107_I20200122", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Equity - Stockholders' Equity (Details)", "role": "http://www.elanco.com/role/EquityStockholdersEquityDetails", "shortName": "Equity - Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ic509b65c24024075b27a9d2788443107_I20200122", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Debt - Long-term Debt (Details)", "role": "http://www.elanco.com/role/DebtLongtermDebtDetails", "shortName": "Debt - Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i01ddab045c6e4535aff2a0e5a619b386_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Financial Instruments and Fair Value - Narrative (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "shortName": "Financial Instruments and Fair Value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i01ddab045c6e4535aff2a0e5a619b386_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i99fe622dd51e4ddf964bed6b7430f456_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Financial Instruments and Fair Value - Fair Value Information (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails", "shortName": "Financial Instruments and Fair Value - Fair Value Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i99fe622dd51e4ddf964bed6b7430f456_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iea5b7ad456724b48b6c3c230d54a329e_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Financial Instruments and Fair Value - Net Gains/Losses on Derivative Instruments (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails", "shortName": "Financial Instruments and Fair Value - Net Gains/Losses on Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "iea5b7ad456724b48b6c3c230d54a329e_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Income Taxes - Provision for Taxes on Income (Details)", "role": "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails", "shortName": "Income Taxes - Provision for Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ica8ff639ed8445078dcc1fa467e0db99_I20201016", "decimals": "2", "first": true, "lang": "en-US", "name": "elan:LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ica8ff639ed8445078dcc1fa467e0db99_I20201016", "decimals": "2", "first": true, "lang": "en-US", "name": "elan:LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ifa3573d6eb734160938a4f561008b5c6_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Geographic Information - Narrative (Details)", "role": "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "shortName": "Geographic Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "id64911b98c6042ccbcd5a9f00b78911f_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Geographic Information - Selected Geographic Area Information (Details)", "role": "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails", "shortName": "Geographic Information - Selected Geographic Area Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i952464add44a48a69abca3b1d12ab947_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Retirement Benefits (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsDetails", "shortName": "Retirement Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "ie29fbddef6d04924a8092da68779b9ad_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i3a26518d5fda472782990dec02ae7540_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Equity (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "shortName": "Condensed Consolidated Statements of Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i65718070864b466d96465c37a35e2a3d_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Loss Per Share (Details)", "role": "http://www.elanco.com/role/LossPerShareDetails", "shortName": "Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i045c0f0b6ef449e9bfec2ac240fd381d_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Background", "role": "http://www.elanco.com/role/Background", "shortName": "Background", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20220930.htm", "contextRef": "i21ca0b55fe3941678921fb464a75b690_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 76, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "elan_A275SeniorAmortizingNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.75% Senior Amortizing Notes", "label": "2.75% Senior Amortizing Notes [Member]", "terseLabel": "2.75% Senior Amortizing Notes" } } }, "localname": "A275SeniorAmortizingNotesMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_A4.272SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.272% Senior Notes Due 2023 [Member]", "label": "4.272% Senior Notes Due 2023 [Member]", "terseLabel": "4.272% Senior Notes Due 2023" } } }, "localname": "A4.272SeniorNotesDue2023Member", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.9SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.9% Senior Notes Due 2028 [Member]", "label": "4.9% Senior Notes Due 2028 [Member]", "terseLabel": "4.900% Senior Notes due 2028" } } }, "localname": "A4.9SeniorNotesDue2028Member", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A500TangibleEquityUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.00% Tangible Equity Units", "label": "5.00% Tangible Equity Units [Member]", "terseLabel": "5.00% Tangible Equity Units", "verboseLabel": "TEU Amortizing Notes due 2023" } } }, "localname": "A500TangibleEquityUnitsMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CoverPage", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_AquaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aqua", "label": "Aqua [Member]", "terseLabel": "Aqua" } } }, "localname": "AquaMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_AssetImpairmentChargesIncludingInventoryWriteDown": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Impairment Charges, Including Inventory Write-Down", "label": "Asset Impairment Charges, Including Inventory Write-Down", "verboseLabel": "Asset impairment and write-down charges" } } }, "localname": "AssetImpairmentChargesIncludingInventoryWriteDown", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_BexCaFeLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BexCaFe, LLC", "label": "BexCaFe, LLC [Member]", "terseLabel": "BexCaFe, LLC" } } }, "localname": "BexCaFeLLCMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "elan_BusinessCombinationInventoriesStepUpFairValueAdjustment": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Inventories, Step-Up Fair Value Adjustment", "label": "Business Combination, Inventories, Step-Up Fair Value Adjustment", "terseLabel": "Inventory fair value step-up amortization" } } }, "localname": "BusinessCombinationInventoriesStepUpFairValueAdjustment", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentSettlementOfPreexistingLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Settlement Of Preexisting Liability", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Settlement Of Preexisting Liability", "terseLabel": "Measurement period adjustment related to settlement of preexisting liability" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentSettlementOfPreexistingLiability", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNetWorkingCapital": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital", "terseLabel": "Other net working capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNetWorkingCapital", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSettlementOfPreexistingLiability": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedIncludingLiabilitySettlementNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Settlement Of Preexisting Liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Settlement Of Preexisting Liability", "terseLabel": "Settlement of liability related to previous license agreement" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSettlementOfPreexistingLiability", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedIncludingLiabilitySettlementNet": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed (Including Liability Settlement), Net", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed (Including Liability Settlement), Net", "totalLabel": "Total consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedIncludingLiabilitySettlementNet", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_CattleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cattle", "label": "Cattle [Member]", "terseLabel": "Cattle" } } }, "localname": "CattleMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "stringItemType" }, "elan_CommonStockNoParValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, No Par Value", "label": "Common Stock, No Par Value [Member]", "terseLabel": "Common stock, no par value" } } }, "localname": "CommonStockNoParValueMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "elan_ContractManufacturingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Manufacturing [Member]", "label": "Contract Manufacturing [Member]", "verboseLabel": "Contract Manufacturing" } } }, "localname": "ContractManufacturingMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ContractWithCustomerLiabilityForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Foreign Currency Translation", "label": "Contract With Customer, Liability, Foreign Currency Translation", "negatedTerseLabel": "Foreign currency translation adjustments" } } }, "localname": "ContractWithCustomerLiabilityForeignCurrencyTranslation", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "elan_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "negatedTerseLabel": "Payments" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "elan_ContractWithCustomerLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability [Member]", "label": "Contract With Customer, Liability [Member]", "terseLabel": "Contract With Customer Liability" } } }, "localname": "ContractWithCustomerLiabilityMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ContractWithCustomerLiabilityRevenueRecognizedIncludingCurrentYearAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Liability, Revenue Recognized Including Current Year Additions", "label": "Contract with Customer, Liability, Revenue Recognized Including Current Year Additions", "terseLabel": "Reduction of revenue" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingCurrentYearAdditions", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "elan_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Single Customer" } } }, "localname": "CustomerAMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_DebtInstrumentFirstPeriodicPaymentPerAmortizingNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, First Periodic Payment Per Amortizing Note", "label": "Debt Instrument, First Periodic Payment Per Amortizing Note", "terseLabel": "First installment payment per amortizing note" } } }, "localname": "DebtInstrumentFirstPeriodicPaymentPerAmortizingNote", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentInitialPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Initial Principal Amount", "label": "Debt Instrument, Initial Principal Amount", "terseLabel": "Initial principal amount" } } }, "localname": "DebtInstrumentInitialPrincipalAmount", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentPeriodicPaymentPerAmortizingNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment Per Amortizing Note", "label": "Debt Instrument, Periodic Payment Per Amortizing Note", "terseLabel": "Quarterly cash installment per amortizing note" } } }, "localname": "DebtInstrumentPeriodicPaymentPerAmortizingNote", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentRetiredAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Retired Amount", "label": "Debt Instrument, Retired Amount", "terseLabel": "Amount of debt retired" } } }, "localname": "DebtInstrumentRetiredAmount", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "elan_DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Number of Employees Transferred", "label": "Disposal Group, Including Discontinued Operation, Number of Employees Transferred", "terseLabel": "Number of employees transferred" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_DivestitureOfBusinessDurationOverWhichProceedsWillBeReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divestiture Of Business, Duration Over Which Proceeds Will Be Received", "label": "Divestiture Of Business, Duration Over Which Proceeds Will Be Received", "terseLabel": "Duration over which proceeds will be received" } } }, "localname": "DivestitureOfBusinessDurationOverWhichProceedsWillBeReceived", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_FarmAnimalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Farm Animal", "label": "Farm Animal [Member]", "terseLabel": "Farm Animal" } } }, "localname": "FarmAnimalMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_FutureMilestonePaymentsAndSalesRoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Future Milestone Payments And Sales Royalties", "label": "Future Milestone Payments And Sales Royalties [Member]", "terseLabel": "Future Milestone Payments And Sales Royalties" } } }, "localname": "FutureMilestonePaymentsAndSalesRoyaltiesMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_GlobalCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Customers", "label": "Global Customers [Member]", "terseLabel": "Global Customers" } } }, "localname": "GlobalCustomersMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_IncrementalTermFacilityDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Term Facility Due 2025", "label": "Incremental Term Facility Due 2025 [Member]", "terseLabel": "Incremental Term Facility due 2025" } } }, "localname": "IncrementalTermFacilityDue2025Member", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_IncrementalTermFacilityDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Term Facility Due 2028", "label": "Incremental Term Facility Due 2028 [Member]", "terseLabel": "Incremental Term Facility due 2028" } } }, "localname": "IncrementalTermFacilityDue2028Member", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_IncrementalTermFacilityDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Term Facility Due 2029", "label": "Incremental Term Facility Due 2029 [Member]", "terseLabel": "Incremental Term Facility Due 2029" } } }, "localname": "IncrementalTermFacilityDue2029Member", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_InterestRateCashFlowHedgeGainLossStrandedTaxBenefitsReclassifiedToEarningsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net", "label": "Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net", "terseLabel": "Stranded tax benefits reclassified to earnings", "verboseLabel": "Release of stranded tax benefits" } } }, "localname": "InterestRateCashFlowHedgeGainLossStrandedTaxBenefitsReclassifiedToEarningsNet", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_January2021RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2021 Restructuring Plan", "label": "January 2021 Restructuring Plan [Member]", "terseLabel": "January 2021 Restructuring Plan" } } }, "localname": "January2021RestructuringPlanMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_KindredBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KindredBio", "label": "KindredBio [Member]", "terseLabel": "KindredBio" } } }, "localname": "KindredBioMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "elan_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid", "terseLabel": "Operating lease, lease not yet commenced liability" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Percent of TEUs Issued Involved in Lawsuit", "label": "Loss Contingency, Percent of TEUs Issued Involved in Lawsuit", "terseLabel": "Percent of TEUs issued involved in lawsuit" } } }, "localname": "LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "elan_MicrobiomeRDPlatformCarveOutMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Microbiome R&D Platform Carve-Out", "label": "Microbiome R&D Platform Carve-Out [Member]", "terseLabel": "Microbiome R&D Platform Carve-Out" } } }, "localname": "MicrobiomeRDPlatformCarveOutMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_November2021RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November 2021 Restructuring Plan", "label": "November 2021 Restructuring Plan [Member]", "terseLabel": "November 2021 Restructuring Plan" } } }, "localname": "November2021RestructuringPlanMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_NumberOfBrandsInEntitysPortfolio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Brands In Entity's Portfolio", "label": "Number Of Brands In Entity's Portfolio", "terseLabel": "Number of brands in diverse portfolio" } } }, "localname": "NumberOfBrandsInEntitysPortfolio", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/BackgroundDetails" ], "xbrltype": "integerItemType" }, "elan_NumberOfRestructuringProgramsAnnounced": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Restructuring Programs Announced", "label": "Number Of Restructuring Programs Announced", "terseLabel": "Number of restructuring programs announced" } } }, "localname": "NumberOfRestructuringProgramsAnnounced", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "terseLabel": "Forward-starting interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax", "terseLabel": "Interest rate swaps, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossTax", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_PaymentsForLicenseFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment On Agreement", "label": "Payments For License Fees", "terseLabel": "Payment on agreement" } } }, "localname": "PaymentsForLicenseFees", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_PetHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pet Health", "label": "Pet Health [Member]", "terseLabel": "Pet Health" } } }, "localname": "PetHealthMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_PoultryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Poultry", "label": "Poultry [Member]", "terseLabel": "Poultry" } } }, "localname": "PoultryMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ProceedsFromDerivativeInstrumentOperatingActivities": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Derivative Instrument, Operating Activities", "label": "Proceeds From Derivative Instrument, Operating Activities", "terseLabel": "Proceeds from interest rate swap settlements" } } }, "localname": "ProceedsFromDerivativeInstrumentOperatingActivities", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_ProceedsFromDerivativeSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Derivative Settlement", "label": "Proceeds From Derivative Settlement", "terseLabel": "Cash received for derivative settlement" } } }, "localname": "ProceedsFromDerivativeSettlement", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_ProceedsFromPaymentsToTransactionsWithParent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From (Payments To) Transactions With Parent", "label": "Proceeds From (Payments To) Transactions With Parent", "terseLabel": "Other net financing transactions with Lilly" } } }, "localname": "ProceedsFromPaymentsToTransactionsWithParent", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_ProductReturnConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Return Concentration Risk [Member]", "label": "Product Return Concentration Risk [Member]", "terseLabel": "Product Return Concentration Risk" } } }, "localname": "ProductReturnConcentrationRiskMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_RestructuringExpectedPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring, Expected Payment Term", "label": "Restructuring, Expected Payment Term", "terseLabel": "Expected payment term" } } }, "localname": "RestructuringExpectedPaymentTerm", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "SOFR" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_ShawneeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shawnee", "label": "Shawnee [Member]", "terseLabel": "Shawnee" } } }, "localname": "ShawneeMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_SwineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swine", "label": "Swine [Member]", "terseLabel": "Swine" } } }, "localname": "SwineMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "label": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "terseLabel": "Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share)", "verboseLabel": "Applicable Market Value (usd per share)" } } }, "localname": "TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "elan_TangibleEquityUnitDebtComponentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Debt Component", "label": "Tangible Equity Unit, Debt Component [Member]", "terseLabel": "Debt Component" } } }, "localname": "TangibleEquityUnitDebtComponentMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitEquityComponentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Equity Component", "label": "Tangible Equity Unit, Equity Component [Member]", "terseLabel": "Equity Component" } } }, "localname": "TangibleEquityUnitEquityComponentMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit", "label": "Tangible Equity Unit [Member]", "terseLabel": "Total" } } }, "localname": "TangibleEquityUnitMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "label": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "terseLabel": "Shares issued upon conversion of prepaid stock purchase contracts (in shares)" } } }, "localname": "TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elan_TangibleEquityUnitSettlementRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Settlement Rate", "label": "Tangible Equity Unit, Settlement Rate", "terseLabel": "Settlement rate" } } }, "localname": "TangibleEquityUnitSettlementRate", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "elan_TangibleEquityUnitSharesConsideredDilutiveAtASpecifiedMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Additional Shares Considered Dilutive At A Specified Market Value", "label": "Tangible Equity Unit, Shares Considered Dilutive At A Specified Market Value", "terseLabel": "Additional dilutive shares (in shares)" } } }, "localname": "TangibleEquityUnitSharesConsideredDilutiveAtASpecifiedMarketValue", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elan_TaxIncrementalFinancingCommitmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Incremental Financing, Commitment Amount", "label": "Tax Incremental Financing, Commitment Amount", "terseLabel": "Tax Incremental Financing, commitment amount" } } }, "localname": "TaxIncrementalFinancingCommitmentAmount", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_TaxIncrementalFinancingEstimatedTotalIncentiveToBeFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Incremental Financing, Estimated Total Incentive To Be Funded", "label": "Tax Incremental Financing, Estimated Total Incentive To Be Funded", "terseLabel": "New corporate headquarters, estimated total incentive to be funded by TIF" } } }, "localname": "TaxIncrementalFinancingEstimatedTotalIncentiveToBeFunded", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_TaxIncrementalFinancingExpectToRefundWithinNextThreeMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax Incremental Financing, Expect To Refund Within Next Three Months", "label": "Tax Incremental Financing, Expect To Refund Within Next Three Months", "terseLabel": "Refund within next three months" } } }, "localname": "TaxIncrementalFinancingExpectToRefundWithinNextThreeMonths", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_TermBLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term B Loan Facility", "label": "Term B Loan Facility [Member]", "terseLabel": "Term Loan B due 2027" } } }, "localname": "TermBLoanFacilityMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_WorldwideRightsToOsurniaAndUSRightsToCapstarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Worldwide Rights To Osurnia And U.S. Rights To Capstar", "label": "Worldwide Rights To Osurnia And U.S. Rights To Capstar [Member]", "terseLabel": "Worldwide rights to Osurnia and U.S. rights to Capstar" } } }, "localname": "WorldwideRightsToOsurniaAndUSRightsToCapstarMember", "nsuri": "http://www.elanco.com/20220930", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r127", "r272", "r276", "r281", "r505", "r506", "r510", "r511", "r578", "r656" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r127", "r272", "r276", "r281", "r505", "r506", "r510", "r511", "r578", "r656" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r63", "r65", "r125", "r126", "r287", "r326" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r206", "r360", "r365", "r634" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r266", "r267", "r268", "r269", "r286", "r325", "r454", "r460", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r631", "r635", "r657", "r658" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r266", "r267", "r268", "r269", "r286", "r325", "r454", "r460", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r631", "r635", "r657", "r658" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r206", "r360", "r365", "r634" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r201", "r267", "r268", "r360", "r363", "r594", "r630", "r632" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r201", "r267", "r268", "r360", "r363", "r594", "r630", "r632" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r250", "r266", "r267", "r268", "r269", "r286", "r325", "r398", "r454", "r460", "r463", "r464", "r465", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r631", "r635", "r657", "r658" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r250", "r266", "r267", "r268", "r269", "r286", "r325", "r398", "r454", "r460", "r463", "r464", "r465", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r631", "r635", "r657", "r658" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r64", "r65", "r125", "r126", "r287", "r326" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r142", "r455" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r142", "r147", "r265", "r455" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r202", "r203", "r360", "r364", "r633", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r202", "r203", "r360", "r364", "r633", "r645", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r142", "r147", "r265", "r455", "r582" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r50", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r208", "r209" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances of $10 (2022) and $12 (2021)", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r69", "r74", "r81", "r82", "r83", "r508" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension and Retiree Health Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r25", "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "verboseLabel": "Property and equipment, net of accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r74", "r81", "r82", "r83", "r84", "r507" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash Flow Hedge Gain (Loss)" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r72", "r73", "r74", "r619", "r640", "r643" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r71", "r74", "r81", "r82", "r83", "r129", "r130", "r131", "r508", "r576", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r67", "r74", "r81", "r82", "r83", "r508", "r560", "r561", "r562", "r563", "r565" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r36", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r129", "r130", "r131", "r466", "r467", "r468", "r533" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Issuance of stock under employee stock plans, net" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r462", "r469", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r42", "r210", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net of allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r113", "r231", "r238" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares not included in calculating diluted loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentChargesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges [Abstract]", "terseLabel": "Acquisition related charges:" } } }, "localname": "AssetImpairmentChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r28", "r121", "r186", "r191", "r197", "r216", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r505", "r510", "r554", "r579", "r581", "r602", "r617" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r20", "r49", "r121", "r216", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r505", "r510", "r554", "r579", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r2", "r3", "r10", "r12", "r15", "r247" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r519", "r523" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r450", "r456", "r502" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r450", "r456", "r496", "r497", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement": { "auth_ref": [ "r223", "r500" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid or received to resolve the preacquisition contingency.", "label": "Business Acquisition, Preacquisition Contingency, Amount of Settlement", "negatedTerseLabel": "Settlement of liability related to previous license agreement" } } }, "localname": "BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Common stock price (usd per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 5.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Transaction and integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r499" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r499" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income taxes, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r499" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Intangible assets, primarily acquired in-process research and development (IPR&D)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r498", "r499" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedIncludingLiabilitySettlementNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r498", "r499" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 7.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility exit costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r18", "r23", "r115" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r110", "r115", "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at September 30", "periodStartLabel": "Cash and cash equivalents at January\u00a01" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r110", "r558" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r33", "r34", "r35", "r118", "r121", "r152", "r153", "r154", "r156", "r158", "r168", "r169", "r170", "r216", "r272", "r276", "r277", "r278", "r281", "r282", "r323", "r324", "r328", "r332", "r339", "r554", "r665" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CoverPage", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r59", "r606", "r623" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r129", "r130", "r533" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r35", "r339" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, no par value, 5,000,000,000 shares authorized, 474,124,115 and 473,119,786 shares issued and outstanding as of September 30, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r77", "r79", "r80", "r90", "r610", "r626" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r174", "r175", "r206", "r551", "r552", "r646" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r174", "r175", "r206", "r551", "r552", "r644", "r646" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r174", "r175", "r206", "r551", "r552", "r644", "r646" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r174", "r175", "r206", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)", "verboseLabel": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r171", "r174", "r175", "r176", "r551", "r553", "r646" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r174", "r175", "r206", "r551", "r552", "r646" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Activity in Sales Rebates and Discounts Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetGross": { "auth_ref": [ "r211", "r221", "r348", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, before Allowance for Credit Loss", "terseLabel": "Contract with customer, asset, before allowance for credit loss" } } }, "localname": "ContractWithCustomerAssetGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r348", "r349", "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r348", "r349", "r361" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Sales rebates and discounts" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r93", "r594" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r92" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Costs, expenses and other" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, expenses and other:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r172", "r206" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r117", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r300", "r307", "r308", "r310", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r29", "r30", "r31", "r120", "r127", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r313", "r314", "r315", "r316", "r570", "r603", "r604", "r616" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r31", "r311", "r604", "r616" ], "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Number of consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r283", "r313", "r314", "r568", "r570", "r571" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r56", "r284" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "verboseLabel": "Interest rate on debt component" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r57", "r120", "r127", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r313", "r314", "r315", "r316", "r570" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r57", "r120", "r127", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r313", "r314", "r315", "r316", "r340", "r343", "r344", "r345", "r567", "r568", "r570", "r571", "r615" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r296", "r569" ], "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r113", "r122", "r479", "r488", "r489", "r490" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r472", "r473" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r375", "r414", "r438", "r444", "r445" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of net actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r375", "r415", "r439", "r444", "r445" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r375", "r413", "r437", "r444", "r445" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r375", "r380", "r412", "r436", "r444", "r445" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r410", "r434", "r444", "r445" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 4.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 }, "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "terseLabel": "Net periodic benefit income", "totalLabel": "Net periodic benefit cost (income)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "auth_ref": [ "r376", "r417", "r441" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "negatedTerseLabel": "Net curtailments and settlements (Note 6)" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r378", "r411", "r435", "r444", "r445" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTypeExtensibleList": { "auth_ref": [ "r371", "r372", "r373", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r427", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.", "label": "Defined Benefit Plan, Type [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Type [Extensible Enumeration]" } } }, "localname": "DefinedBenefitPlanTypeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r430", "r431", "r432", "r433", "r444" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r113", "r184" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Derivative assets (liabilities)" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r521" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Foreign exchange forward contracts" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r65", "r520", "r522", "r525", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r518", "r520", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r360", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r241", "r243", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r12", "r241", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Held for Sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]", "terseLabel": "Non-cash and other items:" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Cash received in agreement to divest" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r2", "r3", "r10", "r247" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r2", "r3", "r10", "r247" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r113", "r243", "r246" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 6.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedTerseLabel": "Settlements and other" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r113", "r243", "r246" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Asset write-down" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r450", "r456" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r91", "r139", "r140", "r141", "r142", "r143", "r150", "r152", "r156", "r157", "r158", "r162", "r163", "r534", "r535", "r611", "r627" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r91", "r139", "r140", "r141", "r142", "r143", "r152", "r156", "r157", "r158", "r162", "r163", "r534", "r535", "r611", "r627" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r159", "r160", "r161", "r164" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r558" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r81", "r82", "r83", "r129", "r130", "r131", "r135", "r144", "r146", "r167", "r217", "r339", "r346", "r466", "r467", "r468", "r481", "r482", "r533", "r559", "r560", "r561", "r562", "r563", "r565", "r576", "r636", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r24", "r187", "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r298", "r313", "r314", "r548" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r539", "r540", "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r539", "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r298", "r313", "r314", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r444", "r540", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r298", "r313", "r314", "r539", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r539", "r540", "r541", "r542", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r298", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r298", "r399", "r401", "r406", "r444", "r540", "r583" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r298", "r313", "r314", "r399", "r401", "r406", "r444", "r540", "r584" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r298", "r313", "r314", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r444", "r540", "r585" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Information" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r298", "r313", "r314", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r444", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r543", "r546" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r232", "r234", "r237", "r240", "r595", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r232", "r236" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r237", "r595" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r65", "r399", "r527" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Cross-currency fixed interest rate swap", "verboseLabel": "Foreign exchange contracts not designated as hedging instruments" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "terseLabel": "Gain on disposal" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r113", "r509" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Loss (gain) on divestiture" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedTerseLabel": "Loss on sale of assets" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r113", "r317", "r318" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Debt extinguishment loss" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r173", "r646" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r26", "r224", "r225", "r226", "r228", "r581", "r601" ], "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedIncludingLiabilitySettlementNet", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r518", "r529" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r113", "r242" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Asset impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Intangible assets, primarily acquired in-process research and development (IPR&D)" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r87", "r186", "r190", "r193", "r196", "r199", "r600", "r607", "r613", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r450", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r123", "r476", "r477", "r478", "r486", "r491", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r145", "r146", "r185", "r474", "r487", "r492", "r629" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r112" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedTerseLabel": "Changes in operating assets and liabilities, net of acquisitions" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r233", "r239" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r233", "r239" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r230", "r235" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r85", "r183", "r566", "r569", "r612" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net of capitalized interest" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "terseLabel": "Unrealized gains associated with cancelled swaps" } } }, "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Unrealized gains" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r65", "r399", "r526" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Forward-starting interest rate contracts designated as cash flow hedges" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r43" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r48" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r47" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedTerseLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r19", "r48", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r48" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r44" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lessee, operating lease, lease not yet commenced, term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r53", "r121", "r192", "r216", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r506", "r510", "r511", "r554", "r579", "r580" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r121", "r216", "r554", "r581", "r605", "r621" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r55", "r121", "r216", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r506", "r510", "r511", "r554", "r579", "r580", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "verboseLabel": "Credit facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r59", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Liabilities related to litigation" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation settlement charges" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r297", "r312", "r313", "r314", "r604", "r618" ], "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/DebtLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Net proceeds", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.elanco.com/role/DebtLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Less current portion of long-term debt", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.elanco.com/role/DebtLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r57", "r271" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r16", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions, Divestitures and Other Arrangements" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r110" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash (Used for) Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r110" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used for Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r110", "r111", "r114" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r15", "r75", "r78", "r83", "r88", "r114", "r121", "r134", "r139", "r140", "r141", "r142", "r145", "r146", "r155", "r186", "r190", "r193", "r196", "r199", "r216", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r535", "r554", "r608", "r624" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss available to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r132", "r133", "r136", "r137", "r147", "r148", "r149", "r213", "r214", "r218", "r219", "r483", "r484", "r485", "r532", "r536", "r537", "r538", "r555", "r556", "r557", "r572", "r573", "r575", "r577", "r596", "r597", "r598", "r639", "r640", "r641", "r642", "r643" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "verboseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainsLossesonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "negatedTerseLabel": "Long-term debt, including current portion" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of countries in which the entity operates as of balance sheet date.", "label": "Number of Countries in which Entity Operates", "terseLabel": "Number of countries in which entity operates (more than)" } } }, "localname": "NumberOfCountriesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/BackgroundDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Summary of Gain (loss), Net of Tax" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r17", "r513" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Background" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/Background" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r68", "r72" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Cash flow hedges, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r68", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r66" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r76", "r79", "r81", "r82", "r84", "r89", "r339", "r559", "r564", "r565", "r609", "r625" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive loss, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r70", "r72" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit pension and retiree health benefit plans, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r54", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash operating activities, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r108" ], "calculation": { "http://www.elanco.com/role/EquityStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Less: Issuance costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r98", "r101" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r109", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash paid", "terseLabel": "Cash paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r100" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedLabel": "Purchases of software" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r107" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Early redemption and tender premiums paid" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r106" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r99", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid in acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r99" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r100" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r100" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Net purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r398", "r400", "r406", "r423", "r425", "r426", "r427", "r428", "r429", "r444", "r446", "r447", "r448", "r461" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r32", "r373", "r374", "r397", "r444" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Accrued retirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r371", "r373", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r427", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r34", "r323" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r34", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, no par value, 1,000,000,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r97" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Proceeds from site divestitures" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r103" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r102" ], "calculation": { "http://www.elanco.com/role/EquityStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r103", "r120" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r104", "r108" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r245", "r581", "r614", "r622" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net of accumulated depreciation of $696 (2022) and $1,041 (2021)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r74", "r81", "r82", "r84", "r559", "r563", "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Reclassification from AOCI" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r105", "r120" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Repayments of revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSeniorDebt": { "auth_ref": [ "r105" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.", "label": "Repayments of Senior Debt", "negatedTerseLabel": "Repayments of long-term borrowings" } } }, "localname": "RepaymentsOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Fair value in excess of carrying amount" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r471", "r593", "r659" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "terseLabel": "Expected number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r113", "r251", "r258", "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r252", "r253", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r253", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r253", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "negatedLabel": "Restructuring reserve, accrual adjustment", "terseLabel": "Reserve adjustments" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r253", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "auth_ref": [ "r94" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.", "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Asset impairment, restructuring and other special charges", "totalLabel": "Total expense" } } }, "localname": "RestructuringSettlementAndImpairmentProvisions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring, Settlement and Impairment Provisions [Abstract]", "terseLabel": "Restructuring charges (credits):" } } }, "localname": "RestructuringSettlementAndImpairmentProvisionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r346", "r581", "r620", "r639", "r643" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r129", "r130", "r131", "r135", "r144", "r146", "r217", "r466", "r467", "r468", "r481", "r482", "r533", "r636", "r638" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r371", "r372", "r373", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r427", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r371", "r372", "r373", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r427", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r181", "r182", "r189", "r194", "r195", "r201", "r202", "r206", "r359", "r360", "r594" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Revenue", "terseLabel": "Revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r174", "r206" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Net Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r362", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Selected Geographic Area Information" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/EquityStockholdersEquityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "totalLabel": "Net proceeds", "verboseLabel": "Proceeds after underwriting discounts and commissions" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Number of shares sold in public offering (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Fair value per unit (usd per share)", "verboseLabel": "Offering price (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r174", "r206" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r496", "r497", "r502" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Provision for Taxes on Income" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r57", "r127", "r313", "r315", "r340", "r343", "r344", "r345", "r567", "r568", "r571", "r615" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities Held for Sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic And Diluted Loss" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r22", "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Summary of Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r138", "r141", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Description of Accounting Standards Adopted and Not Yet Adopted" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "verboseLabel": "Summary of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r252", "r253", "r254", "r255", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r256", "r257", "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r253", "r262" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Summary of Activity in Reserves" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r86", "r205" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformationSelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r33", "r34", "r35", "r118", "r168", "r169", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r332", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r177", "r179", "r180", "r186", "r188", "r193", "r197", "r198", "r199", "r200", "r201", "r205", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/GeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and other costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r112" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r33", "r34", "r35", "r118", "r121", "r152", "r153", "r154", "r156", "r158", "r168", "r169", "r170", "r216", "r272", "r276", "r277", "r278", "r281", "r282", "r323", "r324", "r328", "r332", "r339", "r554", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CoverPage", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r60", "r81", "r82", "r83", "r129", "r130", "r131", "r135", "r144", "r146", "r167", "r217", "r339", "r346", "r466", "r467", "r468", "r481", "r482", "r533", "r559", "r560", "r561", "r562", "r563", "r565", "r576", "r636", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r129", "r130", "r131", "r167", "r594" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r34", "r35", "r339", "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of stock under employee stock plans, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r35", "r39", "r40", "r121", "r212", "r216", "r554", "r581" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r119", "r324", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r346", "r347", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r252", "r253", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r505", "r506", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r158" ], "calculation": { "http://www.elanco.com/role/LossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Assumed conversion of dilutive common stock equivalents (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r151", "r158" ], "calculation": { "http://www.elanco.com/role/LossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r150", "r158" ], "calculation": { "http://www.elanco.com/role/LossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r17": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 2.A.6)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105049-122735" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2599-110228" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r461": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r495": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r513": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r660": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r661": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r662": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r663": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r664": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r665": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r666": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" } }, "version": "2.1" } ZIP 79 0001739104-22-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739104-22-000017-xbrl.zip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

    )\ 94SH/4&.'? 6PV^CMPO M(84-1NJ?L2H<#-M/@<4.(F#;7?7@F@9&+'\0 8?#.@@Q'AA!-JG[\,+M"W60)5]?05>DHA7>07-8\!_.!?LT-%I4LZXS?@P).!U)1Z8#F$G%*( M&:^GI]0#K$Y!I3[/ZU/3&OU+5F1U0=>JC.N[)VV[(V_S R11N" ",BIRB!*9 M0<%V2V1KL$@GRD)+,W0![1.SQ8!N8 MQ;H0ZU7-^L*[&5#,.AJ$(X7-UT$96-/:"YSNDM;=CQBQHK67+X<%K?UNZ;G) MM%QL#VO6AW/?_WK4B[6>I4(24D@!^XF MG6O+Z_T^+%P],+?6IRYU;5Z/DZOG8?7<"[H*JK%2 G$,_9OAWOBK=V:6OW-4!J-+<,X9$2NT\E-C8"B*! M#12(93"A"1):,D'#\M6.FYA:C-5:")R)@4<&.H#T(X'KX!EX] P9:$5$P*J&D&7>EU+2EIX1#H33/*,F+G 55$_!K=FJD]'>^ M^J=V$=\-6-<.5&.(']@>F!3BA[\?+<5'=6!::@R^ 8W)%9R'1H/&ZH@9)4$H MQ&I@J]SK@V\;2)%^I M-?C]4;EYH&/-VB&W,7O058U+X(]!],EC8APM$SB"22/G!L<#\3A;..*S^U&X M;54]R8B:'^/UQF)@ZFIAB']:\J3'D8CD\-FC,L))MUX.[=,7]58O;/7$JST8)X.S MTC]L &O>''"X-@/'2X-I4*]Z;)?C"ZW*6 MT7DD&*%XBGN>[8XMOQ<&QPDMOL ']..M[_:V.W.@)='L]3!A!$>&0T5U 9'3 MXZ.8,\AQ47#![/_)/(2GSK8T-5YRAKKIVZ&F2;\]M//P^A%/%- &)IJ>> 53 MS$4L(E'*^79&I9"+[KZDC,LW]!=K^+[BEGGJO?L#VLT'L6 :F IZ(-1+L.$^.R8,0 MOP[.'P3=&'US_P-JP\$?S?^.O?7=B=[PV]RGFY_* MEG8G. ';U]W/Z;]6]'%AEJN':D!7I;QG N="XDS"S"321:H99$A1*)5&2*-$ M"^*5/=35R-2(;;L2LF=H4^C>,XCJA-1_M>@:H,9:+0K!J-=ZT3D0KEHO.GKH MZ.M%Y]PZM5YT]MI^D<_M\N%AN?BVL93Q[0>W;\7=TV;MLJHLSZ'%JQ-76@K4S]P:L*X/!QX6^;784X/5"#0ZY7Y >"\2!/X8-9WRK.:.V] ;LV1HO\/9! M)%*0W=G4J &UC],O@V>O>_I]/S\N?MJ/\G+U_-?549T@3C($,7555;%* M("-:0R$0+1!!J7%)8?D._/PJ#K[@V MAMV RK1X8_NTRY%&\XN'CSI^3SOVN:K?&/WKNG, M2WXZ^GL_9JI30NO*S)]*+MS&1JG7[::P*# 716['(+-CD"L*>:(*B#,L"=*$ MLB)HDZ&SM:D-S#J37-;6@OG.W+"1VHVPW_"-AMO 8[I)OF\@V[-T@#QQ+TPB M44!W6Z/R@I?;+\G"[Z8>J27?;>^78J[KBLV_+\K--[W9U!MQ3JQEEE.:9X@D M,"E,%+GXD/&21'S].4@0 M\;ZI!\6V6NVWRP=1+GB=IRN7]XORO[7ZJ&P+I:G$L=ZLUWJS?B.M#2NMWBS4 M'M/;O]D7KSX ]%EO_K%<_;-I2\.VL-$<2FB21 M*@#]K.X&L#0U@K!%ZV>.3,:V^&_BCTSH+]KRM M"LHV_H)]AT'M,6A=KG0>]@/ YNI_@V!'P!I_56C/0-G5!E@WY?.M(4LY]JV4I\J M=J?MOR]#*X5R*@U/,8-*2@2100CR)$E@D4MMAC!Q7#&( 4$^THT8LJV^J0ZNY>_\5R-H^%8OM"GM M-R/1)D$HA4(X(1Q..10\U5!3RIG(:8YHT#?C3#M3H_V&!S;\5UNG ?PF:E,# MDZ/. 8L)T4B:#&IC&$0RQY!F,H.YSB1'J&!%HL*VJR- .\[N]?#@^GWH(@ V M\+>J07D*J1SI*)P[1\E).MS)R@DJGJ\>9*MV7AW'M>K69?=/W MCO?_JI?W*_[XHY1\WFC-Z,+EJ62%I5:30X0XAS0I*)295B87"_E?M>PMP_8&_+V7[OAWOWL40:[EWOM M4/>[N&=U5FWT:N4"MX9&]E8/;+0W2Y6-K&A:0"82.R%G2$-*;31 ##$R304B M*DBQ^4)[4QO\K;DN$@A-_;@$K5\$$!&P@9E@B]5>2+!G[(V;O48LA.J'2ZQZ MIQ=:&[>LJ9_K1]5+/6^[9G;V;<,WU;[G=D%'Y3K5-$50H4*YF %#E@@$DP(9 MRDR2DK3'[.RHG:D11S,&MG;ZK+H$X1HR?[@*K7'F#T% ]9P^G(4AZO3AN)57 MF#Z<=?7T].'\Y7VCBE7YLRH^\7'A9 2K=:2_VFC%K1N]??Z;5O?EXOZKGE?[ M&NL?Y6-5\DED>4XE93"31+N2FSD46@F8<:&8Y@Q+&53;II\94Z.2QDRP;V>O MPEL]>\4W3AD:ZX&)J _,/:*6:U"*%LST,F+D&.<:H(Y#GZN>UG>#5%6ZBGS^ MA9.%%(UTZS?(A2)!@R.4R(M 0BF(3VWQQFA4PSA22U_PHAD/--38T] M6GF RE30VMI36;T#83_^B(/;P.31%[)@XKB,1B36Z&AH5,JX[/!+OO"XH[]H MUH=R[:1C*[F,#_9WZUE.F$D3E$'&$P)1X:H8*RXMHE)G.L^)\MNTZ6QE:A2Q ME82J+06UJ:"R-5PVZQC4;FJ(!M70*[9]4.HEG'46A:N4LXZ?.KITUEG'3FEG MG;^XKWC6>G-GW%E@5T/NFU[]+*5>?UO.U2SC-);FMK0=Y8ZR:!U>*FW#CS]8H$X* T\ZEN *C.K7/764. LC:D/ M= F-:.I 9QL:61OHDL/'RD 7[^AQ:.S+:BFU5NL/UL+=TL?N4-JL$#S#2YFC^@H#DP@K:G V0IVQNZ=,8T)7L!9I9@@CG32Z!HPPPX'^8+3>;3G MXD/&.YCCZ\_!L1KOF_I%9/_0Y?V/C59O?NH5OV^J=]R9=^7\R?[V6'J0$.I2 ME-VR+Y40F22%/-,82ID8*7DBB DJPAO8_M2HN;&SO\YC*/X)51*G-(,FH0PB M7BA(G<)TKG*>285R^UD,T>0,:C^*%Z3V1BQ2[A[8^:D#?$YJ747[?QUQ=0OJ= M?K2!;EDO,>K'N78_V(G&FX?E:E/^=_5[^T5\U*O-\Q?[4F[LWYR*Q6,5>!&J M-#5&0R/R!*)*":S J:&4:I3E1.4AYW_B&5:R.@=Y\!(:VHUG]:MG3?5&4P[ MD/E>C6JUYWGOE7UX+Y?-Z#US/[D?+NI M+MFZ-TCQZRB QZ^-?9U9KU4Z.PJ8'96UXSS_VE2[6@A@__3_Y@,O5__.YT_N MX.8,%8@*C@MH*':I_)1#)C&!NC"BH!2S' 6F\GNV/+E9QFZ2S6OECM_V]!T# MHUE__/U(=Q!4A]Y'V@':2*'\MF?V7VZ:I@(:6P8:A)(6.2 MPB1Q!3&$%%K2$-[R;7AJM-7:[>+)UO)@/5IOU/W8:@@L!R:K4S#:R*Z5K:WK M1@U3J2X4K4A,Y=WLJ$05"L9+G@J^O\=&6JVL_^:,GL\7H*(_]N?'@'YC_&I7N M?4\.-85N&IFAUB%0>70#G$\'E]P9=\9SO%X*V @KT+*(5, M4IYC!O-<<(ARK2%7KCY5D1O,#,HH]=*"'\:\J7T?W^FU7)6/;37KO1++W]PN M@?UTKL$;M7S<-'*CGY<;\!]V=#>_ZSLIB-+3H5.'L?MO^#7FX[[Z_5&YN,9U M5>V0#7@."V?1I2A3C7FDR$Q/8\U.>J*WT^SRTNYBWK@6W$/%Q M\8\?I?SQWK:W>:YE /5ZEDF>89XJF&49L;1/"\B3/(48&\&+/$F(82&T[]?L MU.A\MZ4O6[L= ?SI+ >Z,KV19+5_^.UAN=)@8SLQ<"W:LTO\^#D^T /S[@[C MVV.,:ZM!:W8\2@V#*1)5>C8Z*@6& ?&2V@+OOKK8>+6(/(T+QN8&@T=%A1?+,$C7X&?]:8,ODF2I/U/F_#%GS8_ MEBLG.7X#4(%NTLS^)\55'(.*W/[,;@I*VLO+]?JI"4CW4\7XNDIFLB]1=286 MY,D-<.]T=>$[+:O?_L__)R7)O^5I]2?[W_9YC]IIR.KY<^]BSW4W^Q'>-9TW M,+4=%G5N=M$^5F /4L[YP/_X)9SKQ[]6V>8#YSI*-1]>UY-Q^&KU7$E+/"Y7 M+@/LP?';=A?M7;F6\^7Z::4;R8(B4829A$+$L/TOK%,H))90DC0O&*))AL*. M;86U/SF^:LP'M=V!-!"(O2=+#(?HP"326ESS!_B[YL[,6G,KNH!$3YAB<4U@ MZ^-243]HCIBJYV/ZIAF)S4X[Y[-]S1J1A(2F.>&2P4PD"B*3:2A,+F#JJHJ) M%&<%"IK?G6MH:M3D[ 0[0V^ ,[6G!L59YS9<^'ZGAHU3:6BJ@31NI+"::H1M:^Q2K265"8P4](M_1<(LCRC MT!U1EYE" A$2)%5SJ<6ID<6VG-B>Q3=MO;"^K'$9=S_ZB(KFP#QR+9#A>C:^ MX,22M;G8WKCJ-K[N'XG<>-]X'>GLE4?[N-CH^U53*:W*RW:GZ]W:#QG!PVPEQ;VKR1RLR1WDT_"IDY0_(.=8*>$+/W J] M*)>KS\N-7C>K#U(EAAA+4%)SYI:B4TB%2"!+N;3_CPG/LZ#TB))X9!]= ,C"+[*,QP'+,6==C[=T?/7_<[?=S[AWMH)^]L-\X_K)J MBBI4*\;U2=XWVSV369+E*F4)ADQ)"I'.[4^YPC#)&"D,020OBI!!W=WX$_#Z.EX.0OH &I/%'!W:D;'T?@"-EX =!U)EH[_>D\?+I@SP[2)L/NS,* M-3?2+F\>'^>E= F\?^>K?^I-M17W?57>W^M5N;C_N)!S.\5TL\I;/I=/=;V) M\THP7_2J^MTL-2)+\D) @=P96&XDY%A32#."B3%%EN;J"I8?UOJI?3!:G26^ M=1<\5/[6J5!@H:5>K_GJV557%RY3V_JMJI+J0.X<=SE-JA',.J6/];16X%&O MZK]YAK>O\W;E>:*+5!"H4YY!)#,#:4H4E#A+#*>&I;3P$_J9_/LUCAK0SE%0 M>]KD7/P?]$[T"GNFT\^O$D&UQ'*N^W<0@"T&]B>PAX([GM>J\)U2?[-8U+^? M\KMS580WG7?H58/%2;Q+UX:BX_1E8%0[L%&O&2"/@_>%6'LD(_HFY*Y_N/\X M;'1= M)_RGH4F]U_2?5(;G6+MJYEK5_4<3F<*$,^:2 3@K4--_[Q=JDKW7VO5*?;=_ MB&/,GO-;T!^M+P8.+YUE-Z#JB#T#;\#.=E!?XKKIQ2_W[XB9SQT!V6C9W=?8 M,G*N=P38CC._8SRTW_>S2Y'BPW*ER_M%K<(DG_>RC:Q!U;_JC_P;]9]/M6S% M5MI%"I51(AC,.4LAHCJ!5* ,)DF1%9Q(1).@RL_#F#FUA:S&$R ;5\!F9WT8 M.0_4K7ZL_?J=-3"=>XCWM%W9.@I>YNKM^0IVSM:2/LM(DC[C=$BDK\! 1H[Z M>1@6Z)??C8%;ZU.H2F_^IOE\\Z,]_H@13C%GL!!*N%J5&:0F5[;S,=&&$$J( M5[[,J8=/C;RM>:"V+Z18T@O /%9IKX!AZ*R6+0)]-IM?0A%2)JH_)&-5A;K\ M<@06?SKMMIQ?WC%C:Z;2UAY6FVZEM^8*9)@5D@&69$A MB#1.H2N. W&:,R6Q5+SPW#N_T-+T=KD/U60.)6!Z)_:>P]ES ?!Z[(9>VCN0 M6 F*49>.@LK-TTK?F?8#=GQT]:E>&VBI1,T:5,GF20Y2Y@A2IR2%%6D$[4S-&D2)'Q*LZ M4TBC4Z/*;WQNQ^1*BTIXW(U-5:XKB?) FO1"W#L^BXKC\)%:92[XT]H+6H-O MMHOFN]IR48,V;XCBA6^7FQP[D/,&X41(YW]OCXWM*OWJ25JZ*Q?W[W\Y(6NM MOO!G-\7\KE1+>;:*)C-C##')AZ [;H-=:"[Y'1"]A)CXGB2%OK5Z$9MNGN MBT[G+OS%AXRW+>_KS\$^O?=-_4*]KWI3UBK6KK+Z=_N01OR2$X:00@FD1>%2 M2K%TA6<22'*9$\(+1OV*;UYJ:&KDNK,3.$.!L[2GPNA9;/T"N1B(#4ZM?< * MCMD[EK\1EZ]O82 MFD%J(71@$/%,S'$;HY]U.>OFJ3,LYR_N-^*WM0_>K->Z*H2WEPW4E+M0=XNO MVIV7L(W:"SXO%ZOVGV_YNESO-I.X$AD7-G20F-H9FA88"IDIF. L*Y 1A0HK M;!#5NJDQC'.NK4M4^UZ.8 :OIL4$=:47],KB1UM-#\.E<4_=ZT'CKZB%^':RM!]W8L\R[WKBY^I?5 M\F>IM'K[_/M:JX^+.F/6162N1&\5KLTP3PC.4@U3EC.(C$90T%1 EF6:\)P+ M6EBF7EIC_6;,_DT'4?;6@.%&A#N47ZTL.8N!6:[ UFBPLSJPN+M_1_C-6H>! M=V BWR+;F@W$,_BM@KE<_"4,YO!:[\&(Q:KW[M_PN#7?@P$YJOL>_H08!4PM M4^JZ8.HL3ZG*2)9"D1ALXTOL!/3MC(\HA 412N,\:)_P7$-3"RLK-?)RKR2G ML=8049=U+YCE"2H+S*1*F1 A@8U/HU,+:6H-(WF@ M832W]MZ 1:U M.&_0D,:+_ S1%2!50(+E>40<:X@&YRE89\##K:FMHWX/:(_8.U M'<["ZD4&O-EL5J5XVE3R[ILE^,)CGQ.X"%<\*8BS+8TM!W') MY1.2$!=ON3(CI7M7L]K&_*Y_;=Y:3_XYXY*F.=',%?LI($K<$EHN"=2%R@6F M64K]BOU<9<740J!O3P\/KB2/'3J[M 0[MLQR]=!#\+1?S_B1U.!X#TQ?^VD? MEW,]FM2.[Q6'.7= Y<\0"1Y]\(R=R!%DP^LD;/2!Z6QB1J^']6/+O^O5O662 M-_*_GLIUZ<:T2PAY5ZX?E\T_[<_2AAWN%/=N4$J3N\[AJB<_;U8K>X_N(UP'UDCVO?%H_^OSX\&A) MVXWE._-IN;C_9,>\JO/JOB_?ZKIUR]YFAK4I9*XDE G+(4(D@=PD"*9<\91D M69YD.H0QO5N>'$DZ&T&Y-3^, _T!]Z.]06 X.25L60089-"GI ,ZASAPFAL[/_XIMUV-30U%JIMW2H';ZT%M;G^:;F= MZ'9S4$S,!J:$LM>$+#LK+.-/.U,B@V>IK7NYY7^7UGE-;\H M_UNKC\HV4)K2+3,VAX7<[&IE0Y2#0T/V;T\/6KW31EN;U'?^:^^/,RDRA61" M8,%=B(&PAMPM&&F))$HH)9G*9PM]SS?V5G]N&=YRKZ''ZJ%W9/^0B5&UL6TV M0I4$4B4CA-'5"%WOQWP3Z?FR0CV[,4]Y;QK43-72_% ]&PF M,Y*D!<90):F=RJH\A5P)"H6Q,'+%#5$D2*O[3$-3F\M6!W4>>7F^L$T8CMIP M3*4-W#/#;?0NJ;0X,@IYJG/)E10)-SVB]ZO@'#_FCHVJ'XW&>.<&9M+6Q.K MW8&1$97%+\ 02S;\7#/C:H)?YS[\@WMR4+GF]_D/S3&_@P@G& Y%8Q-+5 MU+B$XN'T$9'XW-.S0N3#XWSYK/4W^\@5MQXT\C D1P1AA&&1.9G)C&DHB#!0 M$9$21)2A.&AN>*:=J='&UKS BI!G4/1CA@C8#$P*K85@:^( >K078(A5$_), M*^/6A.QV]:@FY(7+KR_SYJK-N@??F6]Z42Y7+M'*2?>XX^TS.T41)",,VBE+ M8KF ,R@XYY J3*G3HB4RJ%JL;\-3(X?#6F)E8[G[1,Y=@J&K%@*4M;M_);?. M;O!<$!D W*$72 YP_;B':VUVG;]927B]ZX+WJGIL/E@-4'RML]E7J[3F T97 M636O^WLH,WYRU=GTW:-V12\7]Y\TMX/>_=?GY>8_],85T=:VV>V>VK/+$/W" M2S4CAJ6,YAA:KK+Q#.(%Y"[A@O!$$R$53K!7;OEU9DR-T;8N@+DS_Z;^'[!8 M;L"SWCAEA]J1;<+7@+^P^F* MM;X<%&_[O@1O-?CBO=Y^99<$R$6.TC4C:4@.W45A0I-7(]NI/MG_Z>-)4EZ- MP(%.Y?5/ZQ=Y?]LLY3_=-U*K=]5.Q!>]*I?JVP]NW]UML.\N^F)?Y!_6(%>" M9CW+L,2,"@ZU,L9M)J20NZ4]G28TU3F5F0ZJ$M/3CJE]Q?8CQK6S%CPM;&< MWM,@[4+H#:!U [<0-J M-V[ ;C&ANKAUI:IT%3$9[THP(\7Z?:T8-?2_$JJ7,X%K'Q=&JNO59G;K)/?T MZI&O-L^?[>OYYE>YGJ5:B%00!?.<9I8MBPP*G2N7VT:D-$(Q(7W8\EP#4Z/! M?1N!,Q+\X/?ZP_]IQQ]G'CD(* MEYQJ1_O%ZWK&1O*'5D]S[78Y7N;/MN<^.[-GJUV1G;2#YMI047"8\L1._).$ M048S =,4.3TCJ@BG81FND2T,&2GCY,;N:1J=2+K?':*^E'(?&%I%[GC/D.OU M.G/H4*SQ[.IN'%1$:2#\8T5OD:T;-ZH;!MJC:&^@9GHL#[_5OV[Y!_WITVVS M_YK)1&:4"\@D5A )BB'53$&:$XE25J0R8-7WY=.G%O\U]MT :V' FN 1:!ZK MK]= ,3#M[:/0IWC.$1P!*Y_7P#+2@J;72Q*V*GG.Z\[%QJ.;QEM#/&?OP=+@ MV8NNC6JK>>_;Y]LY7Z_K]#%.,4U19OF)"@F104[V**?0N')_DKA-M:#M]8ZV MID99^S%*O1HDGD%E;K\TO2Z80^/!J\ ;,;8+Q.V*".TL(M&CK>.67BER.NOR M^2CH_"U]=8F<]N_J<;FJ/@U.W$17\^[5\^U2Z5F&F40LQY 5"D.D1 (%MC^E M2"F$4I*+Q*L0@6=[4Z.01G;GP.:;2G/'C@ZGHU]9#ISIH8I%W;AW\\D : [, M*3& [*%EY 7/%9)&W<\?6=G(R]EC@2._VWJJFSBIW#OS1DKW2+=8OYR7\KG^ M[]UJ"K:S**P5@ZDHB"MW*B#E60(3(8C.\L)23I#XMU^S4R.;6E3:?G2_V*>V MP7J@I(@?WG[12GP4AYZ=M0#N3+X!M;G@C^9_!UEG"D,JEKR&7Z/C2F0$ 7$D M/J![WS)?#XQ =[D>@K]R-0X=TVQYL_0-?JW!N M414KO:E+EN[9?@-V;C67N-Y]\7*9'DTFUC)G&,6 /Q3I1,H"% MXYY&&0[BHY,L S;5^Q2,?6LWSRX%96/;<4]^= NQG_5F1@M.)%,I.@M/I-&IAPU]D]?AP?"_2!R;HU\Z9*A-M4P+W?P?ZY M0[NPS\&7BY#$.^QROJFQ#[A<=/K$H9;+]_25#S'E0JNW>F%_V+@&OML'O?^U M<06_Q%Q_*M>;6:*YQ)DI8&$$MK3C2B)@IF"N,D'R(B'V]V'R(9<;G1H1-3:# MQNAJ>-P 9S?X8V+]X>FC"C]##_3X]X<XQH*D2HH1:**)-,ISVDKF>;'; -9ZC58#\761J)#T8S9 MQ]JY*EZHO=+@A^;SS8_=);N3#_$K8E_S&OB1ZFMV[>O5?/ZM=O(OX%-5SOPT M57-CO\ NO<_M-I:FE'4,OG.VO62T6M$1.F2$\M+76#F9BM01H XI8AVCN1Y) M?6Y]:<7EYA_EYL>M?:ZU9JOQ__QAN=+E_:(6^I?/WU>V^7F=J<4ISE".)"0) MMZ$S3U)(DZ2 0A*44X-SE&=Z/FM MN*JSNC\$@V,_UD&4V@/@7 "M#P='AMLN:1T!>YZ,T T!N8XC=,=(*9%#=4M8 M%N65>'8F6_9]]G@YF5=Z?Y"Z>>VS>BLQ/B[7?/[7U?+I\?-RXRIIUCLC6FWW M1?[*RX7[E-XMVLMG69HJZCY.(CHA']S1GHE^J M;WJSF=?U@*MYSM(%(,$*CKWZQW/=9T"X1]-]K$P"E0LWE;3%OA>[S;T;X!P! MOSE7_N+V$MM;HRI#7@-G/-'(7E:,K2=Y#50GI":O>EP_\GPSGR__=!(.EI[? M+9_$QCS-FQR3M9W_ANG:ET_6]7 M6I6;9JTF>LF_7L!%8L&PMD?EOEZPO&2\?@_IQW,'>HY9@@C30D/[OP5$S##( M;.0.I6&)I(CGE 15$IVR=.9G2T:/C4!@& \=0(9I+K KI, +12'"EOE91BR" M)C6%,EKF13+;+#=\/C!DVR:&@^R[:Z.'GF@/S=")ZH(.)?LYH+3GZ\EW^DAT M1I#AW"4"SQUG?ONA]>;3LMYVJ.1B),XS(W,)L3%NV363D"6L@#+'3.-"%"D* MRE@XU]#4&*ZQ$U2&@M;2( F>B]CZC>88B T\LON!U2/IOQN):&G^9YH9.;&_ MV]GC5/X+U_<\Z \%TD"L';\ 1:R#X^>:&??4^ 5GCXZ,7[J^'P$[U5IW M2M0^ME964%,D6*>P<$3B MCJZ61J4/#Y=?,HC/+3T7Y%^4('XCUM6>ZBS%66ZP2FW8)G*("F0#.%PH6!0X MX<;2BHT]0H*,,Y?AH-[ MZ&E-#*1[",WWPBN:P'Q8ZR,+R_>"YEA0OM]CPH7D_\Y_E0]/#XWTH]!/8G2?O.H2P/3J4"%38N0B#&2%N.1E) M* 1.H-:LL/]O[&0$!4U$PMJ?V@C>,[_.CG3%V_:^?W-K>^"4);!#/&C^EQKNE_ M\\437ST[38Q*V^1);NIB.?:/S7>58F)TGA2.U#!$:89M_&$Y3HA"&U/CM,9BX$P&!S97IQ\#SL-X8-U-7P,@.#!=70"OCS2Z!XH!!XCBHCG2 M6:&^KV3862!_:#J/_7@\9KP3/OX^'1SF";CM6F7VMT_KZ !4V/I?2WRU@.P[\*- M$R??^\6UTNZ>_>2YV#4@^D.O=D4'_@IM^##TH@O&>S;_2BKR8>"=&B@8%KGA2&L4E(1PNIFIL8TS#I2+^AQ-Z&K>&23]2.5Z? 9FD:V!-Z!% MJ3'RQIUG[@ KF#JZL8C$%6<:&94_TNKQ?N&7S-^N_:75OO_\?%VZYQJW)-6N# M,B6JD*: AE,)D6 "TI1E4.:$ZRS5*F&!6K87VYS:)WQGLAW2H#$:[*P.U:V] M#+K?N(\,Y%/ M]@$?-_IA/:.,(BU<9$%LC($RKFR,035,$B44,SF5VJNBWA#&38_1CF5):XVF M>H_\T,$7E[VL*P[^<'Z"RM&K-;RO> %\2?-UNG5P=AV]1R-(AU\/_6 2XU>8 M]LI2Y->#>EFR/$(;/14,CA?3]SX!FBM![5R3(*7M)Z!0D!*60-O;M, XSR1* M@E0,.AJ;&J6?VDNZ@ID[OO\=\W73TVLX8J:5@([FN",%<+-_)2K",BP820M M%),T:.9WH;VI#>D]&T%=J;>/?-$ED/V^^1&A&WC4!Z,6_+7WQ"+2!_]2:Z-^ M\SU=?_G9][WM2AK9>_:'E?ZO)R7 M48E-.1TMO@[M7(;@+/5XW-KW//Y2_O/'L+>%VH_ MPAD$OH%I9]_F_P_45KOR !KL[ 9_[-9\HQZM#X0KVJ%ZWW9'/DX?",?Q0?K0 M!UQ[J.*S;I=R;Y?KS8NEW)DQ*-5)6L T23.(,%902$.A0-1H9*BF/$PIQ*_= MJ05*WYX>'MRIHJ6ICHVV6RJ5Y7U/270#[\E6\>$P>_VGG.X76WEYYB!> ]IRH M18-O8 )JD*LL!3M3P58>34?,7O1#)=8MM'JS4&UMNE*O[=^>'IQURNV3GS-V MEF2:)%QBF#&60%00!D4B"BBEH+HJ'1)6.61$VZ?&=!]?DMN-T^BVT5@Y?P:\ M<=12(&Q.70#;N+8O1WUH2>F?>KY\K%9D?OOXY>O_Y ^/__8N4#QVS#V[?@)WC8-_SAM!!ZWOU.NQY#QKW;\ .@'-?A?AI 2-V7.0L@S$L M?Y6DA1&[Y%P.Q)@FA*=4?-/R:55NGM-,?"\WJKANS4%]< M8-3H[]P9&VKSA2SY?"O=N3ZU:(Z)UKA($VAR;F?9% M(,1,0:SON=:$H(D%I MEK$-G!I-O.7RG_>KY=/BO-3^.!WG%T>^9G<,S%#[KMV ^>J4'#?/4=D6P?! MSL/A]T^&ZH!(05]T\T:-[(8"]V7X-E@[_3X";L=H_84_NX!QN]>]:V96Y#K' M.,DA5]*&;40FD!LGDB42IK%.*56H1T'["\UZ4NK$I8;5\+2%?*\ >5" MSI^4.Z[8'NU^7*Y:WKB$HD$ M+[4V*J=YNOZ2HGQO"Q=DWQ&>5E4^L)N*NBQ2&SHR2@2'V* <(L62YH0.=\+0 MJ<@37OAJLY]K9&KAW[Z=H#4T*$>W$])NUH@%U,!4T0NC('7W2R!<(?1^]M&C M:;Y?K'6ZQE*D1 &&:A-9B,*D]G80@@&,<\* MC A11*@0X9>7#00-\Q&T7RK[;H!NS*OF$Y6F>VA1NA/7%ONM'/'!>7.7-=#W_SCPGX2]7KSU=*#$XG[,%_^ MZ<0?]%]YN7 BZM\V*]N5-@[GOYHLC_57+>=\O2Y-:7^]?,]7"QLJ5VD"T@C# M<2:AX"F#+CG#J3,@2 PJ>*$$H5GF+84>U;2I!0FM[6##?P'16 ]6>^:#S1+H MQH$ ^>^X'4HDR0Q& LHB25S]C@(R2KF3V\@1SE1*E?)+37[=+ATG=_FKGFN^ MKI;$UZ?Z]]6ZL?N;\KI=,_#7J/4+.,=J_5+G6B5(I(%S;EL,9#LFK8MM3N(: M?'TQ)ELWN[.$AN[1 G_5^O9D=3^7ZF'PXH%#-()G74%XK8X7@F"09 ZJ%8P M3 O]IE%?]2-_KM: [\PGM_]_9VY76I5VA",I#4<$$BSL!Y?K%#*$*224R#3' M6.=IGQ7:LPU.=&UV9Z_[K*[TS^7\9[4R6QD-#)!.,Z' M[Q"XRLJJX&9E9[P9V44H(DW-SKH.PVL'S-$ M@&M@7NB%5 _MMTX/Q=6Z+X^6V/YFH:ITOSU1I< :TV$/ MG= [?BI)N%J1K&P_5/X:H-9T/]R&R]'M:ORUTVP]@/'(E/5Y2L]]#A?VWYGJ M3.[N8\!)QE"B$"12%A!)DT%>4 WS(LT9):D1TJOF8V;0KTGEQO\'_91NZ5U_M M]?J)6\.K_9>9IADQFMN!G[O$]YP*2 F5$!>*R"0SC&6JQ_R\H\F)SM"K@+)L M# 4R_#A\%\I^I' M:.-0PY>]^7@=A;>@=6L(!-.#!QR12**KI5&IPL/EEX3A MZ]=PF6H!:0]LR.OPBJQ^96)*C&G9F[4XV5H:"V-!)< 3M'D6 ; M:1^H+WQA&SD>F'1NRW3=/]XFBX<7!ULF/M?W%"'2]_4CJQ3KQ?VI/KO??%YN7//+A37DR?[Z4:^JH;=N M2G<5/,66X!.H!7?30,(@$SJ!&9/,F$QE.O$Z_QS=LJDQ6.L8J#R[ (9.!=OG((AV/<2[-P,W-:)UN.>&T&OT8]#!ZBQNW"(&G"Q M<8^U517-KG$WMV+#>;0=%KV!OOOIJ_*G?=[/;1;0W6+W.Y=RQR31 LL<$EDD M[LBD@2+3&2P2(8S)$=?XK5TW^ZF)8+D ^W^**D#GC4^T7?E+[8V\/^_I_O%. MO>^-_2AG7[=GH8Y5?[>[]9AHQ9A*H-0XM_/?5$.6RP(:FBF4$EHHY76*,K3A MJ1'0OG)7=;ZHAU:X-^A^W#,$E -3T&D4!TF$"$4G$@%Y-SLJ#X6"\9*.@N_O MQTKOUYOR@6_TG=F>$3]Q6+R9"Z$T(YEF$N*$"X@,*R!C2,(T8TJ*E+/,KYI: MG\:GQDX[O8,P1@H"W(^5AH)Q8&9JS:ZD>';J$?L55>)/&/M@%8FG@IH>E:OZ M@/*2KWH]X\I23XTVXH$F8O/ZJ#NGI_BT6I6+>WO!Y^5BU?ZSJCA5Z9;/!"5% MFI <"I)1B#*E($-40J.R0G!NBMR07@6AKK5LNFRW/S[7E11K;7L57.P[TRC[ M]ZTC=77?^G'GJ_38P,2Z7^/KBO[I7Z,J%I:Q*UE=;=?KU+N*!>?9JEC1&K@N M[^[[LI&Y/9+(%@+)C*8*\KBP%<1E\/R*-@^7(J7F;92L6/J0"N#_,MQ_.P#6E>5@N3/]7\/8*+A+ M_,AI2* 'YJHMQHWMH#:^.G-0H[UG_PUX5\Z?W-5#K._U13$2K04W/RK+]07G M)>GU?D[/A#RW^5H?HW#2<:5JMEEMT*==,8&[Q?<57ZQM0RY_-,5IQHFD-OIR M16Y2ED'&C(84I4JE"GLH3UD"F,2!22D*59:GN()) JBF%&2"XSPNUO M9(@NWV#],X9HGZLV^-CTT)"@^WV$!H-RX"_0-U[7?:@LKW75M[:#UGBWI;UG M?L3DB$',R/K>3VR12?CXN?-NQ?KI[3FUDQM;"[M:SLT-J,V =^[#8XL@.S MW,MLQZT+9[(9W16-&P.E,X:".$3JHK<-KY>F& I39TIB\,/ZD>'V05596Z8) M$9F 62HD1,B&; P7".89,L+^0 D-*KB]__#_:ZCK$#&5:\5U!@EVVW:&2"<\ MFT#-"I1+:E2A1$B0VQNQ$6+8.(CY<7A?' :FYJU9D3,E3[D;B40/'CTJ-YYR MZB7EG;RF'Y.]D?4H &'L1;;+858QH;XXWG;@PBC>PSC8PZ MQKL=?3G:+US=5\G4'0^6FR>W$WS[@Z_N]7I&[$N08\$@LS&-VQ])(;43-YAC MDV@D!Q]->O1$ M$R.KCIYW\EAPM./:/GHF_K.A=FOB_+F8&95J96?$D$GNCOIAZ?+/&4R-RC-<")33 MH(2BLRU-[=/7& KV+05_U+8&9HR?1];F2HU[)D95$[U JA!I' %5",Q0@!*?>G@# AQN>!E(Z]!!&<G^\+1Q9^/*N9W,+Q>ZS7MVYWZY_=W7Y3.?UV5E@CWC, MFX?#>6"F"8+X\HG=J[$.F.H.A_E(,]HXKW?8;+4?:)V3TL!'CC?W[.?KP12S MYR/"OA)*E[.JFO?S!]O0ZI9O]/UR]3S+"!62X!2F2!<0%51 9D-#F)%4:FT2 MC'.OPA1GGC\UMJ]-!)6-H#72CVG.(=C-W!%P&9B=PR#Q9H(+CI^(_=9:_LO] M\N?_LG?689_]81?MG7O>*$/]@C/M<+YTV;"'S-QI6CE#A<%&9LC5?4PA(FD& MF302"D08LFBFDM(A3IA5K4]MN%=&@=_*17.N["_#G"6KD=>"Y GE! I12#O9 M1A)2GBJ8*6U[A"B2I)ZUKP?'?IRC+4>'^]P)EN7BQ!F_L;K(;^H^&.P#,WG@ M0;_*_/'/]AV@-O+!OKKM29[J.X"E[Y&^PX?TKC!?CXOTOJ5WQI%N^6CV[HX1UJ8@D)]H82WYIP35$3NR48YY#P0N-*95;_MF-:=:,5 XF$:KT!R7T/&KJ!\)6 G2BQ?^\0>2[0M:1_D6WU9 MN3(=#W:RO[#/EUK-"I-IPK2$64HP1'F*7+4G!E4AC2AP@FGJG_;DU^;4R'(7 MMJP.<@$?&\,!;RT/6"/TA-]C'38^J ,S8(/GG0&'N96MS>#-<'@&K+7&QW6D M-=8(^(8ML(8AU;FPZOFH\194PWP[6$@-O+7OP3L[B]7?[#M5"1B^Y7-7!?#; M#ZTWKJBP4E4Q83[?*5:NWSX?9!&MN].(&O'!O. DQY+#-%7*QM(%LV&T3*'* M3,)5HK#1)NQ,WRAV3^U;.2XS8=]RJK#7*OGV>_?9D6B"-8:PPPIX8I2*\AP MPJ!F+,$<2Y4(K_-6NT=.[0/@YGAVW%=]X9F_L8=/-]WV\WI@)OS]\\?O[]^! M;]_??'__[7IR._:Q8^NNN;BFG>8?.\;9>]0H9'!L>CM.3_PEPB%&.[2KQ$ZM M7%'H][\>M;0_MU'IE^6Z&O7K]_/RH5RXRV:I$E@PG4.B,W?FGW%P'^YBZX[OMD;V2$.>H8;\WI'0GL#UWEXM/]3>RRG M?F]T?.M:-M5*[DH_\K(N=-/J6]\VE>;JG;*/Z[4-HGY_7"[L[W]:!G-K4H6D M.*>9@5*;'-HP2$%1< XI+BC%6EH2]A((BVK5U*BXV3\N*U/!D[75%?%KC*V( MN783K)V?X+%Q=%?I+WR'/VXO>ZSKOD;?#4S?K4MMS:YF!ZSIJ\HOT#H&6L]N MVFR!VCG@O ,[]UZC]P)6D5^C%T=:9QZU-\-6I&.CWKEF':VQ\5:U8^-SL.X= M_>']YD*W3I]XT^8NWU9K%O=Z(4N]GJ4I(U@6R,YL"@81I1FD.BT@R; NM)WN M>(HY>+0UM4_GGJE5 'U@;-C+[W-(C?G^#D^28N-HC.DF.<8H2"I,$:X@24D"F$P5UII7.I$)%[K4P M"7[ MG-;KQBT@U(^&WTCQ>Y^A'1:&>R'2&5MW/V&\@-G+DX,HV.^.\%-SWURU.ONT M][]L&&V_?)]M#\]R+"R%I@G,F> 0(6,@YYK#)&,B,5F1"^.U:'2N@:E]E5H; M06LD<%;Z'YP["6(W1<: 9F!B#$0EZ.QZW-D_/M=Y7;]Y MZ5]YN?BT7*_O%O4.>[4*?6?J G"ITTA)BEQR-Q=U]6X*:H>R(!!)&VI297(B M@@I$=#M6P&/7 M?/2#)=($]4)CH\Y1_1Q_.4WUO*MGZ1F]*G_:Z/"GMK.%*G.G.4>#4D137B#( M.+*L]TO6Q#I1YP8LEN"1-T?3;T!ZDR1)^Y]6IX,_ M;7XL5^5_:_5O]G([7NLLH#!R/86_'U]>B>K %+@#M"ENVM#AQVZ,@CFM X5( M-'6JA5&9I\/%EV32=>G@Q45/'M_8EI//9)IQ;J> 6N:%G1$JY0I<)Y"8W" L MJ5!9.E"]T4[#IL9$GY<+*/GZ1[7!O]S\T"M0.I[_U\$*DG;WF^?<\Q5Z8^BY M:G#-@YUG8,\U\$?K7,10+C;>XUF%_V'RQ+^ WO?I92NV.H@Q>ZV"[L>NW8>F$3;NNMJ:^3].P^WCS?Q?&[J1QJ?2B[* M>>F$]3];%^J2QMO5 &9T@0F6,"DR!9%6.>0*85@HDB.N>):';=-UMC8UTMA9 M"/;L#J./;GC]Z",:: /3QYZ=;KM_"]X0"R)>F$2BC^ZV1J4/+[=?TH??3>$9 MP;=+._OV?)>/KI_0>UO9%?4M/>MMKXS5PR>-EJIZTH']'-73%_2-7<7FX\*) M*+A=SUKC#66""889-$9C.R'G!E(M%(>VD8?@#,<["SO*OD>8?>^%68\(]BPJT>+6XQ9& MCE;/NG@;\H32FYC:Q^7RS%VDX%'-J@-AW\5AD/\L "(EUH M^[%$) P'9HO]7*W:T!O0(';Y$%__%*SSF,3.KCK1TNLD3IUW^6Q.5,R(0);0A-(DC0';<\-7XY+W6V ML]TG6+ZR/WQW!09 >?"]@#@ Q]*,.P_6L/)P)]J=@A+<>3@\1=\Z'C!5J?5/ MV]SM-,$\1X6"(E'<)0#DD.M402EDBDFF&99!&] CVCXU(JU=WZ5[O\P-=R/_ M3 J1> 9]A+P_]4WY'_,-\R/VB;XW W\:IOG*3% _JCS_H\1@?_T.L<97J%+ MQA>#/S9AD,RY[_K7YJT%]Y\S@;%&2*0P+PH,D1.09P4M8&9RA3*3%)2IB.E: MVX:G]JD;(E=HA[+O5" ^=H//!"YF!8$_G.&@LCSJ5" ,K''R?W;-3BGIYPB, MP$R?X_O[L=(W?>]X0)Q4)HD^R;U N^*I2%0QJDS%W]BJ%@B $!3-%C@QU M"9+')M!S?,I"D@(@Q!EF49 M-()CAC EJ=:SA;YWRY#?KTGE/6N"UWN^/:/PPI#AWOE]>UT>P,(MELC-D^TM M/@=V-AF8MA?2*;XY%'$Q?LV,X)=H[PF"#9D@?!&PP=*%S[?\RLG#%R&YG$I\ M^1%7)Q:_6=0'U'\LY_;^=:U*.E.)2CE5!=0L1Q#9%Q!: N/VGPE61682E*/9 M9KGAC=DUZ<2<4\3.,3S?W6DG&GX-,67U=+^N'EV_.86EUW[CV[R M-5/2)-2IG&89PQ )5D!N2 8+BK6=(EG22<-R2B,8-;7)5&OHEH\>Z[TH&U0- M)DIQOL<\PZN1^V'HN"M8C*+UZJ:*T39;5JP\>Q4ABHLXCR]"<=ZDJ0I07 3Q M"O&)R\_N&?DM%_S-'!]^B2BGD'=E3@-'<@=).S[010>S75@ M$"N".]7$N%%;AY-'D5K7M?T&_>?EXO>V=@F16B9IED!.M(*H*%(HDH)!BG/" MJ$B52&B8BLS>TT->WG'483XN+)8+7FQD[%[/=O R30 MGW WTHC=?_*H _6$2R_'YZE+^@W+N]4]7S2K.[?+Q7HY+U6M/+507^P;T%;[ MN3/'VJ.[9&Q42"9((6&&<^7DW1/(,L6AR1A#AAB3%D&SIBA63>UKO^_4#3AP MJXK&]QUSJZ8G%('[)];'Z6<_"AJ]]P8FK[$Z+IC\H@(=B3;CV#0JX4:%\255 MQWUX[]A+Z75Y7Q63;Z()::=;4EJBUIH[);^$0RH)ARG)4R0XEH($I2:>:&-J M!/QYN;&SB-9&P-?@;UK=NT63W<'4X/#L"%CO,.T:N 8/URXC-4PP=PZ4>$'= M40MC!W?G7#P1Y)V]-,(*^:5D:5=1[-WR@9>+65H@Q12WY* S!)&B%(JLR&"J M,DL9)!>2ADF#];-C:GQRN A;U;0#?]2FADHO].R8'FO?P\ ]ZG*W)]+7K5V' MXS3$>B=(_']:QUP9^K*.O[\HW\KZ=RI=\^KHR#("5>(JF.%<0L$+#IDI"&6YX45"V]0J/Q8,:;Y'6M7 MY.>L X^\5, L5X [.^M:V%E^ S[76%?=\>82UN'E-'J %JO.1DC3XQ;@Z '*466./L^(IY.3M3HY M7-&,Z0)*ZE;BLTQ @;,$%@1KI0J62AQ4VJ>CK:E%;_LZ.7=578V[A@)QX&YZ;Q63C:25DXVR"RQJZ57U\K)NF>-/K>$\4A5-?ZVJC+]<7'J M %N;U_7\=3F??UBN_N0K-3.8*",2#$5>I';.J&VHE) 4FD(2C&W$5!3&AUEZ MM3XUKJGMMV-D=XKS'X?:[ELOP!_.#] XXCF/[-=%W50T./ #D],T,5=+6:V> M55.9U\/^P(S_H_K ^[-Q%8;UA\0]HOHZ)"Q/JB]$OX>.\LVXRM_V*W+=0WI( M!-=BPQ_L1)_/_T/SU?N%>F=GKS.6,R.%RF"!2>+RAAUX8"9RFPI@)GJQ\G=4+:3?>Q@!J:U?M@%*;+? &$?A+-YQXZ MGEKS!;<.A)LO7=MO(NHJF6S6=R8@!74F4HY$B@S$!&&(",ZA2&@&B_KKW':[$A')C(=N8V#%7O%ORVJR/7&AWQ6'8(1M%$^3R:'%E-SQ^$8QF\@'O[ M\<][OEK8IZV_Z-4W5[O^73E_VF@UTY(FEEXX1$8:B"0EEFU, 5,LBY1+RHHD M2-SU3#M38YG&+/#;TUH!2_%@[8P-7/,_AZD?LT1 :F R:2T$UD10V7@#&BOC MD<<%&"+QQ;E61J6("ZZ^9(5+E_>4C+.3ACM3G<1V615WYON*+]9%(9<;G)J]. L=EOLE]9]/ZTV;X[ 5[_W" M2_5Q<0;MQ A#+A.,J7ULF@85Y!C:X,G16C4HY9X?@P MYUK3A+IM8#I]\^7C[4T=>\&WSAO09!&!-ZN5V[*I93@^+N1*VS]7RX*N BS8 M\RGB(M5(P,=:T1K:W'&7OT8"_VBM;*QV>\:S3:F_.]-H+J^=Z/+[7]7YZWF[ MA^G4A]P)]T_E3ZWJ279=[="8C+CZ)I FJ?VDZ-1 1NP_)2,,YU(H9<)BW:O, MF=P'8Z^.8NM/+4W>>K3=UZ]%MRKMALJK9OVI7UW**SO5,ZX>K:N&CKF'[Z7P M.#T*N+%B^.N,&3>^CP+<4>P?YZG]*/K6>>[R2JJ/0KG^Y]OGK6(-UEJD2C*8 MYM1 I"2&@G #75DI1HLL0SR(?SO:FAJY'I@*G*W]U8"Z(/9CPTC #9T+T@^S M8/KR0",2-W6U-"KQ>+C\DE5\;KE:*;;)3)GQK$"&2@55(0A$+$^AT F%6!0H MS5!!J90]M6&;)J:9]2&;]*<]5=C>4K MEGZ4D)10%9;"P7_]< M(R:87\;GT9,G]ZFO; M),M^'J7NT7N7\T)_KRJS+!X,N !"20=\3B+&RX[M? MA,!,]Q.^=F>Q[]\P8H;Z"3L/L\]/7=!SKM%,98Y"D^952G,D!$H49%+9*"*G M%%*F"D@*D60ITZP@-&B^T=W>Y(BHK2%W'$@'3C@NX.PYZ8B'WM!,=AZX N(2:PIRH;5QIR%^KA]-13QOZUO]"$4%H9 D MQ!6O< >K&6%0<*.5R3,;Z@35W/-I=&K\Q0#]<PM(^GU^A=XV!S !2J(D\F4 )RRO7U*7ONI"LB59B\'D.(Y$5GT2/U456556LRZ- MELP9Z"D:$CL9.Z,C-SGQ#+[?/?K5@C]XFWK_QA^"^^Q8) C3@!%3&E'2WM;&%(,6$I0PB27F%F5 MF>F=96D\4PD:U"+>-#\$Y3?Z;NV0TML-;#_9C ;7Q.3BC9138N\@$EZ9O=VC MSI;:.ZC8<6[O\,7>^[H7C%+N&O]1;+;;>Y+HET 1!DB&M3_$A 24P 1 1B(1 MQXI1$3MN[?9,MS0J./U@\GWUBS*)]R9@4FT*&=#5:O.#ZL==GMSCA13YSJ,W MZ<"3L S&C(;OU+&85ENDSLG=0WM[ NV;"MH/?=#Z[!);(#;>1G'?9'/O%5LH MWK)=;'.7SZY2/?+?Z?I9T=KK:CK/Q$F417$(4IEQ@%(*M0-$"8 AYI))*9(H MM.L\,S25RQ*9IPW-?J6<2.NR#=,#K,VVU#A@S<4G)V)Z[5KUP.6RB34.;'/M M:7G"Y[C9-8Q)_]Y7S_TS;H4-:W&Z,V9QO65>5 M*5"-H*:S?"VI1[T"UV=A9\]-B/#$A-Q(7H6>7NWK(6M#[K>Z<.M>@>"@P8@U MD/V@&ZL,LN/L\U9"]H/FHABRYS#C>:K[LG;W,&$JB7 ,:&8*3@E, &,1U!:B M]E-1B%&6IO=/9?+*EQTM=O[NZGY.E\5V/O-TZ^ZU?,C7)N<\8'1E7*?KO= # MRCP6&580 TA9"$R%+\ 2F@)">0PU\B*+:8WRV[5E/?V1,6[FG3+L)2:"U]_' M]P+LA5S\O:S3.O$7D$SHPQ_F>G$7_D)M&P_^\B8O!_[Q<;.N^NROJQ.HRS8O0)%4T92!+ M" -(Q@K@#$E "(J8(@GGQ*J25]<$2Z/'6L;R,%0MIE/J7">0_;0X!CS3N\^N MR%BOY2'U^PPE?>^1D:3_=C"0.H>=96D/*=4LZ<'K/"R?+Y(_%U+_>Y^?(0F)*(A" 34 $<6:JX @@4XEI%H:,(WLKR'+2I2UY M(YG#A]P66@L[: + )B:!6N)@+_)1R,P(';PR8O_F8R!9O[+VQM($^,YD.%GB M/)(5Y8A3KT5E.]9\UI6C=B>6ENN]GH'$%=UNZR)J=1$_3&#,LC@$,HY,T6:1 M 9+%,4B$RG"20:ZIV>F8R\442Z/A4L)KRR.V(&D9PKH*GZD]44=HW*-5G=J/ M%:*ZG&#>N%2G@A?!J.XK/7ME2Y6OI7@MU_J'W2?]8-_^?))\)\5GN7LNUG=K M\[NJ+LH]C8F""GW:( M_3K'(=A:X* H)0XVZ^!)7U"WKW#LDNWR2.SX8W2$9VI148D=U'('1LB;8(]U M)7OPRAQP^\U ;OY]]"X5/MB-U2/;9>IY&V-[@'+1#=MGC!%R&>N4I+(2[*JT ME _E_NY#&":1#!& 0O^!0AP"HA@R59K"5"8JD;%3;7CKF9=F\+S;%#)_6->E M6/BO8'>0.J"'^HA7I#3V/@@[8IL$WHE9[32YL1;Z)F@ ?], ?J1'\(?^TM=$ M-U'"HPUX4V0]]L[[ 1._MCM6%'U>OJL ,,21A#E@$!S7$. MA"A@<9CJGT@J0\R2*$NL(V6M4RR-GRHA#T4>'6(Y[1!:1,2N!F9B9CG'Q"?0 MU0Z.0UCK:I!F"F)9OT!NT:I>]7MC4^UWSA>)ZI7\).[4?Z6?B;9OZ&TZD:TV MVV?]K&_9MCQZ<9]$"18"

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�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end

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